

BNF name	PACE bulletin	Page	Date
28 day prescribing	Vol 7 No 7	4	2013 May
Abasaglar	Vol 9 No 21	6	2015 December
Abatacept for the treatment of rheumatoid	Vol 5 No 17	10	2011 October
Abatacept for the treatment of rheumatoid	Vol 2 No 10	6	2008 July
Abatacept, Adalimumab, Etanercept, Infliximab and Rituximab for the treatment of rheumatoid arthritis after the failure of a	Vol 4 No 18	12	2010 October
Abilify (Aripiprazole) IM injection	Vol 3 No 5	3	2009 May
Abilify (Aripiprazole) treatment of schizophrenia aged 15 to 17 years	Vol 5 No 9	6	2011 May
Abstral	Vol 3 No 5	4	2009 May
Abstral	Vol 12 No 3	1	2018 June
Acapella Vibratory PEP Therapy System	Vol 10 No 5	6	2016 March
Accolate	Vol 7 No 21	10	2013 December
Accolate	Vol 9 No 4	1	2015 March
Accrete D3	Vol 11 No 13	2	2017 October
Accrete D3 tablets	Vol 9 No 8	6	2015 May
Accu-Chek Active Blood Glucose Meter and	Vol 8 No 7	8	2014 April
ACE Inhibitors and Angiotensin Receptor Blockers in patients with ischaemic heart	Vol 3 No 13	12	2009 December
ACE Inhibitors and Angiotensin II Receptor Antagonists- Recommendations on use	Vol 3 No 7	17	2009 June
Aceclofenac 100mg tablets	Vol 9 No 4	2	2015 March
Acetazolamide 250mg tablets	Vol 9 No 6	3	2015 May
Acetylcholinesterase inhibitors for the treatment of moderately severe Alzheimer's	Vol 3 No 7	16	2009 June
Acetylcysteine 600mg effervescent tablets	Vol 11 No 15	4	2017 November
Aciclovir 3% eye ointment	Vol 8 No 19	6	2014 December
Acid suppressive medications - increased hospital-acquired pneumonia risk in patients	Vol 3 No 10	8	2009 October
Acitretin	Vol 7 No 14	17	2013 August
Aclasta	Vol 2 No 2	3	2008 February
Aclasta	Vol 3 No 4	6	2009 April
Acidinium bromide dry powder inhaler	Vol 7 No 2	7	2013 January
Acne	Vol 7 No 14	17	2013 August
Acomplia	Vol 2 No 17	1	2008 October
Actikerall (5-Fluorouracil 0.5%/salicylic acid 10% cutaneous solution	Vol 6 No 8	6	2012 May
Actinic Keratosis	Vol 7 No 14	1	2013 August
Actonel Combi	Vol 2 No 6	3	2008 May
Actos	Vol 3 No 9	7	2009 August
Acute cough / bronchitis	Vol 7 No 13	7	2013 August
Acute exacerbation of COPD	Vol 7 No 13	8	2013 August
Acute Otitis Media (AOM)	Vol 7 No 13	7	2013 August
Acute Rhinosinusitis	Vol 7 No 13	7	2013 August
Adalimumab	Vol 9 No 8	11	2015 May
Adalimumab	Vol 11 No 13	6	2017 October
Adalimumab	Vol 1 No 8	8	2007 December
Adalimumab and Dexamethasone	Vol 11 No 13	7	2017 October

Adalimumab for psoriatic arthritis	Vol 1 No 5	8	2007 October
Adalimumab for the treatment of adults with	Vol 2 No 13	5	2008 August
Adalimumab for the treatment of crohn's	Vol 4 No 14	4	2010 September
Adalimumab for the treatment of psoriatic	Vol 4 No 20	5	2010 November
Adalimumab, etanercept and infliximab for ankylosing spondylitis	Vol 2 No 12	6	2008 July
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the treatment of rheumatoid arthritis after the failure of a	Vol 4 No 18	12	2010 October
Adapalene and Benzoyl Peroxide Gel	Vol 5 No 12	6	2011 July
Adcal D3 caplets	Vol 9 No 8	6	2015 May
Adcal D3 Chewable tablets	Vol 9 No 8	6	2015 May
Addiction to benzodiazepines and codeine	Vol 5 No 15	10	2011 September
Adenuric	Vol 4 No 9	4	2010 June
Admission with Acute Coronary Syndrome / Non ST segment elevation myocardial infarction (NSTEMI) Treatment Algorithm	Vol 7 No 9	8	2013 June
Adrenaline Auto-injector	Vol 8 No 13	8	2014 July
Adrenaline tartrate auto-injector device	Vol 6 No 16	4	2012 September
Adusave	Vol 7 No 14	8	2013 August
Aerivio Spiromax 50/500micrograms powder inhaler(Salmeterol as Xinafoate)	Vol 11 No 11	3	2017 August
Afatanib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non small cell lung cancer	Vol 8 No 16	7	2014 September
Afibercept TA 486	Vol 12 No 2	8	2018 January
Aflibercept	Vol 8 No 12	7	2014 June
Aflibercept for treating diabetic macular oedema NICE TA346	Vol 9 No 18	10	2015 November
Aflibercept in combination with irinotecan and fluorouracil	Vol 8 No 12	7	2014 June
Agomelatine	Vol 9 No 1	6	2015 February
Agomelatine – risk of dose related hepatotoxicity and liver failure.	Vol 7 No 2	12	2013 January
Agomelatine 25mg tablets	Vol 3 No 11	4	2009 October
Agomelatine 25mg Tablets	Vol 4 No 20	2	2010 November
Agomelatine for the treatment of major depressive episodes (terminated appraisal)	Vol 6 No 2	7	2012 January
Agrippal	Vol 11 No 6	5	2017 March
Airflusal Forspiro	Vol 10 No 6	4	2016 May
AirFluSal Forspiro	Vol 11 No 11	3	2017 August
AirFlusal Forspiro powder inhaler	Vol 11 No 8	7	2017 April
Alateris	Vol 1 No 8	4	2007 December
Aldara	Vol 8 No 5	6	2014 March
Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teiparatide for the secondary prevention of osteoporotic fragility fractures in	Vol 2 No 19	7	2008 December
Alendronic acid 70mg effervescent tablets	Vol 10 No 3	3	2016 February
Alfentanil	Vol 12 No4	3	2018 May

Alfentanil sub-lingual spray 4mg/5ml 140 micrograms per spray(unlicensed)	Vol 6 No 16	4	2012 September
Alfuzosin 10mg modified tablets	Vol 8 No 10	7	2014 May
Alfuzosin 2.5mg tablets	Vol 8 No 10	7	2014 May
Algesal topical	Vol 11 No 4	8	2017 March
Aliskiren (Rasilez)	Vol 1 No 8	2	2007 December
Aliskiren (Rasilez) - Risk of Angiodedema and Renal Dysfunction	Vol 3 No 7	16	2009 June
Aliskiren (Rasilez) emerging safety concerns around the use of	Vol 6 No 5	8	2012 February
Aliskiren (Rasilez) risk of cardiovascular and renal adverse reactions – new contraindications and warnings	Vol 6 No 8	12	2012 May
Alitretinoin	Vol 7 No 14	17	2013 August
Alitretinoin capsules	Vol 3 No 5	3	2009 May
Alitretinoin for the treatment of severe chronic hand eczema	Vol 3 No 11	10	2009 October
Alli	Vol 4 No 3	7	2010 March
Almiral	Vol 9 No 4	2	2015 March
Alogliptin	Vol 8 No 10	4	2014 May
Alogliptin 6.25mg, 12.5mg and 25mg tablets	Vol 10 No 12	2	2016 August
Alogliptin/metformin 12.5mg/1g tablets	Vol 10 No 12	2	2016 August
Alpha drugs	Vol 8 No 7	2	2014 April
Alpha Inhibitors	Vol 8 No 12	7	2014 June
Alpha Treatments	Vol 8 No 7	2	2014 April
Alprostadil	Vol 8 No 18	5	2014 October
Alprostadil cream	Vol 11 No 10	3	2017 May
Alteplase for acute ischaemic stroke	Vol 1 No 2	5	2007 July
Alternatives to prescribing unlicensed pharmaceutical 'specials'	Vol 6 No 11	1	2012 September
Aluminium Chloride 15%/Salicylic Acid 2%	Vol 5 No 5	2	2011 March
Alupent (Orciprenaline) reminder of withdrawal from the market on September	Vol 4 No 14	9	2010 September
Alupent (orciprenaline) planned withdrawal	Vol 3 No 13	15	2009 December
Alzain	Vol 10 No 10	3	2016 July
Alzain	Vol 11 No 8	3	2017 April
Alzheimers Disease	Vol 1 No 6	5	2007 November
Alzheimer's disease - acetylcholinesterase inhibitors and the treatment of	Vol 3 No 7	16	2009 June
Amantadine for the treatment of influenza	Vol 3 No 4	8	2009 April
Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza	Vol 2 No 18	8	2008 November
AMCO Price Increases review	Vol 9 No 21	3	2015 December
Amifampridine Phosphate Tablets (Firdapse)	Vol 5 No 7	4	2011 April
Amiodarine supply difficulties	Vol 10 No 6	9	2016 May
Amitiza	Vol 8 No 5	7	2014 March
Amlodipine	Vol 9 No 11	2	2015 July
Amlodipine 5mg and 10mg tablets and lercanidipine 10mg and 20mg tablets	Vol 8 No 1	10	2014 January
Amlodipine 5mg and 10mg tablets generic	Vol 9 No 11	2	2015 July

Amlodipine prescribing notes with	Vol 8 No 23	8	2014 December
Amlodipine/olmesartan tablets (Sevikar) 5/20mg 10/20mg and 10/40mg	Vol 3 No 11	6	2009 October
Amoxicillin	Vol 9 No 4	7	2015 March
Amoxicillin in Acute Otitis Media	Vol 3 No 11	7	2009 October
Amoxicillin in otitis media	Vol 8 No 22	2	2014 December
Amphetamine	Vol 8 No 16	10	2014 September
Ananafil tablets	Vol 12 No 6	4	2018 May
Anastrozole and Risedronate - Patent Expiries	Vol 5 No 11	4	2011 June
Anastrozole for the prevention of breast cancer in high risk post menopausal women	Vol 8 No 4	7	2014 February
Angiotensin 2 Receptor	Vol 5 No 9	4	2011 May
Angiotensin 2 receptor antagonist (A2RA)	Vol 5 No 9	8	2011 May
Angiotensin 2 receptor antagonists (A2RAs) and cancer risk	Vol 4 No 14	8	2010 September
Angiotensin converting enzyme inhibitor	Vol 5 No 9	8	2011 May
Angiotensin Converting Enzyme Inhibitors - The Case for First Line	Vol 4 No 10	1	2010 July
Angiotensin II receptor antagonists: evidence doe not suggest any link with cancer	Vol 6 No 4	11	2012 February
Angiotensin receptor blockers and	Vol 5 No 11	8	2011 June
Anion exchange resins - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	2	2013 February
Anoro Ellipta	Vol 12 No 7	2	2018 August
Antenatal care - Routine care for the healthy pregnant woman	Vol 2 No 10	7	2008 July
Anthelios	Vol 9 No 8	4	2015 May
Antibacterial drugs: Winter 2013	Vol 1 No 7	1	2007 November
Antibiotic	Vol 7 No 13	1	2013 August
Antibiotic Awareness Campaign	Vol 2 No 16	1	2008 October
Antibiotic Guidance 2015-16	Vol 9 No 22	1	2015 December
Antibiotic Prescribing	Vol 3 No 11	7	2009 October
Antibiotic Prescribing (July 2008)	Vol 2 No 16	2	2008 October
Antibiotic resistance	Vol 4 No 14	7	2010 September
Anticoagulant treatment booklets	Vol 1 No 3	5	2007 August
Anticoagulants - NPSA Safety Alert	Vol 4 No 19	1	2010 November
Anticonvulsants for mental health problems in women of childbearing potenetial guidance	Vol 9 No 15	7	2015 October
Anti-D Prophylaxis - routine antenatal for women who are rhesus D negative	Vol 2 No 18	7	2008 November
Antidepressant prescribing continues to rise	Vol 3 No 13	12	2009 December
Antidepressant use in primary and secondary care	Vol 4 No 5	1	2010 May
Antiepileptic - MHRA Update	Vol 3 No 5	12	2009 May
Antiepileptic Drugs	Vol 2 No 18	11	2008 November
Antiepileptic drugs	Vol 8 No 5	2	2014 March
Antimicrobial resistance through implementation of an antimicrobial stewardship programme	Vol 9 No 18	10	2015 November

Antipsychotic - use in elderly patients	Vol 4 No 7	7	2010 May
Antipsychotics in dementia	Vol 6 No 10	3	2012 May
Antipsychotics in early psychosis	Vol 4 No 20	5	2010 November
Antisocial personality disorder - Treatment management and prevention	Vol 3 No 5	9	2009 May
Antiviral Supply	Vol 4 No 21	1	2010 December
Anusol cream/ ointment/suppositories	Vol 11 No 4	2	2017 March
Apidra - supply problems	Vol 5 No 18	12	2011 December
Apidra SoloStar Insulin pen	Vol 2 No 1	4	2008 January
Apidra supply problems	Vol 5 No 16	1	2011 October
Apixaban	Vol 8 No 21	9	2014 December
Apixaban (Eliquis)	Vol 7 No 10	1	2013 June
Apixaban (FAQs)	Vol 7 No 15	15	2013 August
Apixaban for the prevention of stroke and systemic embolism in atrial fibrillation (Second Edition) NICE TA 275	Vol 7 No 16	1	2013 October
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE TA245	Vol 6 No 7	7	2012 May
Apixaban in newly diagnosed AF	Vol 8 No 21	6	2014 December
Apnoea syndrome	Vol 2 No 9	5	2008 May/June
Apollo Twist	Vol 9 No 10	1	2015 July
Apomorphine with Domperidone	Vol 10 No 10	8	2016 July
Apraclonidine 0.5% solution	Vol 9 No 6	3	2015 May
Apraclonidine 0.5% solution	Vol 9 No 6	3	2015 May
Apremilast	Vol 11 No 6	10	2017 March
Apremilast (Otezla): Risk of suicidal thoughts and behaviour	Vol 11 No 6	10	2017 March
Apremilast 10mg, 20mg and 300mg tablets	Vol 10 No 11	2	2016 August
Apremilast for the treatment of psoriasis and active psoriatic arthritis	Vol 10 No 11	10	2016 August
Aprepitant (Emend) Capsules and Fosaprepitant (Ivemend) Injection	Vol 6 No 3	7	2012 January
Aptamil Anti -Reflux Milk	Vol 11 No 4	7	2017 March
Aptamil comfort Formulary	Vol 11 No 4	8	2017 March
Aquamax cream	Vol 9 No 5	3	2015 May
Argatroban infusion	Vol 7 No 7	8	2013 May
Aripiprazole (Abilify) for the treatment of schizophrenia and the treatment and prevention of mania	Vol 8 No 1	14	2014 January
Aripiprazole (Abilify) IM injection	Vol 3 No 5	3	2009 May
Aripiprazole (Abilify) treatment of schizophrenia aged 15 to 17 years	Vol 5 No 9	6	2011 May
Aripiprazole prolonged-release suspension for injection	Vol 8 No 6	4	2014 March
Artherosclerotic events in patients with acute coronary syndromes prevention of	Vol 7 No 9	1	2013 June
Artificial Tears and Ocular Lubricants for the treatment of dry eye	Vol 7 No 6	1	2013 June
Asacol	Vol 7 No 4	1	2013 February

Asacol	Vol 11 No 13	4	2017 October
Asasantin retard	Vol 11 No 8	9	2017 April
Asenapine 5mg and 10mg sublingual tablets (Sycrest) New Drug Assessment	Vol 6 No 8	6	2012 May
Aspirin - stroke prevention in AF	Vol 8 No 21	5	2014 December
Aspirin and cancer prevention	Vol 6 No 10	4	2012 May
Aspirin daily reduces risk of cancer	Vol 8 No 18	4	2014 October
Aspirin for primary prevention of cardiovascular disease	Vol 3 No 13	3	2009 December
Aspirin for primary prevention of cardiovascular disease	Vol 3 No 8	5	2009 August
Aspirin for primary prevention of cardiovascular disease	Vol 3 No 10	8	2009 October
Aspirin prolonged release 162.5mg capsule	Vol 3 No 10	6	2009 October
Atarax, Ucerax: Risk of QT interval prolongation and torsade de pointes	Vol 9 No 9	12	2015 June
Atomoxetine	Vol 8 No 10	11	2014 May
Atomoxetine (Strattera) - risk of psychotic or manic symptoms	Vol 3 No 4	14	2009 April
Atopic Eczema	Vol 5 No 12	8	2011 July
Atopic Eczema in Children	Vol 2 No 3	11	2008 April
Atopic Eczema in Children	Vol 2 No 2	4	2008 February
Atorvastatin - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	1	2013 February
Atorvastatin 80mg and acute coronary syndrome	Vol 5 No 2	2	2011 February
Atorvastatin Chewable tablets (Lipitor)	Vol 6 No 4	3	2012 February
Atorvastatin generic price reductions	Vol 6 No 12	5	2012 June
Atorvastatin patent expiry and the future role of rosuvastatin	Vol 6 No 4	8	2012 February
Atorvastatin patent expiry and the future role of rosuvastatin	Vol 6 No 8	3	2012 May
Atorvastatin primary prevention of CVD	Vol 8 No 23	2	2014 December
Atrial Fibrillation and Atrial Flutter with Bisphosphonates	Vol 3 No 5	8	2009 May
Atripia	Vol 7 No 7	8	2013 May
Attention deficit hyperactivity disorder	Vol 3 No 1	10	2009 January
Attia	Vol 11 No 8	10	2017 April
Avamys	Vol 9 No 7	2	2015 April
Avamys	Vol 11 No 7	4	2017 March
Avamys (fluticasone furoate)	Vol 3 No 7	4	2009 June
Avanafil 50mg, 100mg and 200mg tablets	Vol 8 No 12	7	2014 June
Avanafil 50mg, 100mg and 200mg tablets	Vol 10 No 5	4	2016 March
Avastin	Vol 7 No 14	7	2013 August
Avastin (bevacizumab) - hypersensitivity & infusion reactions	Vol 4 No 12	9	2010 August
Aveeno	Vol 11 No 4	10	2017 March
Aveeno cream & lotion	Vol 9 No 5	2	2015 May
Avloclor	Vol 11 No 4	6	2017 March
Avodart (dutasteride)	Vol 4 No 18	5	2010 October

Axalid	Vol 11 No 8	1	2017 April
Axitinib	Vol 9 No 8	12	2015 May
Axorid (ketoprofen/omeprazole) Capsules	Vol 4 No 2	9	2010 March
AYMES Shake	Vol 8 No 8	7	2014 May
Azacididine (Vidaza) treatment of myelodysplastic syndromes	Vol 5 No 9	7	2011 May
Azathioprine	Vol 9 No 8	11	2015 May
Azelaic acid 15% gel	Vol 9 No 8	9	2015 May
Azelastine HCL 0.05% eye drops	Vol 11 No 7	6	2017 March
Azelastine HCL 0.1%	Vol 11 No 7	5	2017 March
Azelastine hydrochloride	Vol 9 No 7	1	2015 April
Azelastine hydrochloride	Vol 9 No 7	2	2015 April
Azelastine hydrochloride	Vol 9 No 7	3	2015 April
Azilect (Rasagiline)	Vol 3 No 1	5	2009 January
Azilect (Rasagiline)	Vol 5 No 7	3	2011 April
Azithromycin (Azyter) Eye Drops	Vol 6 No 2	4	2012 January
Azithromycin incident	Vol 10 No 5	13	2016 March
Azopt	Vol 9 No 6	3	2015 May
Azyter (azithromycin) Eye Drops	Vol 6 No 2	4	2012 January
Bacterial resistance	Vol 7 No 13	2	2013 August
Balneum	Vol 11 No 4	10	2017 March
Balneum cream	Vol 9 No 5	3	2015 May
Baricitinib (rheumatoid arthritis)	Vol 11 No 13	8	2017 October
Barrier Preparations and Skin Protectants	Vol 9 No 19	1	2015 November
Beclometasone (Clipper) 5mg tablets	Vol 1 No 5	8	2007 October
Beclometasone 50 microgram	Vol 9 No 7	1	2015 April
Beclometasone 50 microgram	Vol 9 No 7	2	2015 April
Beclometasone CFC containing MDI	Vol 2 No 3	5	2008 April
Beclometasone dipropionate 200microgram	Vol 10 No 6	6	2016 May
Beclometasone Metered Dose Inhalers containing CFC final withdrawal	Vol 4 No 3	5	2010 March
Beclometasone/formoterol inhaler (Fostair NEXThaler)	Vol 8 No 20	7	2014 December
Beclomethasone nasal spray	Vol 11 No 7	3	2017 March
Beconase	Vol 9 No 7	1	2015 April
Beconase Hayfever relief nasal spray	Vol 11 No 7	2	2017 March
Beconase Hayfever relief nasal spray	Vol 11 No 7	4	2017 March
Bendamustine (Levact) for the first line treatment of chronic lymphocytic leukaemia	Vol 5 No 8	11	2011 May
Bendamustine (Levact) for the treatment of indolent (low grade) non-hodgkins lymphoma that is refractory to rituximab	Vol 5 No 2	6	2011 February
Benefits & risks of warfarin to dabigatran & rivaroxiban	Vol 8 No 21	24	2014 December
Benpali	Vol 10 No 7	10	2016 May
Benzbromarone tablets	Vol 12 No 7	5	2018 August
Benzodiazepines - addiction to	Vol 5 No 15	10	2011 September
Benzodiazepines reduce use of	Vol 6 No 2	8	2012 January

Benzodizepines	Vol 8 No 16	10	2014 September
Berinert (C1 - esterase inhibitor)	Vol 3 No 11	7	2009 October
Beta blockers - are they all the same in heart failure?	Vol 5 No 12	9	2011 July
Betamethasone valerate adhesive plaster (Betesil)	Vol 3 No 13	6	2009 December
Betaxolol 0.25% and 0.5% eye drops	Vol 9 No 6	2	2015 May
Betesil (betamethasone valerate adhesive plaster)	Vol 3 No 13	6	2009 December
Bethamethasone/calcipotriol gel	Vol 3 No 4	4	2009 April
Betmiga	Vol 7 No 14	1	2013 August
Betmiga	Vol 9 No 20	7	2015 November
Betoptic	Vol 9 No 6	2	2015 May
Bevacizumab	Vol 4 No 12	9	2010 August
Bevacizumab	Vol 7 No 14	7	2013 August
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer NICE TA263	Vol 7 No 4	11	2013 February
Bevacizumab for the first line treatment of metastatic breast cancer	Vol 2 No 13	5	2008 August
Bevacizumab for the treatment of non-small-cell lung cancer	Vol 2 No 13	6	2008 August
Bevacizumab for treating relapsed platinum resistant epithelial ovarian, fallopian tube or primary peritoneal cancer - NICE TA353	Vol 9 No 20	9	2015 November
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer	Vol 5 No 8	10	2011 May
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer	Vol 5 No 8	10	2011 May
Bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and or metastatic renal cell carcinoma	Vol 3 No 11	10	2009 October
Bexsero	Vol 8 No 4	3	2014 February
Bexsero	Vol 9 No 8	5	2015 May
Bexsero	Vol 9 No 18	5	2015 November
Bicalutamide (Amber)	Vol 2 No 3	9	2008 April
Bilastine 20mg tablets	Vol 5 No 15	4	2011 September
Bimatoprost	Vol 2 No 18	5	2008 November
Bimatoprost	Vol 9 No 6	1	2015 May
Bimatoprost 0.01% Eye Drops	Vol 4 No 14	3	2010 September
Bimatoprost 300mcg / timolol 5mg per mil eye drops	Vol 9 No 6	2	2015 May
Bimatoprost 300mcg per mil drops (Lumigan) discontinuation	Vol 9 No 6	8	2015 May

Bimatoprost 300mcg/ml (0.03%) preservative-free single dose eye drops-approved use AMBER	Vol 7 No 17	7	2013 October
Bimatoprost	Vol 8 No 4	4	2014 February
Binosto	Vol 10 No 3	3	2016 February
Biosimilar insulin glargine 100 units/ml injection	Vol 9 No 21	6	2015 December
Biosimilar Insulin Products high strength fixed combination - minimising the risk of medication error	Vol 9 No 9	13	2015 June
Bipolar disorder	Vol 7 No 14	8	2013 August
Bisphosphonates	Vol 4 No 7	7	2010 May
Bisphosphonates and Atrial Fibrillation	Vol 2 No 13	7	2008 August
Bisphosphonates and atrial fibrillation	Vol 3 No 4	7	2009 April
Bisphosphonates and atrial fibrillation and atrial flutter	Vol 3 No 5	8	2009 May
Bisphosphonates and cancer risk	Vol 4 No 20	6	2010 November
Bisphosphonates and osteonecrosis of the jaw	Vol 3 No 13	14	2009 December
Bisphosphonates: atypical femoral fractures.	Vol 5 No 12	9	2011 July
Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal	Vol 10 No 3	10	2016 February
Bivalirudin for the treatment of st-segment-elevation myocardial infarction	Vol 5 No 18	11	2011 December
Bladder Cancer	Vol 5 No 12	2	2011 July
Blood Glucose - self monitoring	Vol 3 No 5	8	2009 May
Blood glucose and cardiovascular outcomes	Vol 3 No 8	5	2009 August
BNF 1.6.4 Osmotic laxatives	Vol 8 No 1	10	2014 January
BNF 2.5.5 Drugs affecting the renin angiotensin system	Vol 8 No 1	10	2014 January
BNF 2.6.2 Calcium channel blockers	Vol 8 No 1	10	2014 January
Boceprevir	Vol 9 No 1	7	2015 February
Bonviva	Vol 3 No 10	4	2009 October
Borderline personality disorder - Treatment and management	Vol 3 No 5	10	2009 May
Bortezomib and Thalidomide for first line treatment of multiple myeloma	Vol 5 No 17	9	2011 October
Bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation	Vol 8 No 16	7	2014 September
Bortezomib monotherapy for relapsed multiple myeloma	Vol 1 No 8	7	2007 December
Bosutinib for previously treated chronic myeloid leukaemia November 2013	Vol 8 No 1	13	2014 January
Bovine Insulins	Vol 11 No 15	5	2017 November
Bowel Cancer Screening Programme	Vol 4 No 1	8	2010 January / Feb

Bowel Cleansing Solutions (Oral) - NPSA Reducing risk of harm	Vol 3 No 4	15	2009 April
Bowel Cleansing Solutions (oral) - Reducing Risk of Harm from	Vol 4 No 8	1	2010 May
Braltus (Tiotropium) -safety update	Vol 12 No 7	6	2018 August
Bramox	Vol 9 No 21	11	2015 December
Brancico XL (Quetiapine MR)	Vol 12 No 7	6	2018 August
Breast Cancer - early and locally advanced diagnosis and treatment	Vol 3 No 7	11	2009 June
Breast cancer, advanced. Diagnosis and treatment	Vol 3 No 7	14	2009 June
Bretuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma	Vol 11 No 15	7	2017 November
Brimonidine 0.2% / timolol 0.5% eye drops	Vol 9 No 6	3	2015 May
Brimonidine 0.2% eye drops	Vol 9 No 6	3	2015 May
Brimonidine gel - Mirvaso	Vol 11 Vol 12	4	2017 September
Brimonidine gel (Mirvaso): Risk of exacerbation of rosacea	Vol 11 No 1	12	2017 February
Brimonidine tartrate 3mg/g gel	Vol 8 No 13	2	2014 July
Brimonidine tartrate 3mg/g gel	Vol 9 No 8	8	2015 May
Brinzolamide 1% brimonidine 0.2%	Vol 9 No 6	3	2015 May
Brinzolamide 1% eye drops	Vol 9 No 6	3	2015 May
Brivaracetam	Vol 12 No 6	2	2018 May
Brivaracetam 10mg, 25mg, 50mg, 75mg and 100mg tablets and 10mg/ml oral solution	Vol 10 No 13	5	2016 August
Briviact	Vol 12 No 6	2	2018 May
Broad spectrum antimicrobials	Vol 7 No 13	1	2013 August
Bromfenac eye drops 900microgram/ml	Vol 6 No 3	8	2012 January
Buccal Midazolam (Buccolam) new authorised medicine for paediatric use - care needed when transferring from unlicensed formulations	Vol 6 No 2	12	2012 January
Buccolam	Vol 6 No 5	4	2012 February
Buccolam(Midazolam Hydrochloride)	Vol 12 No 2	4	2018 January
Budenofalk 2mg/dose rectal foam	Vol 11 No 10	2	2017 June
Budesonide	Vol 9 No 7	2	2015 April
Budesonide 200microgram/formoterol 6 microgram per actuation metered does inhale (Symibcort PMDI)	Vol 10 No 16	5	2016 October
Budesonide 2mg/dose rectal foam	Vol 11 No 10	2	2017 June
Budesonide 3mg castro-resistant capsules	Vol 9 No 12	2	2015 July
Budesonide 3mg gastro-resistant release gastro-resistant tablets	Vol 9 No 12	2	2015 July
Budesonide 64 mcg nasal spray	Vol 11 No 7	4	2017 March
Budesonide 9mg gastro-resistant granules	Vol 9 No 12	2	2015 July
Budesonide 9mg multimatrix tablets (cortiment)	Vol 10 No 16	9	2016 October

Budesonide 9mg sustained release gastro resistant tables (Cortiment) New Drug Assessment	Vol 9 No 12	5	2015 July
Budesonide CFC free MDInhalers 100mcg and 200mcg	Vol 3 No 7	7	2009 June
Budesonide/Formoterol Fumerate Dihydrate Breath Actuated dry Powder Inhaler (DuoResp Spiromax)	Vol 8 No 20	5	2014 December
Buprenorphine once weekly transdermal patches Butec, Butrans, Panitaz, Reletrans, Sevodyne	Vol 10 No 17	6	2016 December
Buprenorphine patches	Vol 3 No 11	3	2009 October
Buprenorphine Patches	Vol 8 No 15	5	2014 August
Buprenorphine twice weekly transdermal patches Bupeaze, Hapoctasin, Transtec	Vol 10 No 17	7	2016 December
Bupropion Hydrochloride (Zyban)	Vol 8 No 17	7	2014 October
BuTrans	Vol 3 No 11	3	2009 October
Butrans and Transtec	Vol 8 No 15	5	2014 August
Bydureon	Vol 5 No 18	3	2011 December
Bydureon	Vol 9 No 18	3	2015 November
Byetta	Vol 1 No 5	5	2007 October
Byetta	Vol 2 No 9	2	2008 May/June
Byetta	Vol 3 No 4	14	2009 April
C Difficile	Vol 7 No 13	4	2013 August
C Difficile associated disease (CDAD)	Vol 7 No 13	4	2013 August
C1-esterase inhibitor human injection (Berinert)	Vol 3 No 11	7	2009 October
Cabazitaxel 60 mg concentrate and solvent for solution for infusion	Vol 10 No 11	2	2016 August
Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel containin regimen - TA255 - (MAY 2012)	Vol 6 No 18	5	2012 September
Cabozantinib	Vol 11 No 13	7	2017 October
Calceos Chewable tablets	Vol 9 No 8	6	2015 May
Calcipotriol/betamethasone gel (Dovobet)	Vol 5 No 8	3	2011 May
Calcitonin (Miacalcic): increased risk of cancer with long-term use – all intra-nasal formulations for osteoporosis to be withdrawn	Vol 6 No 16	12	2012 September
Calcium & Vitamin D Supplementation	Vol 9 No 8	6	2015 May
Calcium Acetate	Vol 8 No 19	6	2014 December
Calcium and Vitamin D	Vol 2 No 6	4	2008 May
Calcium and Vitamin D	Vol 2 No 9	8	2008 May/June
Calcium and Vitamin D supplementation	Vol 4 No 6	9	2010 May
Calcium and Vitamin D Supplementation updated guidance	Vol 10 No 14	6	2016 October
Calcium and Vitamin D: Studies of cardiovascular risk	Vol 6 No 2	13	2012 January

Calcium supplements and risk of MI and CV Events	Vol 4 No 18	13	2010 October
Calmurid cream	Vol 9 No 5	4	2015 May
Calogen Liquid	Vol 8 No 8	10	2014 May
Caloreen	Vol 8 No 8	12	2014 May
Calshake	Vol 8 No 8	7	2014 May
Camcolit	Vol 9 No 21	13	2015 December
Canagliflozin	Vol 8 No 14	4	2014 August
Canagliflozin	Vol 9 No 15	2	2015 October
Canagliflozin	Vol 10 No 10	12	2016 July
Canagliflozin	Vol 11 No 6	11	2017 March
Canagliflozin	Vol 11 No 10	4	2017 May
Canagliflozin (involana, vokanamet): Signal of increase risk of lower extremity amputations observed in trial in high cardiovascular risk patients	Vol 10 No 13	10	2016 August
Canagliflozin (Risk of Diabetic Ketocidosis)	Vol 9 No 12	10	2015 July
Canagliflozin/metformin (Vokanamet)	Vol 8 No 20	7	2014 December
Canakinumab for treating systemic juvenile idiopathic arthritis terminated appraisal November 2014	Vol 8 No 4	10	2014 February
Candesartan and valsartan: generic versus other Angiotensin Receptor Blockers	Vol 6 No 16	10	2012 September
Canestan Combi Pack	Vol 8 No 1	11	2014 January
Cangrelor	Vol 9 No 15	2	2015 October
Cannabis	Vol 8 No 16	10	2014 September
Cannabis (THC)	Vol 9 No 7	7	2015 April
Capecitabine - Treatment of advanced gastric cancer	Vol 4 No 18	10	2010 October
Capecitabine risk of severe skin reaction	Vol 8 No 6	6	2014 March
Caphosol solution	Vol 3 No 13	6	2009 December
Captopril oral solution 5mg in 5ml and 25mg in 5ml	Vol 8 No 10	8	2014 May
Carbomer 0.2% ophthalmic gel (Viscotears), treatment of dry eyes, approved for joint formulary, alternative first line carbomer preparation	Vol 7 No 6	1	2013 June
Carbomer 980 ophthalmic 980 ophthalmic gel, treatment of dry eyes, approved for joint formulary alternative first line, carboner preparation	Vol 7 No 6	1	2013 June
Cardiovascular safety of NSAIDs	Vol 5 No 5	10	2011 March
Care Homes - Use of Medicines	Vol 4 No 3	8	2010 March
Carfilzomib	Vol 11 No 13	6	2017 October
Carisoprodol	Vol 2 No 3	10	2008 April
Carmustine implants for the treatment of recurrent glioblastoma multiforme	Vol 2 No 13	6	2008 August
Carteolol 1% eye drops	Vol 9 No 6	10	2015 May
Casilan 90	Vol 8 No 8	12	2014 May
Castric Gancer - Capecitabine	Vol 4 No 18	10	2010 October

CDAD	Vol 7 No 13	4	2013 August
Cefixime	Vol 9 No 15	3	2015 July
Cellcept	Vol 9 No 4	1	2015 March
Celvapan and Pandemrix	Vol 3 No 13	10	2009 December
Cephalosporin	Vol 7 No 13	1	2013 August
Cerazette75mcg-review patients to a more lower cost brand	Vol 7 No 17	6	2013 October
Certolizumab Pegol - Treatment of rheumatoid arthritis	Vol 4 No 6	11	2010 May
Cerumol ear drops	Vol 11 No 4	10	2017 March
Cervarix	Vol 1 No 8	6	2007 December
Cetirizine	Vol 11 No 4	3	2017 March
Cetirizine	Vol 11 No 7	1	2017 March
Cetraban ointment and lotion	Vol 10 No 7	9	2016 May
Cetraben	Vol 11 No 4	10	2017 March
Cetraben cream	Vol 9 No 5	3	2015 May
Cetrizine	Vol 9 No 7	4	2015 April
Cetuximab	Vol 11 No 10	6	2017 May
Cetuximab (recurrent or metastatic squamous cell cancer of the head & neck)	Vol 11 No 15	7	2017 November
Cetuximab for the first line treatment of metastatic colorectal cancer	Vol 3 No 11	9	2009 October
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck	Vol 2 No 13	5	2008 August
Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin containing chemotherapy	Vol 2 No 13	7	2008 August
Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck	Vol 3 No 10	10	2009 October
Cetuximab, Bevacizumab and Panitumumab for the treatment of metastatic colorectal cancer after first line chemotherapy. NICE TA242	Vol 6 No 7	6	2012 May
Chest Pain	Vol 4 No 9	8	2010 June
Chloramphenical eye preparations for conjunctivitis	Vol 4 No 1	4	2010 January / Feb
Chloramphenicol	Vol 9 No 15	3	2015 July
Chlorhexidine Solution	Vol 9 No 1	8	2015 February
Chlorquine	Vol 11 No 4	6	2017 March
Cholestagel	Vol 2 No 3	3	2008 April
Cholestagel	Vol 8 No 10	9	2014 May
Chronic Asthma Guidance	Vol 9 No 17	1	2015 November
Chronic Fatigue Syndrome	Vol 1 No 6	6	2007 November
Chronic Heart Failure	Vol 5 No 8	11	2011 May
Chronic Kidney Disease	Vol 3 No 4	9	2009 April
Chronic Obstructive Pulmonary Disease	Vol 9 No 17	1	2015 November
Chronic Obstructive Pulmonary Disease in Primary and Secondary Care	Vol 5 No 1	1	2011 January

Cialis Once-A-Day	Vol 3 No 4	5	2009 April
Ciclosporin	Vol 4 No 1	6	2010 January / Feb
Cilostazol	Vol 8 No 9	2 & 10	2014 May
Cilostazol	Vol 9 No 15	3	2015 July
Cilostazol for the treatment of intermittent claudication in people with peripheral arterial disease	Vol 5 No 12	7	2011 July
Cimizt	Vol 8 No 9	4	2014 May
Cinacalcet	Vol 8 No 10	11	2014 May
Cinacalcet - Shared Care Guidelines	Vol 1 No 6	7	2007 November
Cinutren Dessert	Vol 8 No 8	10	2014 May
Circadin	Vol 2 No 13	3	2008 August
Circadin	Vol 8 No 13	6	2014 July
Citalopram – suspected drug interaction with cocaine	Vol 10 No 14	11	2016 October
Citalopram and escitalopram associated with does-dependant QT interval prolongation	Vol 6 No 2	10	2012 January
Citalopram Associated with dose-dependent QT interval prolongation	Vol 5 No 18	6	2011 December
Clarithromycin	Vol 9 No 4	7	2015 March
Clarithromycin in pharyngitis / sore throat / tonsillitis	Vol 8 No 22	1	2014 December
CliniFast Elasticated Tubular Bandage	Vol 10 No 5	7	2016 March
Clipper (beclometasone) 5mg tablets	Vol 1 No 5	8	2007 October
Clofoam 10% foam	Vol 11 No 10	2	2017 June
Clonazepam	Vol 8 No 16	10	2014 September
Clonazepam	Vol 9 No 7	7	2015 April
Clopidogrel	Vol 7 No 9	1	2013 June
Clopidogrel - risk of acquired haemophilia	Vol 8 No 4	9	2014 February
Clopidogrel 75mg tablets	Vol 3 No 10	3	2009 October
Clopidogrel and modified release dipyridamole for the prevention of occlusive vascular events	Vol 5 No 5	7	2011 March
Clopidogrel and PPIs - Interaction	Vol 3 No 10	12	2009 October
Clopidogrel and PPIs - interaction	Vol 4 No 7	8	2010 May
Clopidogrel and PPIs population based study	Vol 3 No 2	5	2009 March
Clopidogrel generic prescribing	Vol 3 No 13	4	2009 December
Clopidogrel interaction between proton pump inhibitors	Vol 3 No 8	9	2009 August
Clopixol acuphase	Vol 6 No 12	3	2012 June
Clopixol Acuphase	Vol 9 No 7	1	2015 April
Clopixol Dept/Clopixol Conc	Vol 9 No 7	1	2015 April
Clopixol Injection	Vol 9 No 7	1	2015 April
Clostridium difficile	Vol 7 No 13	1	2013 August
Clostridium difficile infection	Vol 4 No 14	6	2010 September
Clostridium difficile	Vol 2 No 19	6	2008 December
Clostridium difficile reminder	Vol 2 No 2	6	2008 February
Clozapine	Vol 12 No 2	7	2018 January

CoaguChek XS	Vol 9 No 1	5	2015 February
Co-amoxiclav in acute rhinosinusitis	Vol 8 No 22	2	2014 December
Coban 2 and Coban 2 Lite Multi-Layer Compression Bandage Kit	Vol 8 No 11	8	2014 June
Cocaine	Vol 8 No 16	10	2014 September
Cocaine and a cocaine metabolit BZE	Vol 9 No 7	7	2015 April
Co-Danthrusate 50mg/60mg capsules (Danthron/Docusate)	Vol 10 No 14	8	2016 October
Codeine	Vol 5 No 2	7	2011 February
Codeine - addiction to	Vol 5 No 15	10	2011 September
Codeine containing pain relief for children: safety review	Vol 7 No 4	11	2013 February
Codeine for cough and cold - restricted use in children	Vol 9 No 9	12	2015 June
Codeine linctus	Vol 11 No 4	3	2017 March
Codeine use in children	Vol 7 No 14	18	2013 August
Coeliac disease	Vol 3 No 11	12	2009 October
Coeliac Uk	Vol 8 No 3	6	2014 January
Colecalciferol	Vol 8 No 4	4	2014 February
Colecalciferol 1000IU and 25000IU Tablets (Stexerol-D3)	Vol 10 No 3	3	2016 February
Colecalciferol 20,000IU capsules (Bio-Vitamin D3)	Vol 6 No 19	2	2012 October
Colecalciferol 20,000IU Capsules (Bio-Vitamin D3)	Vol 6 No 19	8	2012 October
Colecalciferol 20,000IU capsules (Dekristol)	Vol 6 No 19	2	2012 October
Colecalciferol 800iu tablets (Desunin)	Vol 7 No 4	1	2013 February
Colesevelam	Vol 2 No 3	3	2008 April
Colesevelam 625mg capsules	Vol 9 No 8	10	2015 May
Colesevelam 625mg capsules for the treatment of bile acid malabsorption	Vol 8 No 10	9	2014 May
Colistimethate Sodium	Vol 9 No 1	7	2015 February
Combigan	Vol 9 No 6	3	2015 May
Combined hormonal contraceptives	Vol 8 No 7	10	2014 April
Combined Hormonal Contraceptives	Vol 8 No 10	14	2014 May
Combodart	Vol 4 No 18	5	2010 October
Commonly occurring infections in Lincolnshire Primary Care: Winter 2012/13 Update - Guidelines	Vol 7 No 1	1	2012 January
Commonly Occuring Infections in Primary Care - Lincolnshire Guidelines for the treatment of - Winter 2015/16	Vol 9 No 22	1	2015 December
Community acquired pneumonia	Vol 7 No 13	8	2013 August
Comparing dabigatran, rivaroxiban & apixaban	Vol 8 No 21	18	2014 December
Complan and Build Up	Vol 8 No 8	2	2014 May
Complan Shake	Vol 8 No 8	7	2014 May
Constella approved use for IBS	Vol 7 No17	3	2013 October
Contra - indications of apixaban, dabigatran & rivaroxiban	Vol 8 No 21	14	2014 December

Controlled Drug Legislation -Changes	Vol 9 No 20	4	2015 November
Controlled drugs	Vol 8 No 7	12	2014 April
Controlled drugs and driving	Vol 8 No 20	11	2014 December
COPD	Vol 5 No 9	8	2011 May
Co-Proxamol	Vol 11 No 4	4	2017 March
Co-proxamol	Vol 12 No 3	1	2018 June
Co-Proxamol Reminder	Vol 1 No 8	7	2007 December
Co-Proxamol Update	Vol 2 No 1	5	2008 January
Cornflast Elasticated Tubular Bandage	Vol 10 No 5	7	2016 March
Corticosteroid injections	Vol 8 No 1	11	2014 January
Cortiment New Drug Assessment	Vol 9 No 12	5	2015 July
Cough and cold medicines for children - over the counter	Vol 3 No 5	13	2009 May
Coversyl - Product discontinuation	Vol 2 No 3	5	2008 April
Coversyl Plus - Product discontinuation	Vol 2 No 3	5	2008 April
Covonia	Vol 11 No 4	4	2017 March
Cow Gate Anti -Reflux Milk	Vol 11 No 4	7	2017 March
Cozaar Comp	Vol 2 No 6	6	2008 May
Creon 40,000 (Pancreatin) 40,000 gastro-resistant capsule - product supply problem	Vol 9 No 9	9	2015 June
Crizotinib	Vol 7 No 21	11	2013 December
Crizotinib (Xalkori) risk of cardiac failure	Vol 9 No 21	14	2015 December
Crizotinib for previously treated non small cell lung cancer associated with an anaplastic lymphoma kinase fusion gene September 2013	Vol 7 No 21	11	2013 December
Crystacide	Vol 3 No 10	4	2009 October
Cyprindiol	Vol 7 No 14	17	2013 August
Dabigatran	Vol 10 No 1	4	2016 January
Dabigatran	Vol 8 No 21	9	2014 December
Dabigatran (FAQs)	Vol 7 No 15	15	2013 August
Dabigatran etexilate	Vol 9 No 7	2	2015 April
Dabigatran etexilate	Vol 9 No 7	5	2015 April
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults	Vol 2 No 18	8	2008 November
Dabigatran for the prevention of stroke in patients with atrial fibrillation (Second Edition)	Vol 7 No 16	1	2013 October
Dabigatran in newly diagnosed AF	Vol 8 No 21	6	2014 December
Dabigatran risk of serious haemorrhage - need for renal function testing	Vol 6 No 4	10	2012 February
Dabigatran, Guidance on the prescribing of for the prevention of stroke and systemic embolism in atrial fibrillation	Vol 6 No 13	1	2012 August
Dabrafenib	Vol 9 No 1	4	2015 February
Daclatasvir 30mg and 60mg tablets	Vol 10 No 2	2	2016 January
Daclizumab	Vol 11 No 10	5	2017 June
Daclizumab suspension	Vol 12 No 6	5	2018 May
Daktarin OTC gel	Vol 11 No 15	7	2017 November

Dapafliglozine	Vol 7 No 21	10	2013 December
Dapagliflozin	Vol 7 No 14	1	2013 August
Dapagliflozin	Vol 7 No 14	8	2013 August
Dapagliflozin	Vol 8 No 14	7	2014 August
Dapagliflozin	Vol 8 No 20	7	2014 December
Dapagliflozin	Vol 9 No 15	3	2015 July
Dapagliflozin	Vol 11 No 6	10	2017 March
Dapagliflozin (Risk of Diabetic Ketocidosis)	Vol 9 No 12	10	2015 July
Dapagliflozin / Metformin	Vol 11 No 6	2	2017 March
Dapoxetine 30mg and 60mg tablets (Priligy)	Vol 8 No 1	5	2014 January
Daptomycin: risk of eosinophilic pneumonia	Vol 5 No 7	13	2011 april
Darbepoetin	Vol 9 No 2	7	2015 February
Darbepoetin Alfa for cancer treatment induced anaemia	Vol 2 No 12	6	2008 July
Darbepoetin alfa prefilled syringe (Aranesp) - AMBER shared care guideline available. Approved for Joint Formulary for this indication	Vol 7 No 10	2	2013 June
Darifenacin 15mg tablets	Vol 8 No 10	7	2014 May
Darifenacin 7.5mg tablets	Vol 8 No 10	7	2014 May
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib resistanc chronic myeloid leukaemia (CML) and dasatinib and nilotinib for people with CML for whom treatment has failed because of intolerance. NICE TA241	Vol 6 No 7	5	2012 May
Dasatinib, Nilotinib and Standard-Dose Imatinib for the first-line treatment of chronic myeloid leukamia - TA251 (APRIL 2012)	Vol 6 No 18	4	2012 September
Daxas risk of suicidal behaviour	Vol 7 No 7	2	2013 May
Decapeptyl & Leuprorelin patient letter ULH	Vol 11 No 5	6	2017 February
Decapeptyl SR	Vol 7 No 21	7	2013 December
Decapeptyl SR	Vol 11 No 5	1	2017 February
Deep Freeze topical	Vol 11 No 4	8	2017 March
Deep Heat topical	Vol 11 No 4	8	2017 March
Deep Vein Thrombosis	Vol 7 No 15	1	2013 August
Degarelix Acetate Injection	Vol 4 No 12	3	2010 August
Degarelix for treating advanced hormone-dependent prostate cancer NICE TA404	Vol 10 No 16	10	2016 October
Denosumab	Vol 8 No 18	8	2014 October
Denosumab - fatal cases of severe symptomatic hypocalcaemia and risk of hypocalcaemia	Vol 7 No 2	13	2013 January
Denosumab - Prolilia, Xgeva	Vol 11 Vol 12	3	2017 September
Denosumab 60mg (Prolia) rare cases of atypical femoral fracture with long term use	Vol 7 No 7	2	2013 May

Denosumab and bisphosphonates and osteonecrosis of the jaw; Latanoprost (Xalatan) increased reporting of eye irritation since reformulation	Vol 9 No 15	11	2015 October
Denosumab for the prevention of osteoporotic fractures in postmenopausal women	Vol 5 No 3	6	2011 February
Denosumab for the treatment of therapy induced bone loss in non metastatic prostate cancer	Vol 4 No 18	11	2010 October
Depo-Medrone Injection	Vol 8 No 1	11	2014 January
Depot Antipsychotic drugs	Vol 8 No 6	5	2014 March
Depot Antipsychotic Medication Prescribing	Vol 6 No 19	3	2012 October
DermaSilk	Vol 8 No 14	9	2014 August
Dermol	Vol 11 No 4	10	2017 March
Dermol cream & ointment	Vol 9 No 5	3	2015 May
Desloratadine	Vol 11 No 7	2	2017 March
Desmopressin oral lyophilisate tables	Vol 12 No 6	2	2018 May
Desogestrel 150 microgram tablets	Vol 8 No 9	1	2014 May
Desogestrel 75 microgram tablets	Vol 8 No 9	1 & 5	2014 May
Desogestrel 75mcg-review patients to a more lower cost brand	Vol 7 No 17	6	2013 October
Desunin	Vol 7 No 4	1	2013 February
Determir insulin - new trial in brief	Vol 4 No 6	11	2010 May
Detrunorm	Vol 8 No 10	7	2014 May
Detrunorm XL	Vol 8 No 10	7	2014 May
Detrusitol	Vol 8 No 10	7	2014 May
Dexamethasone injection reformulation	Vol 8 no 20	10	2014 December
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion	Vol 5 No 17	9	2011 October
Dexamethasone intravitreal implant for treating diabetic macular oedema NICE TA349	Vol 9 No 18	11	2015 November
Dexamfetamine	Vol 8 No 10	11	2014 May
Dexibuprofen tablets	Vol 2 No 19	3	2008 December
Dexketoprofen tablets	Vol 2 No 19	4	2008 December
Diabetes - Type 2	Vol 2 No 14	1	2008 September
Diabetes in pregnancy - Management of diabetes and its complications from pre-conception to the postnatal period	Vol 2 No 10	8	2008 July
Diabetes type 2 - blood pressure control	Vol 4 No 7	7	2010 May
Diabetes Type 2 - the management of	Vol 3 No 9	3	2009 August
Diabetic ketoacidosis - new trial in brief	Vol 4 No 6	11	2010 May
Diabetic Ketocidosis	Vol 9 No 12	10	2015 July
Diagnosis and Management of Vitamin D Deficiency in Primary Care - Summary Algorithm	Vol 6 No 19	8	2012 October
Diamorphine	Vol 8 No 16	10	2014 September
Diamorphine Shortage	Vol 10 No 3	8	2016 February

Diamox	Vol 9 No 6	3	2015 May
Dianeal, Extraneal and Nutrineal peritoneal dialysis solutions: risk of aseptic peritonitis due to presence of endotoxin	Vol 5 No 7	14	2011 April
Dianette	Vol 7 No 14	17	2013 August
Diarrhoea and vomiting in children	Vol 3 No 10	10	2009 October
Diazepam	Vol 8 No 16	10	2014 September
Diazepam	Vol 9 No 7	7	2015 April
Diclofenac	Vol 7 No 14	1	2013 August
Diethylamine salicylate topical	Vol 11 No 4	8	2017 March
Dificlir	Vol 7 No 2	4	2013 January
Diltiazem 120mg, 180mg, 240mg and 300mg SR capsules (Zemtard XL)	Vol 10 No 13	7	2016 August
Diltiazem 120mg, 180mg, 240mg, 300mg and 360mg SR capsules (Viazem XL)	Vol 10 No 13	7	2016 August
Diltiazem 60mg modified release tablets (Retalzem)	Vol 10 No 13	6	2016 August
Diltiazem 60mg modified release tablets (Tildiem)	Vol 10 No 13	7	2016 August
Diltiazem prescribing notes with simvastatin	Vol 8 No 23	8	2014 December
Dimethyl Fumarate	Vol 8 No 19	11	2014 December
Dimethyl fumarate for treating moderate to severe plaque psoriasis	Vol 11 No 15	7	2017 November
Dimethyle fumarate	Vol 9 No 8	12	2015 May
Dipeptidyl peptidase-4 (DPP-4) Inhibitors or Gliptins	Vol 6 No 3	3	2012 January
Dipeptidylpeptidase-4 inhibitors (DPP-4 inhibitors or gliptins) - risk of acute pancreatitis.	Vol 7 No 2		2013 January
Dipipanone	Vol 5 No 8	6	2011 May
Dipipanone 10mg/cyclizine30mg	Vol 11 No 4	5	2017 March
Diprobace cream & ointment	Vol 9 No 5	2	2015 May
Dipyridamole	Vol 11 No 8	10	2017 April
Dipyridamole /aspirin MR caps	Vol 11 No 8	9	2017 April
Domperidone	Vol 8 No 12	4	2014 June
Domperidone and possible increased cardiac risk	Vol 6 No 3	10	2012 January
Domperidone risk of cardiac side effects	Vol 8 No 18	11	2014 October
Domperidone –small risk of serious ventricular arrhythmia and sudden cardiac death.	Vol 6 No 12	9	2012 June
Domperidone with Apomorphine	Vol 10 No 10	8	2016 July
Donation of patient returned medicines to charitable organisations	Vol 5 No 8	7	2011 May
Donepezil	Vol 8 No 10	11	2014 May
Donepezil	Vol 1 No 6	5	2007 November
Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimers's Disease	Vol 5 No 11	4	2011 June

Dopamine agonists for restless legs syndrome	Vol 5 No 11	10	2011 June
Doripenem (Doribax): current dosing regimen is insufficient in some patients – updated dosing recommendations	Vol 6 No 16	12	2012 September
Dorzolamide 2% eye drops	Vol 9 No 6	3	2015 May
Dorzolamide Hyrdochloride/Timolol Maleate (Cosopt)	Vol 8 No 10	14	2014 May
Dorzolamide hyrochloride / timolol (cosopt) preservative free single dose eye drops: report of eye injury	Vol 8 No 4	9	2014 February
Dosulepin	Vol 12 No 3	2	2018 June
Doublebase	Vol 11 No 4	10	2017 March
Doublebase gel	Vol 9 No 5	3	2015 May
Dovobet (Calcipotriol/betamethasone gel)	Vol 5 No 8	3	2011 May
Doxazosin 2mg tablets	Vol 8 No 10	7	2014 May
Doxazosin prolonged release	Vol 12 No 3	3	2018 June
Doxycycline 100mg capsules	Vol 9 No 8	10	2015 May
Doxycycline 40mg modified release capsules	Vol 4 No 9	3	2010 June
Doxycycline 40mg modified release capsules (MR)	Vol 7 No 2	5	2013 January
Doxycycline 40mg modified release capsules (MR) (Efracea)	Vol 10 No 13	3	2016 August
Doxycycline in acute rhinosinusitis	Vol 8 No 22	2	2014 December
DreamSkin	Vol 8 No 14	9	2014 August
Dronedarone	Vol 5 No 18	8	2011 December
Dronedarone for the treatment of non-permanent atrial fibrillation	Vol 5 No 5	5	2011 March
Dronedarone for the treatment of non-permanent atrial fibrillation	Vol 6 No 2	9	2012 January
Drospirone 3mg tablets	Vol 8 No 9	5	2014 May
Drug Induced QT Prolongation	Vol 9 No 14	1	2015 September
Drug Tariff - Changes April and July 2012	Vol 6 No 12	12	2012 June
Dual chamber pacemakers	Vol 9 No 2	8	2015 February
Dulaglutide solution for injection	Vol 9 No 18	5	2015 November
Duo Trav	Vol 9 No 6	2	2015 May
Duocal	Vol 8 No 8	12	2014 May
DuoResp Spiromax	Vol 8 No 20	5	2014 December
Dutasteride (Avodart) capsules	Vol 4 No 18	5	2010 October
DVT	Vol 7 No 15	1	2013 August
DVT and Pulmonary Embolism	Vol 7 No 15	1	2013 August
Dymista	Vol 9 No 7	1	2015 April
Dymista	Vol 9 No 7	2	2015 April
Dymista nasal spray	Vol 7 No 12	3	2013 July
Dysmista nasal spray	Vol 12 No 2	2	2018 January
E45	Vol 11 No 4	10	2017 March
E45 cream	Vol 9 No 5	2	2015 May
E45 Cream accidental death of a patient	Vol 10 No 17	10	2016 December
Easyhaler Budenonide	Vol 12 No 6	2	2018 May

Ebixa	Vol 5 No 3	10	2011 February
Edoxaban	Vol 10 No 1	5	2016 January
Edronax	Vol 5 No 18	3	2011 December
Edronax	Vol 5 No 3	9	2011 February
Efexor XL for Generalised Anxiety Disorder (GAD) and Social Phobia	Vol 2 No 12	4	2008 July
Effentora	Vol 3 No 5	4	2009 May
Effentora	Vol 12 No 3	1	2018 June
Efient	Vol 3 No 11	5	2009 October
Efient	Vol 8 No 6	6	2014 March
Eflornithine 11.5% Cream	Vol 6 No 3	8	2012 January
Eflornithine 11.5% cream	Vol 11 No 6	8	2017 March
Eflornithine 11.5% Cream (Vaniqa)	Vol 11 No 6	8	2017 March
Efracea	Vol 4 No 9	3	2010 June
Efracea	Vol 7 No 2	5	2013 January
Eklira Genuair	Vol 7 No 2	7	2013 January
Eliquis	Vol 10 No 1	4	2016 January
Eliquis (apixaban) for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE TA245	Vol 6 No 7	7	2012 May
Eliquis (FAQs)	Vol 7 No 15	15	2013 August
Eliquis for the prevention of stroke and systemic embolism in atrial fibrillation (Second Edition) NICE TA 275	Vol 7 No 16	1	2013 October
Ellaone	Vol 4 No 1	3	2010 January / Feb
Ella-one	Vol 6 No 16	5	2012 September
Eloine and daylette	Vol 10 No 4	2	2016 February
Eltrombopag for the treatment of chronic immune idiopathic thrombocytopenic purpura	Vol 5 No 2	5	2011 February
Eluxadoline	Vol 12 No 4	4	2018 May
Eluxadoline for IBS with diarrhoea TA 471	Vol 12 No 2	8	2018 January
Emedastine eye drops /Emadine	Vol 11 No 7	6	2017 March
Emend	Vol 6 No 3	7	2012 January
Emerres	Vol 9 No 20	6	2015 November
Emollients - Prescribing for Dry Skin Conditions	Vol 9 No 5	1	2015 May
Emollients with no or low paraffin content	Vol 10 No 5	8	2016 March
Emollin Emollient Spray	Vol 1 No 5	8	2007 October
Emollin spray	Vol 9 No 5	4	2015 May
Empagliflozin	Vol 9 No 15	4	2015 July
Empagliflozin	Vol 11 No 6	11	2017 March
Empagliflozin (Risk of Diabetic Ketocidosis)	Vol 9 No 12	10	2015 July
Empagliflozin/empa-reg outcome	Vol 10 No 11	11	2016 August
Empagliflozin/metformin tablets	Vol 9 No 21	9	2015 December
Emselex	Vol 8 No 10	7	2014 May
Emulsifying ointment	Vol 9 No 5	4	2015 May
Encephalopathy	Vol 1 No 6	6	2007 November
Endocarditis	Vol 2 No 8	1	2008 May
Enfamil AR pre-thickened formula	Vol 11 No 4	8	2017 March

Enshake	Vol 8 No 8	7	2014 May
Ensure	Vol 8 No 8	2	2014 May
Ensure liquid	Vol 11 No 4	7	2017 March
Ensure Plus Crème	Vol 8 No 8	10	2014 May
Ensure Plus Fibre	Vol 8 No 8	8	2014 May
Ensure Plus Juice	Vol 8 No 8	9	2014 May
Ensure Plus Milkshake Style	Vol 8 No 8	6	2014 May
Ensure Plus Savoury	Vol 8 No 8	6	2014 May
Ensure Plus Yoghurt	Vol 8 No 8	8	2014 May
Ensure TwoCal	Vol 8 No 8	10	2014 May
Entecavir for the treatment of chronic hepatitis B	Vol 2 No 18	6	2008 November
Enzira	Vol 11 No 6	5	2017 March
Epaderm cream	Vol 9 No 5	3	2015 May
Epiduo	Vol 5 No 12	6	2011 July
Epilim Chronosphere	Vol 3 No 1	3	2009 January
Epilim Chronospheres	Vol 5 No 18	6	2011 December
Epinastine eye drops / Relestat	Vol 11 No 7	6	2017 March
Episenta	Vol 1 No 2	4	2007 July
Episenta	Vol 3 No 1	4	2009 January
Epistatus	Vol 3 No 2	2	2009 March
Epistatus (Midazolam Maleate)	Vol 12 No 2	4	2018 January
Eplerenon (Inspra) is approved for use in left ventricular dysfunction (LVEF < 30%) and heart failure (NYHA II)	Vol 7 No 11	3	2013 July
Eplerenone	Vol 1 No 4	4	2007 September
Epoetin	Vol 9 No 2	7	2015 February
Epoetin alfa prefilled syringe (Eprex) - AMBER shared care guideline available. Approved for Joint Formulary for this indication	Vol 7 No 10	2	2013 June
Epoetin Alfa, Epoetin Beta & Darbepoetin Alfa for cancer treatment induced anaemia	Vol 2 No 12	6	2008 July
Epoetin beta prefilled syring (NeoRecormon) - AMBER shared care guideline available. Approved for Joint Forumulary for this indication	Vol 7 No 10	2	2013 June
Erbitux	Vol 11 No 10	6	2017 May
Erectile Dysfunction	Vol 3 No 4	5	2009 April
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer (June 2012) TA258	Vol 7 No 2	11	2013 January
Erlotinib for the treatment of non-small-cell lung cancer	Vol 3 No 1	10	2009 January
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer	Vol 5 No 15	7	2011 September
Erythromycin	Vol 9 No 8	8	2015 May
Erythromycin in otitis media	Vol 8 No 22	2	2014 December
ESBLs	Vol 7 No 13	1	2013 August

Esmya	Vol 7 No 2	6	2013 January
Esomeprazole 40mg	Vol 9 No 4	6	2015 March
Esomeprazole/Naproxen 20mg/500mg tablets	Vol 5 No 5	3	2011 March
Estradiol valerate/dienogest combined oral contraceptive pill	Vol 3 No 13	5	2009 December
Estradiol/nojmegestrol 1.5mg/2.5mg tablet	Vol 7 No 14	1	2013 August
Esyma	Vol 12 No 6	5	2018 May
Esyma (Ulipristal acetate) 5mg tablets	Vol 11 No 11	2	2017 August
Etanercept	Vol 1 No 8	8	2007 December
Etanercept 50mg SB4 Biosimilar	Vol 10 No 7	10	2016 May
Etanercept for ankylosing spondylitis	Vol 2 No 12	6	2008 July
Etanercept for the treatment of psoriatic arthritis	Vol 4 No 20	5	2010 November
Etanercept, Infliximab, Rituximab, Adalimumab and Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	Vol 4 No 18	12	2010 October
Ethinylestradiol 30 microgram	Vol 8 No 1	11	2014 January
Ethinylestradiol 30 microgram tablets	Vol 8 No 9	1, 4 & 5	2014 May
Ethinylestradiol 35 microgram tablets	Vol 8 No 9	1 & 3	2014 May
Ethinylestradiol/desogestrel 150mcg- are expensive and should no longer be initiated in new patients	Vol 7 No 17	7	2013 October
Ethinylestradiol/etonogestrel vaginal ring	Vol 3 No 4	3	2009 April
Ethinylestradiol/etonogestrel vaginal ring	Vol 3 No 7	5	2009 June
Ethinylestradiol <50 micrograms	Vol 8 No 7	10	2014 April
Ethinylestradiol 0.02mg/drospirenone 3mg tablets (eloine and daylette)	Vol 10 No 4	2	2016 February
Etonogestrel (Nexplanon) 68mg Subdermal Implant	Vol 5 No 5	5	2011 March
Etonogestrel implant (Nexplanon)	Vol 8 No 19	9	2014 December
Etoricoxib (Arcoxia): revised dose recommendations for rheumatoid arthritis and ankylosing spondylitis	Vol 11 No 1	11	2017 February
Etidronate, risedronate, raloxifene, strontium ranelate, teiparatide and Alendronate for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)	Vol 2 No 19	7	2008 December
Eucreas	Vol 8 No 10	3	2014 May
Eumocream (glycerol 25%)	Vol 10 No 5	2	2016 March
Eurcreas	Vol 2 No 10	4	2008 July
European Medicines Agency Safety Review of Dronedarone (Multaq)	Vol 5 No 12	11	2011 July
Everolimus	Vol 9 No 15	4	2015 July
Everolimus for the second line treatment of advanced renal cell carcinoma	Vol 5 No 11	6	2011 June

Evista effective use for chemoprevention, when woman have no diagnosis for breast cancer	Vol 7 No 17	8	2013 October
Exelon	Vol 2 No 1	3	2008 January
Exelon	Vol 4 No 12	9	2010 August
Exembrol	Vol 7 No 7	8	2013 May
Exenatide	Vol 1 No 5	5	2007 October
Exenatide	Vol 2 No 9	2	2008 May/June
Exenatide	Vol 3 No 9	9	2009 August
Exenatide 2mg sustained release suspension for injection in a pre-filled pen	Vol 9 No 18	3	2015 November
Exenatide - risk of acute pancreatitis	Vol 3 No 4	14	2009 April
Exenatide (Byetta) injection in combination with insulin in type 2 diabetes mellitus	Vol 6 No 12	8	2012 June
Exenatide 2mg Prolonged Release Injection	Vol 5 No 18	3	2011 December
Exenatide polonged release suspension for injectin in combination with oral antidiabetic therapyfor the treatment of type 2 diabetes mellitus (Febuary 2012) NICE TA248	Vol 6 No 8	11	2012 May
Extended spectrum beta lactamase producing organisms	Vol 7 No 13	1	2013 August
Exterol ear drops	Vol 11 No 4	10	2017 March
Eye care - Supplements	Vol 11 No 4	9	2017 March
Ezetimibe	Vol 2 No 19	13	2008 December
Ezetimibe	Vol 4 No 2	4	2010 March
Ezetimibe	Vol 5 No 13	1	2011 October
Ezetimibe - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	2	2013 February
Ezetimibe and CVD	Vol 8 No 23	6	2014 December
Ezetimibe for primary hypercholesterolaemia	Vol 2 No 1	7	2008 January
Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia	Vol 2 No 11	7	2008 July
Ezetrol	Vol 4 No 2	4	2010 March
Ezetrol	Vol 5 No 13	1	2011 October
Faecal incontinence	Vol 1 No 4	5	2007 September
Falls - Medicines, side effects and the risk of falls in the elderly: An aid to medication review	Vol 4 No 1	5	2010 January / Feb
Falls Associated with Medicines	Vol 3 No 11	8	2009 October
Familial hypercholesterolaemia	Vol 2 No 19	11	2008 December
Fastclix	Vol 9 No 10	1	2015 July
Febuxostat	Vol 4 No 9	4	2010 June
Febuxostat for the management of hyperuricaemia in people with gout	Vol 3 No 2	7	2009 March
Felodipine	Vol 9 No 11	2	2015 July
Felodipine 5mg and 10mg modified release tablets Rapid Cost Comparison	Vol 9 No 11	7	2015 July

Felodipine modified release tablets 2.5mg, 5mg and 10mg	Vol 8 No 1	10	2014 January
Fencino	Vol 6 No 2	2	2012 January
Fentalis resevoir patch	Vol 3 No 13	7	2009 December
Fentanyl buccal tablets	Vol 3 No 5	4	2009 May
Fentanyl immediate release	Vol 12 No 3	1	2018 June
Fentanyl immediate release preparations	Vol 10 No 4	5	2016 February
Fentanyl Nasal Spray	Vol 4 No 3	4	2010 March
Fentanyl Patches	Vol 2 No 18	10	2008 November
Fentanyl Patches	Vol 6 No 2	2	2012 January
Fentanyl patches	Vol 8 No 4	6	2014 February
Fentanyl sublingual	Vol 3 No 5	4	2009 May
Fentanyl transdermal reservoir patch	Vol 3 No 13	7	2009 December
Fenticonazole (Ginoxin) vaginal capsules 200mg, 600mg and 2% vaginal cream	Vol 5 No 7	6	2011 April
Feracru	Vol 12 No 7	4	2018 August
Ferric Maltol	Vol 12 No 7	4	2018 August
Fesoterodine	Vol 2 No 15	2	2008 November
Fesoterodine 4mg tablets	Vol 8 No 10	7	2014 May
Fesoterodine 8mg tablets	Vol 8 No 10	7	2014 May
Feverish illness in children	Vol 1 No 1	4	2007 June
Fexofenadine	Vol 11 No 7	2	2017 March
Fexofenadine 120mg and 180mg tablets	Vol 8 No 14	8	2014 August
Fiasp - insulin injection	Vol 12 No 4	4	2018 May
Fiasp Insulin Aspart	Vol 11 No 15	2	2017 November
Fibrates	Vol 2 No 1	11	2008 January
Fibrates - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	2	2013 February
Fibrates and CVD	Vol 8 No 23	6	2014 December
Fidaxomicin	Vol 9 No 15	4	2015 July
Fidaxomicin 200mg tablets (Dificlir)	Vol 7 No 2	4	2013 January
Fidaxomicin tablets and other microbilogist led antibiotics for resistant infections - formulary status	Vol 9 No 15	7	2015 October
Filgrastrim-risk of potentially life threatening capillary leak syndrome	Vol 7 No 18	4	2013 October
Filnarine SR is a new modified release morphine	Vol 8 No 1	11	2014 January
Filnarine SR product discontinuation	Vol 9 No 9	8	2015 June
Finasteride	Vol 4 No 1	7	2010 January / Feb
Finasteride	Vol 8 No 18	7	2014 October
Finasteride 1mg (Propecia) - MHRA safety update	Vol 11 No 11	6	2017 August
Fingolimod (Gilenya) - bradycardia and heart block	Vol 7 No 7	2	2013 May
Fingolimod (Gilenya) and the risk of cardiovascular adverse reactions – new advice	Vol 6 No 12	8	2012 June
Firazyr	Vol 3 No 2	3	2009 March
Firdapse (amifampridine phosphate)	Vol 5 No 7	4	2011 April

Firmagon	Vol 4 No 12	3	2010 August
First Line PDE5 inhibitor of choice for the treatment of erectile dysfunction	Vol 7 No 10	1	2013 June
Fish oils and cardiac mortality	Vol 3 No 4	7	2009 April
Fixonase nasal spray	Vol 11 No 7	4	2017 March
Flamasacard	Vol 3 No 10	6	2009 October
Flecainide supply difficulties	Vol 10 No 6	9	2016 May
Flixonase	Vol 9 No 7	2	2015 April
Flomaxtra XL	Vol 8 No 10	7	2014 May
Fluarix Tetra	Vol 8 No 7	7	2014 April
Fluarix Tetra injection	Vol 11 No 6	5	2017 March
Fluenz Tetra nasal spray	Vol 11 No 6	3	2017 March
Flunitrazepam	Vol 8 No 16	10	2014 September
Flunitrazepam	Vol 9 No 7	7	2015 April
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular odema after an inadequate response to prior therapy November 2013	Vol 8 No 4	10	2014 February
Fluoxetine 20mg Dispersible Tablets	Vol 8 No 16	5	2014 September
Fluticasone furoate 27.5 microgram nasal spray (Avamys)	Vol 7 No 12	3	2013 July
Fluticasone furoate 27.5 microgram nasal spray (Avamys)	Vol 11 No 7	4	2017 March
Fluticasone furoate nasal spray (Avamys)	Vol 3 No 7	4	2009 June
Fluticasone Furoate/Vilanterol Inhalation Power	Vol 8 No 11	5	2014 June
Fluticasone propionate	Vol 9 No 7	1	2015 April
Fluticasone propionate	Vol 9 No 7	2	2015 April
Fluticasone propionate	Vol 9 No 7	3	2015 April
Fluticasone propionate 50 microgram nasal spray (Flixonase)	Vol 7 No 12	3	2013 July
Fluticasone propionate 500 microgram	Vol 10 No 6	4	2016 May
Fluticasone/formoterol metered dose inhaler (Flutiform)	Vol 7 No 2	9	2013 January
Flutiform	Vol 7 No 2	9	2013 January
Flutter oscillating positive expiratory pressure (PEP) device	Vol 7 No 4	1	2013 February
Flutter oscillating positive expiratory pressure (PEP) device - New Treatment Algorithm	Vol 7 No 11	11	2013 July
Flutter oscillating positive expiratory pressure device	Vol 10 No 5	2	2016 March
Fluvastatin low intensity statin	Vol 8 No 23	7	2014 December
Fluxoetine - risk of congenital cardiac defects	Vol 4 No 6	12	2010 May
Foetal malformation	Vol 7 No 14	17	2013 August
Folic Acid (pregnant, obese women)	Vol 12 No 4	3	2018 May
Foodink Complete	Vol 8 No 8	7	2014 May
Formoterol 6microgram per actuation	Vol 10 No 6	6	2016 May
Formoterol/beclometasone MDI	Vol 2 No 3	4	2008 April

Forticreme Complete	Vol 8 No 8	10	2014 May
Fortijuice	Vol 8 No 8	9	2014 May
Fortimel Regular	Vol 8 No 8	2	2014 May
Fortisip	Vol 8 No 8	10	2014 May
Fortisip Bottle	Vol 8 No 8	6	2014 May
Fortisip Compact	Vol 8 No 8	6	2014 May
Fortisip Compact	Vol 8 No 8	6	2014 May
Fortisip Compact	Vol 8 No 8	10	2014 May
Fortisip Compact Fibre	Vol 8 No 8	10	2014 May
Fortisip Compact Protein	Vol 8 No 8	10	2014 May
Fortisip Extra	Vol 8 No 8	9	2014 May
Fortisip Multi Fibre	Vol 8 No 8	8	2014 May
Fortisip Yoghurt Style	Vol 8 No 8	8	2014 May
Fortodol: Risk of Liver Damage	Vol 3 No 7	18	2009 June
Forxiga	Vol 7 No 21	10	2013 December
Forxiga	Vol 11 No 6	11	2017 March
Forxiga	Vol 7 No 14	8	2013 August
Forxigal 5mg & 10mg	Vol 7 No 14	1	2013 August
Fosfomycin	Vol 9 No 15	4	2015 July
Fosfomycin 3g granules (Monuril)	Vol 10 No 16	8	2016 October
Fosfomycin 3g granules for oral solution	Vol 10 No 11	2	2016 August
Fosfomycin 3g granules for oral solution	Vol 10 No 11	8	2016 August
Fostair	Vol 2 No 3	4	2008 April
Fostair 200/6 metered dose inhaler and nexthaler	Vol 10 No 6	6	2016 May
Fostair NEXThaler	Vol 8 No 20	7	2014 December
Freestyle Libre Glucose Monitoring System	Vol 8 No 20	8	2014 December
Freestyle Libre Glucose Monitoring System	Vol 12 No 1		2018 January
Fresubin 2kcal Drink	Vol 8 No 8	10	2014 May
Fresubin 2kcal Fibre Drink	Vol 8 No 8	10	2014 May
Fresubin 5kcal Shot Drink	Vol 8 No 8	10	2014 May
Fresubin Crème	Vol 8 No 8	10	2014 May
Fresubin Energy Drink	Vol 8 No 8	6	2014 May
Fresubin Energy Drink 200ml	Vol 8 No 8	2	2014 May
Fresubin Energy Fibre	Vol 8 No 8	8	2014 May
Fresubin Jucy Drink	Vol 8 No 8	9	2014 May
Fresubin Original	Vol 8 No 8	2	2014 May
Fresubin original	Vol 11 No 4	7	2017 March
Fresubin Powder Extra	Vol 8 No 8	7	2014 May
Fresubin Protein Energy	Vol 8 No 8	9	2014 May
Fresubin Thickened Stage 1 and Stage 2	Vol 10 No 7	11	2016 May
Fresubin YoCreme	Vol 8 No 8	10	2014 May
Fucithalamic	Vol 8 No 15	9	2014 August
Fulvestrant - Shared Care Guidelines	Vol 1 No 6	7	2007 November
Fusidic Acid 1% Gel Eye Drops	Vol 8 No 15	9	2014 August
Fusidic Acid 1% Modified Release Eye Products	Vol 9 No 18	8	2015 November
Fycompa approved use for onset seizures	Vol 7 No 17	4	2013 October
Gabapentin (Neurontin)	Vol 12 No 2	7	2018 January
Galantamine	Vol 8 No 10	11	2014 May

Galantamine	Vol 1 No 6	5	2007 November
Galantamine can cause serious skin reactions	Vol 10 No 5	14	2016 March
Galantamine modified release	Vol 8 No 19	9	2014 December
Galantamine, Rivastigmine, Memantine and Donepezil for the treatment of Alzheimers's Disease	Vol 5 No 11	4	2011 June
Galpseud	Vol 11 No 4	4	2017 March
Galvus	Vol 2 No 10	4	2008 July
Galvus	Vol 8 No 10	3	2014 May
Ganciclovir 0.15% eye gel	Vol 8 No 19	6	2014 December
Ganfort	Vol 2 No 18	5	2008 November
Ganfort	Vol 9 No 6	2	2015 May
Ganfort UD	Vol 8 No 4	4	2014 February
Gapentin for neuropathic pain	Vol 5 No 11	10	2011 June
Gardasil	Vol 1 No 8	6	2007 December
Gardasil	Vol 1 No 4	2	2007 September
Gaviscon Advance	Vol 11 No 13	3	2017 October
Gazyvaro	Vol 9 No 11	2	2015 July
Gefitinib for the first line treatment of locally advanced or metastatic non small cell lung cancer	Vol 4 No 18	10	2010 October
Gefitinib for the second line treatment of locally advanced or metastatic non small cell lung cancer	Vol 3 No 11	9	2009 October
Gemfibrozil and CVD	Vol 8 No 23	6	2014 December
General Medical Council good practice guidance on prescribing and managing medicines and devices	Vol 7 No 12	11	2013 July
Generic Montelukast preparations are now available	Vol 7 No 21	10	2013 December
Generic sildenafil tablets	Vol 7 No 10	1	2013 June
Gerrmoloids cream/ onitment/suppositories/Spray	Vol 11 No 4	2	2017 March
Gilenya - bradycardia and heart block	Vol 7 No 7	2	2013 May
Ginoxin	Vol 5 No 7	6	2011 April
Glargine insulin - new trial in brief	Vol 4 No 6	11	2010 May
Glaucoma - Diagnosis and management of chronic open angle glaucoma and ocular hypertension	Vol 3 No 11	11	2009 October
Glaucoma - Review of treatments	Vol 4 No 6	3	2010 May
Gliclazide	Vol 9 No 11	2	2015 July
Gliclazide 30mt and 60mg modified release tablets (Vamju) for Type 2 Diabets Mellitus Rapid Drug Assessment	Vol 9 No 11	5	2015 July
Glitazones	Vol 2 No 1	11	2008 January
Glitazones	Vol 2 No 9	3	2008 May/June
Glucophage	Vol 8 No 9	2 & 10	2014 May
Glucophage	Vol 8 No 9	10	2014 May
Glucophage Powder	Vol 3 No 10	7	2009 October

GlucoRx Lancets	Vol 9 No 10	1	2015 July
Glucosamine	Vol 1 No 8	4	2007 December
Glucosamine	Vol 4 No 12	6	2010 August
Glucosamine	Vol 5 No 3	10	2011 February
Glucosamine and chondroitin	Vol 12 No 3	2	2018 June
Gluten Free	Vol 8 No 3	3	2014 January
Gluten Free Foods - NON - Prescribing	Vol 11 No 4	7	2017 March
Gluten Free Foods - Prescribing	Vol 8 No 3		2014 January
Gluten Free Prescribing	Vol 6 No 9	1	2012 June
Gluten Free Prescribing Guidance Reminder	Vol 10 No 11	4	2016 August
Glycopyrrolate 0.5% lotion	Vol 2 No 18	6	2008 November
Glycopyrronium bromide 2% roll-on applicator (unlicensed special) rapid drug assessment	Vol 9 No 9	8	2015 June
Glycopyrronium bromide inhaler	Vol 7 No 5	1	2013 March
Golimumab	Vol 9 No 8	11	2015 May
Golimumab for the treatment of ankylosing spondylitis	Vol 5 No 17	10	2011 October
Golimumab for the treatment of methotrexate-naïve rheumatoid arthritis	Vol 5 No 15	6	2011 September
Golimumab for the treatment of psoriatic arthritis	Vol 5 No 11	6	2011 June
Gonadorelin analogues review of	Vol 7 No 21	7	2013 December
Gonadotropin releasing hormone agonists for prostate cancer	Vol 10 No 15	1	2016 December
Gonadotropin releasing hormone agonists for prostate cancer (revised edition)	Vol 11 No 5	1	2017 February
Goserelin	Vol 7 No 21	7	2013 December
Goserelin	Vol 11 No 5	1	2017 February
Gout increasing but urate lowering therapies still under-used	Vol 8 No 6	5	2014 March
Gout Treatment Algorithm	Vol 7 No 10	12	2013 June
Granisetron 3.1mg in 24 hours transdermal patch (sancuso)	Vol 8 No 7	9	2014 April
Grazax	Vol 2 No 1	3	2008 January
Grazax	Vol 3 No 7	7	2009 June
Growth Hormone in the management of growth failure in children and young people and the management of attention deficit hyperactivity disorder SCG	Vol 10 No 2	9	2016 January
Guanfacine	Vol 11 No 6	7	2017 March
Guanfacine (Intuniv) 1g, 2mg, 3mg and 4mg modified release tablets	Vol 11 No 6	7	2017 March
Guidance on switching dabigatran or rivaroxaban or apixaban to warfarin	Vol 8 No 21	17	2014 December
Guidance on switching warfarin to dabigatran or rivaroxaban or apixaban	Vol 8 No 21	16	2014 December
Guidance on the choice of insulin regimens for people with type 2 diabetes mellitus	Vol 7 no 8	1	2013 June

Guidance on the prescribing of aspirin, clopidogrel, prasugrel and ticagrelor for the prevention of atherothrombotic events in patients with acute coronary syndromes	Vol 7 No 9	1	2013 June
Guidance on the prescribing of smoking cessation therapy	Vol 8 No 17	1	2014 October
Guidance on the prescribing of warfarin, dabigatran, rivaroxaban and apixaban for the prevention of stroke & systemic embolism in atrial fibrillation (third edition)	Vol 8 No 21	1	2014 December
Guidance on the use of warfarin and new oral anticoagulants for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Vol 10 No 1	1	2016 March
Guidelines for the treatment of commonly occurring infections in Lincolnshire Primary Care: Winter 2011/12	Vol 6 No 5	8	2012 February
Guidelines for the treatment of commonly occurring infections in Lincolnshire Primary Care: Winter 2012/13 Update	Vol 7 No 1	1	2013 January
Guidelines for the treatment of commonly occurring infections in primary care:winter 2014/15	Vol 8 No 22	1	2014 December
Guidelines for the Treatment of commonly occurring infections in Primary Care (Winter 2010/11)	Vol 4 No 20	7	2010 November
Haloperidol	Vol 9 No 1	4	2015 February
Hay Fever 2008	Vol 2 No 4	1	2008 April
Hay Fever Spring/Summer 2009	Vol 3 No 3	1	2009 March
Hay Fever: Spring/Summer 2010	Vol 4 No 4	1	2010 April
Hayfever	Vol 5 No 6	1	2011 March
Hayfever eye drops	Vol 11 No 4	9	2017 March
Hayfever OTC	Vol 11 No 7	1	2017 March
Healthcare associated infections	Vol 7 No 13	3	2013 August
Heart failure - are all beta blockers the same in?	Vol 5 No 12	9	2011 July
Heart Failure - Clinical Guidance and Management of	Vol 9 No 20	4	2015 November
Herbal supplements	Vol 12 No 3	4	2018 June
Heroin/diamorphine metabolite (6-MAM)	Vol 9 No 7	7	2015 April
Hirsutism	Vol 7 No 14	17	2013 August
Homeopathy	Vol 12 No 3	4	2018 June
Hormonal contraceptives	Vol 8 No 7	10	2014 April
Hormone Therapy in GIC	Vol 8 No 19	11	2014 December
HPV Vaccine	Vol 2 No 12	4	2008 July
Human Papillomavirus 9-Valent Vaccine (Gardasil 9)	Vol 10 No 17	9	2016 December
Human Papillomavirus Vaccine	Vol 1 No 8	6	2007 December
Human Papillomavirus Vaccine	Vol 1 No 1	5	2007 June
Human Papillomavirus Vaccine	Vol 1 No 4	2	2007 September

Human Papillomavirus Vaccine	Vol 2 No 15	4	2008 November
Human Papillomavirus Vaccine	Vol 2 No 18	11	2008 November
Human pre-mixed (biphasic) insulin	Vol 7 No 8	1	2013 June
Humulin R	Vol 2 No 6	8	2008 May
Hydrocortisone modified release - new drug assessment	Vol 7 No 7	7	2013 May
Hydrogen peroxide 1% cream	Vol 3 No 10	4	2009 October
Hydromol cream & ointment	Vol 9 No 5	3	2015 May
Hydrosal	Vol 5 No 5	2	2011 March
Hydroxychloroquine in Rheumatology -SCG	Vol 5 No 11	12	2011 June
Hydroxyzine (Atarax, Ucerax): Risk of QT interval prolongation and torsade de pointes	Vol 9 No 9	12	2015 June
Hypertension	Vol 6 No 1	1	2012 January
Hypnotics - Use of in Lincolnshire	Vol 6 No 5	3	2012 February
Hypoglycaemic episodes and possible risk of dementia	Vol 3 No 7	9	2009 June
Hypopnoea syndrome	Vol 2 No 9	5	2008 May/June
Hypromellose generic 0/3% eye drops, treatment of dry eyes, approved for joint formulary first line	Vol 7 No 6	1	2013 June
Hydrocortisone Acetate 10% foam	Vol 11 No 10	2	2017 June
Ibandronic Acid - Shared Care Guidelines	Vol 1 No 6	7	2007 November
Ibandronic acid 150mg	Vol 3 No 10	4	2009 October
Ibandronic acid 150mg tablets	Vol 8 No 4	6	2014 February
Ibrutinib	Vol 11 No 13	5	2017 October
Ibuprofen 10% gel	Vol 8 No 18	7	2014 October
Ibuprofen High Dose (≥ 2400 mg/day) Cardiovascular Risk	Vol 9 No 12	11	2015 July
Icaps	Vol 9 No 9	2	2015 June
Icaps	Vol 11 No 4	9	2017 March
iCare Advanced	Vol 9 No 10	1	2015 July
Icatibant injection	Vol 3 No 2	3	2009 March
Idelalisib 100mg and 150mg tablets	Vol 10 No 2	2	2016 January
Idelalisib 100mg and 150mg tablets	Vol 9 No 4	2	2015 March
Ikorel	Vol 2 No 12	7	2008 July
Ilaxten	Vol 5 No 15	4	2011 September
Imatinib	Vol 9 No 2	11	2015 February
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours	Vol 4 No 18	13	2010 October
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours	Vol 5 No 7	8	2011 April
Imiquimod 5% cream	Vol 8 No 5	6	2014 March
Immediate release twice daily quetiapine tablets now preferred to modified release formulations	Vol 8 No 1	11	2014 January
Implanon contraceptive implant	Vol 5 No 2	7	2011 February
IMPROVE_IT New Trial Assessment	Vol 9 No 15	5	2015 October

Improving Medicines Optimisation in Lincolnshire: The Patient Journey Through United Lincolnshire Hospitals	Vol 10 No 8	1	2016 July
Improving the use of medicines for better outcomes and reduced waste	Vol 7 No 7	1	2013 May
Imuvac	Vol 11 No 6	5	2017 March
Incruse Ellipta	Vol 12 No 7	3	2018 August
Indacaterol	Vol 4 No 18	3	2010 October
Indapamide 2.5mg tablets vs indapamide 1.5mg sustained release (Natrilix SR)	Vol 6 No 5	2	2012 February
Inegy	Vol 2 No 19	11	2008 December
Infant formula	Vol 11 No 12	3	2017 September
Infant formulary Gastro-Oesophageal Reflux Disease (GORD)	Vol 11 No 4	7	2017 March
Infections - guidelines for the treatment of commonly occurring infections in primary care winter 2008/09	Vol 2 No 16	5	2008 October
Infections - guidelines for the treatment of commonly occurring infections in primary care winter 2009/10	Vol 3 No 12	8	2009 November
Infections in lincolnshire primary care: Winter 2012/13 update - guidelines for the treatment of commonly occurring	Vol 7 No 1	1	2013 January
Inflixamab	Vol 2 No 3	9	2008 April
Inflixamab	Vol 1 No 8	8	2007 December
Infliximab	Vol 9 No 8	11	2015 May
Infliximab for acute exacerbations of ulcerative colitis	Vol 3 No 2	7	2009 March
Infliximab for ankylosing spondylitis	Vol 2 No 12	6	2008 July
Infliximab for the subacute manifestations of ulcerative colitis	Vol 2 No 10	6	2008 July
Infliximab for the treatment of crohn's disease	Vol 4 No 14	4	2010 September
Infliximab for the treatment of psoriatic arthritis	Vol 4 No 20	5	2010 November
Infliximab, Rituximab, Adalimumab, Etanercept, and Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	Vol 4 No 18	12	2010 October
Influenza A (H1N1) v swine flu vaccines	Vol 3 No 13	10	2009 December
Influenza Outbreak 2010/11	Vol 4 No 21	1	2010 December
Influenza Season 2008/09 - Use of Antivirals	Vol 3 No 1	3	2009 January
Influenza Vaccine (Fluarix Tetra)	Vol 8 No 7	7	2014 April
Influvac	Vol 11 No 6	5	2017 March
Ingenol mebutate gel	Vol 7 No 14	1	2013 August
Ingestion of button batteries	Vol 9 No 2	12	2015 February
Inhaled and intranasal corticosteroids	Vol 5 No 2	6	2011 February
Inhaled Corticosteroid (ICS)	Vol 4 No 1	5	2010 January / Feb
Inhaled corticosteroids for children	Vol 2 No 1	6	2008 January

Inhaled corticosteroids for chronic asthma in adults and children over 12 years	Vol 2 No 9	4	2008 May/June
Inhalers combination in COPD	Vol 5 No 18	9	2011 December
Innovation health and wealth: Accelerating adoption and diffusion in the NHS: implications for joint formulary development in Lincolnshire	Vol 6 No 18	2	2012 September
Inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease	Vol 5 No 12	7	2011 July
Inovelon	Vol 2 No 2	2	2008 February
Inspra	Vol 1 No 4	4	2007 September
Instanyl	Vol 4 No 3	4	2010 March
Insujet needle free insulin delivery system	Vol 6 No 8	9	2012 May
Insulin analogues	Vol 7 No 8	1	2013 June
Insulin Analogues - Efficacy and Safety	Vol 3 No 5	7	2009 May
Insulin Degludec	Vol 10 No 9	3	2016 July
Insulin Degludec	Vol 11 No 10	3	2017 June
Insulin Degludec 100 Units(Liraglutid 3.6mg per mil injection (Xultophy) Rapid Drug Assessment	Vol 9 No 9	6	2015 June
Insulin Glargine 300IU/ML	Vol 9 No 21	9	2015 December
Insulin Glargine 300IU/ML - New Product Assessment	Vol 10 No 2	7	2016 January
Insulin glargine, insulin detemir	Vol 7 No 8	1	2013 June
Insulin Glulisine - Apidra - supply problems	Vol 5 No 18	12	2011 December
Insulin Glulisine - Apidra SoloStar Insulin pen	Vol 2 No 1	4	2008 January
Insulin Glulisine supply problems	Vol 5 No 16	1	2011 October
Insulin infusion, subcutaneous, for the treatment of diabetes mellitus - NICE TA151	Vol 2 No 15	6	2008 November
Insulin lispro 200 iu/ml	Vol 10 No 11	9	2016 August
Insulin lispro 200 units/ml	Vol 10 No 11	2	2016 August
Insulin Tresiba	Vol 11 No 10	3	2017 June
Insulin U-500	Vol 2 No 6	8	2008 May
Insuline glargine 300units/ml injection	Vol 10 No 2	2	2016 January
Insuline Glulisine - supply problems	Vol 5 No 18	12	2011 December
Interferon-Beta	Vol 8 No 20	9	2014 December
Intermediate insulin (isophane, NPH)	Vol 7 No 8	1	2013 June
Intrauterine Contraception: Uterine Perforation - Risk Factors	Vol 9 No 12	12	2015 July
Intrinsic testosterone patch - New Product Assessment	Vol 1 No 1	3	2007 June
Intuniv	Vol 11 No 6	7	2017 March
Invega	Vol 1 No 6	3	2007 November
Invita D3 25.000 IU &50.000 IU	Vol 11 No 15	3	2017 November
Invokana	Vol 11 No 6	11	2017 March
Ipilimumab	Vol 8 No 18	7	2014 October
Irritable bowel syndrome in adults	Vol 2 No 9	6	2008 May/June

isosorbide mononitrate standard release	Vol 7 No 5	1	2013 March
Isotretinoin	Vol 5 No 2	6	2011 February
Isotretinoin	Vol 7 No 14	17	2013 August
Isotretinoin	Vol 9 No 4	1	2015 March
Isotretinoin (Roaccutame)	Vol 12 No 2	7	2018 January
Isotretinoin 5mg, 10mg and 20mg capsules	Vol 9 No 4	2	2015 March
Ivabradine	Vol 8 No 16	8	2014 September
Ivabradine	Vol 9 No 4	1	2015 March
Ivabradine (Procoralan) for the treatment of chronic heart failure	Vol 6 No 12	6	2012 June
Ivabradine 5mg and 7.5mg tablets	Vol 5 No 17	7	2011 October
Ivabradine 5mg and 7.5mg tablets	Vol 9 No 4	2	2015 March
Ivabradine and Heart Failure	Vol 6 No 19	12	2012 October
Ivabradine in heart failure	Vol 4 No 20	6	2010 November
Ivabradine tablets	Vol 3 No 2	4	2009 March
Ivabradine tablets 5mg and 7.5mg (Procoralan)	Vol 6 No 19	2	2012 October
Ivemend	Vol 6 No 3	7	2012 January
Ivermectin 10mg/g cream	Vol 10 No 11	2	2016 August
Ivermectin 10mg/g cream	Vol 10 No 11	5	2016 August
Ixekizumab	Vol 11 No 10	6	2017 June
Janumet	Vol 4 No 12	4	2010 August
Janumet	Vol 8 No 10	3	2014 May
Januvia	Vol 1 No 5	6	2007 October
Januvia	Vol 6 No 5	7	2012 February
Januvia	Vol 8 No 10	3	2014 May
Jardiance	Vol 11 No 6	11	2017 March
Jetrea	Vol 7 No 21	12	2013 December
Jext	Vol 6 No 16	4	2012 September
Jupiter Study	Vol 2 No 19	4	2008 December
Katya	Vol 1 No 2	4	2007 July
Keral	Vol 2 No 19	4	2008 December
Ketamine	Vol 8 No 16	10	2014 September
Ketamine	Vol 9 No 7	7	2015 April
Ketamine Injection for Palliative Care	Vol 5 No 15	2	2011 September
Ketamine Oral Solution (50mg in 5ml)	Vol 5 No 15	2	2011 September
Ketamine use in palliative care and chronic neuropathic pain	Vol 5 No 18	10	2011 December
Ketoconazole	Vol 2 No 6	12	2008 May
Ketoconazole 200mg tabs are RED RED for fungal infections	Vol 7 No 18	3	2013 October
Ketoprofen	Vol 4 No 2	9	2010 March
Ketoprofen/omeprazole (Axorid) Capsules	Vol 4 No 2	9	2010 March
Ketotifen 0.25/ml eye drops / Zaditen	Vol 11 No 7	6	2017 March
Klebsiella	Vol 7 No 13	1	2013 August
Komboglyze	Vol 7 No 5	1	2013 March
Konakion MM inj.	Vol 12 No 6	3	2018 May
LABA/ICS combination inhalers in COPD	Vol 5 No 18	9	2011 December
Lacosamide	Vol 4 No 9	5	2010 June

Lacri-lube eye ointment, treatment of dry eyes, approved for joint formulary second line, preservative free paraffin preparation	Vol 7 No 6	1	2013 June
Lactose into	Vol 11 No 4	7	2017 March
Lancets - Diabetes	Vol 9 No 10	1	2015 July
Lancets - Lower Cost Single Use in Diabetes	Vol 9 No 10	1	2015 July
Lansoprazole 15mg capsules	Vol 9 No 4	4	2015 March
Lansoprazole 30mg	Vol 9 No 4	6	2015 March
Lansoprazole 30mg capsules	Vol 9 No 4	3	2015 March
Lanthanum - New Product Assessment	Vol 1 No 1	2	2007 June
Lanthanum - Shared Care Guidelines	Vol 1 No 6	7	2007 November
Lantus SoloStar Insulin Pen	Vol 2 No 1	4	2008 January
Lapatinib or Trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 (June 2012) TA257	Vol 7 No 2	11	2013 January
Lapropiprant Modified Release Tablets	Vol 4 No 2	3	2010 March
Lariam	Vol 11 No 4	6	2017 March
Latanaprost generic 50 microgram per ml eye drops and latanoprost/timolol 50 microgram/5mg per ml eye drops	Vol 6 No 16	7	2012 September
Latanoprost	Vol 9 No 15	4	2015 July
Latanoprost	Vol 9 No 6	1	2015 May
Latanoprost 50 microgram/ml (0.005%) preservative-free single dose eye drops - approved use AMBER	Vol 7 No 17	7	2013 October
Launch of NHS Evidence	Vol 3 No 7	4	2009 June
Laxido Orange	Vol 8 No 1	10	2014 January
Lecaent and Rewisca Rapid Cost Comparison	Vol 9 No 11	6	2015 July
Lecicarbon A Suppositories	Vol 8 No 16	4	2014 September
Lecicarbon C for constipation, bowel clearance and diagnostic Procedures in children under 12 (Rapid Drug Assessment)	Vol 9 No 12	9	2015 July
Lecicarbon C suppositories	Vol 9 No 12	2	2015 July
Lecicarbon C suppositories	Vol 9 No 12	2	2015 July
Ledipasvir 90mg/sofosbuvir 400mg tablets	Vol 10 No 2	2	2016 January
Leflunomide - shared care guideline	Vol 4 No 6	12	2010 May
Leicarbon A suppositories	Vol 12 No 2	3	2018 January
Lenalidamide	Vol 9 No 1	5	2015 February
Lenalidomide	Vol 2 No 1	2	2008 January
Lenalidomide	Vol 6 No 3	9	2012 January
Lenalidomide (Revlimid) risk of serious hepatic adverse drug reactions	Vol 7 No 7	2	2013 May
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy	Vol 3 No 10	9	2009 October
Lenalidomide: risk of thrombosis and thromboembolism	Vol 5 No 7	13	2011 April

Lercanidipine	Vol 9 No 11	2	2015 July
Lercaridipine 10mg and 20mg tablets generic	Vol 9 No 11	2	2015 July
Lestramyl	Vol 8 No 9	4	2014 May
Leukotriene receptor antagonists justified in the treatment of asthma	Vol 5 No 15	7	2011 September
Leuprorelin	Vol 7 No 21	7	2013 December
Leuprorelin	Vol 11 No 5	1	2017 February
Levact - Bendamustine - for the first line treatment of chronic lymphocytic leukaemia	Vol 5 No 8	11	2011 May
Levact - Bendamustine - for the treatment of indolent (low grade) non-hodgkins lymphoma that is refractory to rituximab	Vol 5 No 2	6	2011 February
Levest	Vol 8 No 9	4	2014 May
Levest	Vol 8 No 1	11	2014 January
Levetiracetam tablets 250mg, 500mg, 750mg, 1g and oral solution	Vol 10 No 13	2	2016 August
Levitra	Vol 5 No 12	4	2011 July
Levobunolol 0.5% eye drops	Vol 9 No 6	2	2015 May
Levocetirizine	Vol 11 No 7	2	2017 March
Levomepromazine tablets & inj.	Vol 12 No 6	3	2018 May
Levonogestrel & Ulipristal	Vol 8 No 18	8	2014 October
Levonorgestre 1.5mg tablets - Rapid Cost Comparison	Vol 8 No 9	6	2014 May
Levonorgestrel	Vol 8 No 7	10	2014 April
Levonorgestrel	Vol 8 No 19	9	2014 December
Levonorgestrel	Vol 8 No 16	11	2014 September
Levonorgestrel (intrauterine device)	Vol 12 No 7	4	2018 August
Levonorgestrel 1.5mg Tablets (Emerres)	Vol 9 No 20	6	2015 November
Levonorgestrel 13.5mg T-shaped intrauterine system	Vol 10 No 2	3	2016 January
Levonorgestrel 13.5mg T-shaped intrauterine system	Vol 10 No 5	12	2016 March
Levonorgestrel 150 microgram	Vol 8 No 1	11	2014 January
Levonorgestrel 150 microgram tablets	Vol 8 No 9	1 & 4	2014 May
Levonorgestrel 52mg T-shaped intrauterine system	Vol 10 No 2	3	2016 January
Levonorgestrel 52mg T-shaped intrauterine system	Vol 10 No 5	12	2016 March
Levonorgestrel 52mg T-shaped Intrauterine System - Rapid Drug Assessment	Vol 10 No 2	4	2016 January
Levonorgestrel advices on interactions with hepatic enzyme inducers and contraceptive efficacy	Vol 10 No 17	9	2016 December
Levosert intrauterine device	Vol 12 No 7	4	2018 August
Levothyroxine MHRA Review Tablet Supply Issues	Vol 7 No 4	10	2013 February
Lidocaine Medicated Plaster	Vol 1 No 5	7	2007 October
Lidocaine plasters	Vol 12 No 3	1	2018 June

Linacotide approved use for IBS	Vol 7 No17	3	2013 October
Linagliptin 2.5mg/ metformin 850mg/1g tablets (Jentaduetto)	Vol 6 No 19	2	2012 October
Linagliptin 2.5mg/Metformin 850mg/1g film coated tablets	Vol 6 No 19	10	2012 October
Linagliptin 5 mg tablets	Vol 8 No 10	3	2014 May
Linagliptin 5mg tablets (Trajenta)	Vol 10 No 12	2	2016 August
Linagliptin/metformin 2.5mg/850mg and 2.5mg/1g (Jentaduetto)	Vol 10 No 12	2	2016 August
Lincolnshire Joint Formulary	Vol 7 No 7	1	2013 May
Lincolnshire Joint Formulary update	Vol 8 No 1	10	2014 January
Linezolid	Vol 9 No 15	4	2015 July
Linezolid 600mg tablets and 100mg/5ml oral suspension	Vol 5 No 15	4	2011 September
Liothyronine	Vol 12 No 3	3	2018 June
Liothyronine sodium	Vol 11 No 4	6	2017 March
Lipid Modification	Vol 1 No 3	1	2007 August
Lipid modification	Vol 4 No 2	5	2010 March
Lipid Modification	Vol 2 No 11	1	2008 July
Lipid Modification Guidelines - Review	Vol 4 No 13	1	2010 August
Lipitor - Atorvastatin Chewable tablets	Vol 6 No 4	3	2012 February
Lipitor - patent expiry and the future role of rosuvastatin	Vol 6 No 4	8	2012 February
Lipitor - patent expiry and the future role of rosuvastatin	Vol 6 No 8	3	2012 May
Liraglutide	Vol 10 No 9	3	2016 July
Liraglutide for the treatment of type 2 diabetes mellitus	Vol 5 No 3	5	2011 February
Liraglutide Injection	Vol 4 No 3	2	2010 March
Liraglutide injection 6mg/ml	Vol 3 No 12	2	2009 November
Lisdexamefetamine	Vol 8 No 11	2	2014 June
Lisdexamfetamine	Vol 8 No10	11	2014 May
Lisdexamfetamine capsules (Elvanse) are approved for use in the treatment of attention deficit hyperactivity	Vol 7 No 11	5	2013 July
Lithium carbonate 250mg tablets	Vol 9 No 21	13	2015 December
Lithium monitoring	Vol 8 No 7	10	2014 April
Lixiana	Vol 10 No 1	5	2016 January
Lixisenatide 10microgram/20microgram injection (Lyxumia)	Vol 7 No 11	7	2013 July
Lodotra	Vol 5 No 2	5	2011 February
Lodoxamide 0.1% eye drops / Alomide	Vol 11 No 7	6	2017 March
Long Acting Beta-2 Agonist (LABA)	Vol 4 No 1	5	2010 January / Feb
Long term effects of intensive glucose lowering on cardiovascular outcomes	Vol 5 No 8	6	2011 May
Long term safety concerns & tolerability of dabigatran, rivaroxiban & apixaban	Vol 8 No 21	12	2014 December
Long-acting beta 2 agonists	Vol 5 No 2	6	2011 February
Longtec	Vol 7 No 7	8	2013 May

Loperamide (cardiovascular adverse reaction)	Vol 11 No 15	7	2017 November
Lopidine	Vol 9 No 6	3	2015 May
Loratadine	Vol 9 No 7	4	2015 April
Loratadine	Vol 11 No 4	3	2017 March
Loratadine	Vol 11 No 7	2	2017 March
Lorazepam	Vol 8 No 16	10	2014 September
Lorazepam	Vol 9 No 7	7	2015 April
Loteprednol etabonate 0.5% eye drops (Lotemax)	Vol 10 No 16	8	2016 October
Low back pain - early management of persistent non-specific low back pain	Vol 3 No 12	6	2009 November
Low Cost Galantamine Modified Release Formulations (Consion XL/Gazylan XL and Luventa XL)	Vol 11 No 1	8	2017 February
Lower Cost Blood Glucose Testing Meters & Strips - Prescribing	Vol 8 No 2		2014 February
Lower Cost Branded Products - QIPP Opportunity	Vol 9 No 9	6	2015 June
Lower Cost Brands Update - QIPP Opportunities	Vol 9 No 11	5	2015 July
Lower Cost Single Use Lancets in Diabetes - Guidance	Vol 9 No 10	1	2015 July
Lower Urinary Tract Symptoms in men	Vol 5 No 10	1	2011 May
Loxapine inhalation	Vol 7 No 14	8	2013 August
Lubiprostone 24 microgramme capsules	Vol 8 No 5	7	2014 March
Lucentis	Vol 1 No 4	3	2007 September
Lucentis	Vol 7 No 14	7	2013 August
Lucette	Vol 8 No 9	5	2014 May
Lumigan	Vol 9 No 6	2	2015 May
Lumigan preservative-free single dose eye drops-approved use AMBER	Vol 7 No 17	7	2013 October
Lumiracoxib	Vol 1 No 8	7	2007 December
Lung Flute Secretion Mobilization Device for PEP/bronchial hygiene therapy	Vol 10 No 5	2	2016 March
Lutein and antioxidant vitamins for the prevention of age-related macular degeneration - QIPP Opportunity	Vol 9 No 9	3	2015 June
Lutein and antioxidants	Vol 12 No 3	3	2018 June
Lynlor	Vol 8 No 5	9	2014 March
Lyrinel XL	Vol 8 No 10	7	2014 May
Lysergic acid diethylamide (LSD)	Vol 9 No 7	7	2015 April
Macrogol 3350 13.125g powder	Vol 9 No 12	2	2015 July
Macrogol 3350 6.563g powder	Vol 9 No 12	3	2015 July
Macrogol 3350 6.9g powder	Vol 9 No 12	3	2015 July
Macrogol polyethylene glycol	Vol 8 No 1	10	2014 January
Macrogol products cosmocol range Rapid Drug Assessment	Vol 9 No 12	6	2015 July
Macusheild Lutein	Vol 9 No 9	2	2015 June
MacuShield Gold Capsules	Vol 9 No 9	2	2015 June

Malaria prevention guidelines on malaris prevention in UK travellers - Public Health Update	Vol 9 No 20	8	2015 November
Malaria prevention treatment	Vol 11 No 4	6	2017 March
Malarivon	Vol 11 No 4	6	2017 March
Malarone	Vol 11 No 4	6	2017 March
Malnutrition screening for	Vol 8 No 8	1	2014 May
Management of Chronic Obstructive Pulmonary Disease in primary & secondary care	Vol 5 No 1	1	2011 January
Marvelon- are expensive and should no longer be initiated in new patients	Vol 7 No 17	7	2013 October
Maternal and child nutrition	Vol 2 No 10	6	2008 July
Maxijul	Vol 8 No 8	12	2014 May
MDMA (ecstasy)	Vol 9 No 7	7	2015 April
Medical Devices	Vol 8 No 14	9	2014 August
Medication changes - patient consent	Vol 3 No 10	13	2009 October
Medicines Adherence	Vol 3 No 4	11	2009 April
Medicines and your kidneys leaflet - East Midlands Cardiovascular strategic clinical network	Vol 9 No 21	14	2015 December
Medicines Optimisation The Safe and Effective Use of Medicines enable the best possible outcomes (March 2015) CG NG5	Vol 9 No 16	1	2015 October
Medroxyprogesterone	Vol 8 No 19	9	2014 December
Mefloquine	Vol 11 No 4	6	2017 March
Mefloquine: strengthened warnings on neuropsychiatric side effects	Vol 8 No 4	7	2014 February
Mekinist - risk of gastrointestinal perforation and colitis	Vol 10 No 6	13	2016 May
Melatonin	Vol 2 No 18	3	2008 November
Melatonin Prolonged Release Tablets	Vol 2 No 13	3	2008 August
Melatonin prolonged-release 2mg tablets	Vol 8 No 13	6	2014 July
Memantine	Vol 8 No 10	11	2014 May
Memantine	Vol 1 No 6	5	2007 November
Memantine and acetylcholinesterase combination inhibitor use	Vol 7 No 12	6	2013 July
Memantine Hydrochloride 10mg and 20mg Orodispersible Tablet (Valios)	Vol 11 No 1	9	2017 February
Memantine pump device	Vol 5 No 3	10	2011 February
Memantine, Donepezil, Galantamine and Rivastigmine for the treatment of Alzheimers's Disease	Vol 5 No 11	4	2011 June
Meningoccal Group B Vaccine	Vol 8 No 4	3	2014 February
Meningococcal ACWY Immunisation programme for adolescents	Vol 9 No 18	7	2015 November
Meningococcal Group B Vaccine	Vol 9 No 8	5	2015 May
Meningococcal Group B Vaccine	Vol 9 No 18	5	2015 November
Meprobamate	Vol 2 No 3	10	2008 April
Meprobamate	Vol 10 No 10	11	2016 July

Mercaptopurine	Vol 9 No 8	11	2015 May
Mesalazine	Vol 2 No 2	3	2008 February
Mesalazine	Vol 7 No 4	1	2013 February
Mesalazine gastro-resistant sustained-release granules in 500mg, 1g, 1.5g and 3g sachets	Vol 10 No 11	3	2016 August
Mesalazine gastro-resistant granules	Vol 10 No 11	7	2016 August
Mesalazine gastro-resistant modified release tablets 400mg and 800mg	Vol 10 No 11	3	2016 August
Mesalazine modified release 400mg tablets (Mesren MR)	Vol 6 No 19	3	2012 October
Mesalazine modified release 400mg tablets (mesren mr)	Vol 6 No 19	11	2012 October
Mesalazine modified release 400mg tablets (Octasa)	Vol 6 No 19	3	2012 October
Mesalazine sustained-release granules in 1g, 2g and 4g sachets	Vol 10 No 11	3	2016 August
Meso-zeaxanthin capsules	Vol 9 No 9	2	2015 June
Metformin	Vol 8 No 14	7	2014 August
Metformin	Vol 2 No 10	4	2008 July
Metformin 1mg	Vol 8 No 10	3	2014 May
Metformin 500mg and 100mg powder for oral solution	Vol 3 No 10	7	2009 October
Metformin oral powder 500mg and 1g	Vol 8 No 9	2 & 10	2014 May
Metformin Oral Powder 500mg and 1g - Product Withdrawal	Vol 8 No 9	10	2014 May
Metformin sustained release tables 500mg and 1 g (Sukkarto SR)	Vol 11 No 1	4	2017 February
Metformin/empagliflozin tablets	Vol 9 No 21	9	2015 December
Methadone	Vol 8 No 16	10	2014 September
Methadone	Vol 9 No 7	7	2015 April
Methotrexate Treatment Booklets	Vol 1 No 3	5	2007 August
Methotrexate pre filled pen (metoject)	Vol 8 No 18	6	2014 October
Methylamfetamine	Vol 9 No 7	7	2015 April
Methylnatrexone bromide injection	Vol 3 No 4	3	2009 April
Methylphenidate	Vol 3 No 4	12	2009 April
Methylphenidate	Vol 4 No 2	11	2010 March
Methylphenidate	Vol 8 No 10	11	2014 May
Methylphenidate 18mg and 36mg sustained release tablets	Vol 9 No 8	7	2015 May
Methylphenidate, atomoxetine and dexamfetamine in the management of Attention Deficit Hyperactivity Disorder	Vol 5 No 11	12	2011 June
Methylphenidate, atomoxetinem dexamfetamine and lisdexamfetaminein the management of Attention Deficit Hyperactivity Disorder - Shared Care Guideline	Vol 7 No 12	6	2013 July
Methylprednisolone	Vol 8 No 1	11	2014 January
Methysergide	Vol 8 No 10	12	2014 May

Metoclopramide increased risks at high doses or long term use	Vol 7 No18	3	2013 October
Metoclopramide risk of neurological adverse effects	Vol 7 No 21	4	2013 December
Metoject	Vol 8 No 18	6	2014 October
Metolazone 5mg and 10mg tablets	Vol 8 No 10	9	2014 May
Metricillin Resistant Staphylococcus aureus	Vol 7 No 13	1	2013 August
Metricillin Resistant Staphylococcus aureus	Vol 7 No 13	5	2013 August
Metronidazole	Vol 9 No 4	7	2015 March
Metronidazole	Vol 9 No 8	9	2015 May
Mexiletine 100mg and 200mg capsules	Vol 10 No 7	11	2016 May
Mexitil	Vol 10 No 7	11	2016 May
Mezalazine foam enemas (Salofalk)	Vol 12 No 2	5	2018 January
Mezavant XL	Vol 2 No 2	3	2008 February
Mezavant XL	Vol 7 No 4	1	2013 February
MHRA Drug Safety Update (April 2013) Strontium ranelate (Protelos) risk of serious cardiac disorders	Vol 7 No 11	9	2013 July
MHRA Drug Safety Update (April 2013): Cilostazol (Pletal) - risk of cardiovascular and bleeding events;	Vol 7 No 11	9	2013 July
MHRA Drug Safety Update (March 2013): Aqueous cream - risk of skin irritation, particularly in children, due to sodium lauryl sulfate content	Vol 7 No 10	11	2013 June
MHRA Drug Safety Update (March 2013): Dabigatran (Pradaxa) is now contraindicated in patients with prosthetic heart valves requiring anti-coagulant treatment.	Vol 7 No 10	11	2013 June
MHRA Drug Safety Update Reminder: Quinine for the management of nocturnal leg cramps	Vol 7 No 10	10	2013 June
MHRA: Drug Safety Update (April 2013) - Insulin degludec (Tresiba): available in additional higher strengths than existing insulins care need to minimise risk of error	Vol 7 No 8	2	2013 June
MI: Secondary prevention	Vol 1 No 2	5	2007 July
Miconazole OTC gel	Vol 11 No 15	7	2017 November
Microgynon 30	Vol 8 No 1	11	2014 January
Microgynon 30	Vol 8 No 1	11	2014 January
Midazolam 10mg/ml buccal solution (Epistatus)	Vol 7 No 12	5	2013 July
Midazolam 5mg in 1ml oromucosal solution (Buccolam)	Vol 6 No 5	4	2012 February
Midazolam 5mg/ml oromucosal solution (Buccolam)	Vol 7 No 12	5	2013 July
Midazolam Buccal Liquid	Vol 3 No 2	2	2009 March
Midazolam Hydrochloride (Buccolam)	Vol 12 No 2	4	2018 January

Midazolam Injections - NPSA Reducing risk of overdose	Vol 3 No 2	8	2009 March
Midazolam Injections in Adults NPSA - Reducing Risk of Overdose with	Vol 3 No 6	1	2009 June
Midazolam Maleate (Epistatus)	Vol 12 No 2	4	2018 January
Midodrine 2.5mg and 5mg tablets (Gutron) - AMBER shared care guideline available. Approved for Joint Formulary for this indication	Vol 7 No 10	3	2013 June
Midodrine 2.5mg and 5mg tablets for the treatment of severe orthostatic hypertension due to autonomic dysfunction and unlicensed use for the treatment of severe orthostatic hypotension or syncope in the absence of autonomic dysfunction - Shared Care Guideline	Vol 10 No 3	8	2016 February
Midodrine Hydrochloride 2.5mg and 5mg tablets	Vol 9 No 21	11	2015 December
Mifamurtide for the treatment of osteosarcoma	Vol 6 No 2	8	2012 January
Minocycline goodbye to	Vol 8 No 6	2	2014 March
Mintreleq XL Updated Cost Comparison	Vol 9 No 11	8	2015 July
Mirabegron	Vol 7 No 14	1	2013 August
Mirabegron (Betmiga) - Risk of severe hypertension and associated cerebrovascular and cardiac events (MHRA)	Vol 9 No 20	7	2015 November
Mirapexin (Prampexiole SR)	Vol 12 No 7	6	2018 August
Mirapexin for parkinsons disease	Vol 5 No 3	3	2011 February
Mirena	Vol 8 No 19	9	2014 December
Mirvaso	Vol 8 No 13	2	2014 July
Mirvaso	Vol 9 No 8	8	2015 May
Mirvaso- Brimonidine gel	Vol 11 Vol 12	4	2017 September
Mixtard 30 Insulin Products - Discontinuation of	Vol 4 No 16	1	2010 October
Mizolastine	Vol 11 No 7	2	2017 March
Mizollen	Vol 11 No 7	2	2017 March
Modafinil	Vol 2 No 6	13	2008 May
Modafinil	Vol 4 No 18	15	2010 October
Modafinil - narcolepsy	Vol 5 No 8	9	2011 May
Modified release sodium valproate granules	Vol 5 No 18	6	2011 December
Modigraf	Vol 4 No 3	7	2010 March
Molaxole	Vol 8 No 1	10	2014 January
Molita	Vol 11 No 8	9	2017 April
Mometasone 50ncg nasal spray	Vol 11 No 7	5	2017 March
Monoprost 50 microgram/ml (0.005%) preservative-free single dose eye drops- approved use AMBER	Vol 7 No 17	7	2013 October
Montelukast	Vol 7 No 21	10	2013 December
Montelukast 10mg tablets	Vol 9 No 4	2	2015 March

Morphgesic	Vol 8 No 1	11	2014 January
Morphine	Vol 8 No 16	10	2014 September
Morphine sulfate sustained release tablets (Filnarine SR) product discontinuation	Vol 9 No 9	8	2015 June
Movelat topical	Vol 11 No 4	8	2017 March
Movicol	Vol 8 No 1	10	2014 January
Moxifloxacin Hydrochloride 0.5% eye drops	Vol 5 No 8	4	2011 May
Moxivig	Vol 5 No 8	4	2011 May
MRSA	Vol 7 No 13	1	2013 August
MRSA	Vol 7 No 13	5	2013 August
Multiclix	Vol 9 No 10	1	2015 July
Multi-thick	Vol 8 No 8	2	2014 May
Murine Hay fever eye drops	Vol 11 No 4	9	2017 March
Murine Hayfever relief eye drops	Vol 11 No 7	6	2017 March
Myalgic Encephalomyelitis	Vol 1 No 6	6	2007 November
Mycophenolate - shared care guideline	Vol 3 No 8	8	2009 August
Mycophenolate mofetil	Vol 12 No 6	4	2018 May
Mycophenolate mofetil	Vol 9 No 4	1	2015 March
Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men	Vol 10 No 3	9	2016 February
Myliffe lancets	Vol 9 No 10	1	2015 July
Myocardial infarction	Vol 8 No 6	5	2014 March
Myopathy and Simvastatin 80mg - MHRA Drug Safety Update	Vol 4 No 11	1	2010 August
Nabilone	Vol 11 No 8	7	2017 April
NACSYS 600mg effervescent tablets	Vol 11 No 15	5	2017 November
Naftidrofuryl	Vol 9 No 15	4	2015 July
Naftidrofuryl 100mg capsules	Vol 8 No 9	2 & 10	2014 May
Naftidrofuryl 100mg capsules - Cilostazol 50mg and 100mg tablets are the preferred alternative	Vol 8 No 9	10	2014 May
Naftidrofuryl 100mg capsules - supply difficulties now resolved	Vol 9 No 15	10	2015 October
Naftidrofuryl and intermittent claudication	Vol 3 No 7	10	2009 June
Naftidrofuryl for the treatment of intermittent claudication in people with peripheral arterial disease	Vol 5 No 12	7	2011 July
Nalmefene	Vol 9 No 2	9	2015 February
Nalmefene tablets 18mg (Selincro)	Vol 8 No 7	4	2014 April
Naloxone	Vol 3 No 8	3	2009 August
Naloxone	Vol 9 No 1	9	2015 February
Naloxone 2mg/2ml IM injection-approved for emergency use for reversal of opioid induced	Vol 7 No 17	5	2013 October
Naltrexone	Vol 9 No 1	3	2015 February
Naproxen 125mg in 5ml oral suspension	Vol 10 No 13	3	2016 August
Naproxen effervescent tablets 250mg (Stirlescent)	Vol 10 No 13	9	2016 August

Naproxen Esomeprazole 500mg/20mg tablets	Vol 6 No 2	5	2012 January
Naproxen/Esomeprazole 500mg/20mg tablets	Vol 5 No 5	3	2011 March
Nasobec	Vol 11 No 7	4	2017 March
Nasocort	Vol 11 No 7	5	2017 March
Nasonex	Vol 11 No 7	5	2017 March
Natalizumab	Vol 4 No 6	12	2010 May
Natalizumab - New Product Assessment	Vol 1 No 1	2	2007 June
Natalizumab for highly active relapsing-remitting multiple sclerosis	Vol 1 No 5	9	2007 October
Natecal D3	Vol 9 No 8	6	2015 May
National shingles vaccination programme	Vol 7 No 7	1	2013 May
Natratriptan 2.5mg tablets (generic)	Vol 8 No 11	10	2014 June
NDA: Insulin degludec 100units/ml and 200units/ml Tresiba	Vol 7 No 8	1	2013 June
Nebusal	Vol 5 No 5	3	2011 March
Neditol	Vol 8 No 10	8	2014 May
Neditol XL	Vol 9 No 8	7	2015 May
Nedocromil 2% eye drops / Rapitil	Vol 11 No 7	6	2017 March
Nefopam 30mg tablets escalating cost	Vol 10 No 16	3	2016 October
Neoclarityn	Vol 11 No 7	2	2017 March
Neotigason	Vol 7 No 14	17	2013 August
Nepafenac 1mg/ml eye drops (Nevanac)	Vol 7 No 11	4	2013 July
Nestle	Vol 8 No 8	12	2014 May
Neupro	Vol 1 No 8	3	2007 December
Neuroimaging techniques in first episode psychosis	Vol 2 No 6	8	2008 May
Neurontin (Gabapentin)	Vol 12 No 2	7	2018 January
Neuropathic pain	Vol 5 No 4	1	2011 February
New advice on drug interactions and hormonal contraception	Vol 5 No 11	9	2011 June
New Community Pharmacy Services: New Medicines Service & Targeted Medicines Use Reviews	Vol 5 No 14	1	2011 October
New Drug Assessment Meningococcal Group B Vaccine (Bexsero)	Vol 8 No 4	3	2014 February
New Formulation Assessment: Aripiprazole prolonged-release suspension for injection	Vol 8 No 6	4	2014 March
New Oral Anticoagulants (NOACs) FAQ's - dabigatran, rivaroxiban & apixaban	Vol 8 No 21	26	2014 December
New Safety Data on Dapafloglozine (Forxiga)	Vol 7 No 21	10	2013 December
Nexplanon (etonogestrel) contraceptive implants: Reports of device invasculature and lung	Vol 10 No 13	11	2016 August
NICE CG137: The epilepsies, the diagnosis and management of the epilepsies in adults and children in primary and secondary care (January 2012)	Vol 6 No 10	5	2012 May

NICE CG70 Induction of labour	Vol 2 No 15	8	2008 November
NICE TA 267: Ivabradine for treating chronic heart failure	Vol 7 No 5	14	2013 March
NICE TA 367: Vortioxetine for treating major depressive episodes (November 2015)	Vol 10 No 6	13	2016 May
NICE TA 388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (April 2016)	Vol 10 No 11	13	2016 August
NICE TA 391: Cabazitaxel for home relapsed metastatic prostate cancer treated with docetaxel (May 2016)	Vol 10 No 11	12	2016 August
NICE TA152 Drug eluting stents for the treatment of coronary artery disease	Vol 2 No 15	6	2008 November
NICE TA182 - Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (October 2009)	Vol 6 No 19	12	2012 October
NICE TA182 Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (October 2009)	Vol 7 No 9	10	2013 June
NICE TA236 Ticagrelor for the treatment of acute coronary syndromes (October 2011)	Vol 7 No 9	10	2013 June
NICE TA237 Ranibizumab for the treatment of Diabetic Macular Oedema (November 2011)	Vol 6 No 4	5	2012 February
NICE TA240 Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (December 2011)	Vol 6 No 4	5	2012 February
NICE TA247 Tocilizumab for the treatment of rheumatoid arthritis(February 2012)	Vol 6 No 8	11	2012 May
NICE TA250: Eribulin for the treatment of locally advanced or metastatic breast cancer (April 2012)	Vol 6 No 10	5	2012 May
NICE TA252 Telaprevir for the treatment of genotype 1 chronic hepatitis C (APRIL 2012)	Vol 6 No 18	5	2012 September
NICE TA253 Boceprevir for the treatment of genotype 1 chronic hepatitis C - (APRIL 2012)	Vol 6 No 18	5	2012 September
NICE TA259 Abiraterone for castration resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (June 2012)	Vol 7 No 2	11	2013 January

NICE TA259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (July 2016)	Vol 10 No 17	12	2016 December
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (July 2012)	Vol 7 No 5	12	2013 March
NICE TA262 Adalimumab for the treatment of moderate to severe ulcerative colitis	Vol 7 No 4	11	2013 February
NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	Vol 7 No 4	11	2013 February
NICE TA264: Alteplase for treating acute ischaemic stroke	Vol 7 No 5	12	2013 March
NICE TA265: Bone metastases from solid tumours – denosumab	Vol 7 No 5	13	2013 March
NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis	Vol 7 No 5	13	2013 March
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma	Vol 7 No 5	15	2013 March
NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	Vol 7 No 5	15	2013 March
NICE TA270: Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)	Vol 7 No 5	16	2013 March
NICE TA271: Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy	Vol 7 No 10	8	2013 June
NICE TA272: Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract	Vol 7 No 10	8	2013 June
NICE TA273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)	Vol 7 No 10	8	2013 June
NICE TA274: Ranibizumab for treating diabetic macular oedema	Vol 7 No 10	8	2013 June
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation(Second edition)	Vol 7 No 16	8	2013 October
NICE TA276: Colistijmethat sodium and tobramycin dry powders for inhalation for treating pseudomona lung infection in cystic fibrosis (March 2013)	Vol 7 No 11	8	2013 July

NICE TA277: Methynaltrexone for treating opioid induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (March 2013)	Vol 7 No 11	9	2013 July
NICE TA279 Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (April 2013)	Vol 7 No 12	8	2013 July
NICE TA280 Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (April 2013)	Vol 7 No 12	8	2013 July
NICE TA281 Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (April 2013)	Vol 7 No 12	9	2013 July
NICE TA282 Pirfenidone for treating idiopathic pulmonary fibrosis (April 2013)	Vol 7 No 12	9	2013 July
NICE TA289 Ruxolitinib for disease related splenomegaly or symptoms in adults with myelofibrosis (June 2013)	Vol 7 No 18	6	2013 October
NICE TA291 Pegloticase for treating severe debilitating chronic tophaceous gout (June 2013)	Vol 7 No 18	7	2013 October
NICE TA294 Afibercept solution for injection for treating wet aged related macular degeneration (July 2013)	Vol 7 No 18	7	2013 October
NICE TA296 Crizotinib for previously treated non small cell lung cancer associated with an anaplastic lymphoma kinase fusion gene September 2013	Vol 7 No 21	11	2013 December
NICE TA297 ocriplasmin for treating vitreomacular traction October 2013	Vol 7 No 21	12	2013 December
NICE TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia November 2013	Vol 8 No 1	13	2014 January
NICE TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia	Vol 8 No 1	13	2014 January
NICE TA299 Bosutinib for previously treated chronic myeloid leukaemia November 2013	Vol 8 No 1	13	2014 January
NICE TA299 Bosutinib for previously treated chronic myeloid leukaemia	Vol 8 No 1	13	2014 January
NICE TA300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people	Vol 8 No 1	13	2014 January
NICE TA300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people November 2013	Vol 8 No 1	13	2014 January

NICE TA301 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular odema after an inadequate response to prior therapy November 2013	Vol 8 No 4	10	2014 February
NICE TA302 Canakinumab for treating systemic juvenile idiopathic arthritis terminated appraisal November 2014	Vol 8 No 4	10	2014 February
NICE TA308 Rituximab in Combination with Glucocorticoids for treating anti-neutrophil cytoplasmic anitibody-associated vasculitis	Vol 8 No 16	6	2014 September
NICE TA309 Permetrexed maintenance treatment following induction therapy with permetrexed and cisplatin for non squamous non small cell lung cancer	Vol 8 No 16	6	2014 September
NICE TA310 Afatanib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non small cell lung cancer	Vol 8 No 16	7	2014 September
NICE TA311 Bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation	Vol 8 No 16	7	2014 September
NICE TA313 Ustekinumab for treating active psoriatic arthritis	Vol 8 No 16	7	2014 September
NICE TA335 Rivaroxaban for preventing adverse outcomes after acute managment of acute coronary syndrome (March 2015)	Vol 9 No 11	10	2015 July
NICE TA336 Empagliflozin in combination therapyt for treating type 2 diabetes (March 2015)	Vol 9 No 9	10	2015 June
NICE TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy (March 2015)	Vol 9 No 9	11	2015 June
NICE TA443 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)	Vol 9 No 11	10	2015 July
NICE TA444 Obinutuzumnab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)	Vol 9 No 11	10	2015 July
NICE TA385 Ezetimibe for Treating Primary Heterozygous-Familial and Non-Familial Hypercholesterolaemia (February 2016)	Vol 10 No 7	13	2016 May
NICE TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Vol 10 No 9	8	2016 July

NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	Vol 10 No 9	9	2016 July
NICE TA390 Canagliflozin, Dapagliflozin and Empagliflozin as monotherapies for treating type 2 diabetes (May 2016)	Vol 10 No 14	10	2016 October
NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (August 2016)	Vol 10 No 17	12	2016 December
NICE TA398 Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (July 2016)	Vol 10 No 17	12	2016 December
NICE TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (July 2016)	Vol 10 No 17	12	2016 December
NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma (July 2016)	Vol 10 No 17	12	2016 December
NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia (August 2016)	Vol 10 No 17	12	2016 December
NICE TA402 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (August 2016)	Vol 10 No 17	12	2016 December
NICE TA403 Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (August 2016)	Vol 10 No 17	12	2016 December
NICE TA405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer (August 2016)	Vol 10 No 17	12	2016 December
NICE TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016)	Vol 10 No 17	12	2016 December
NICE TA407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (September 2016)	Vol 10 No 17	12	2016 December
NICE TA408 Pegaspargase for treating acute lymphoblastic leukaemia (September 2016)	Vol 10 No 17	12	2016 December
NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (September 2016)	Vol 10 No 17	13	2016 December
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes (November 2016)	Vol 11 No 6	10	2017 March

NICE TA68 Stroke and transient ischaemic attack	Vol 2 No 15	6	2008 November
Nicorandil	Vol 2 No 12	7	2008 July
Nicorandil desiccants -risk of ingestion	Vol 9 No 1	8	2015 February
Nicorette Fresh Mint Lozenges	Vol 5 No 8	5	2011 May
Nicorette Gum	Vol 8 No 17	11	2014 October
Nicorette Invisipatch	Vol 3 No 8	4	2009 August
Nicorette Invisipatch	Vol 8 No 17	9	2014 October
Nicorette Quickmist Oromucosal Spray	Vol 5 No 9	2	2011 May
Nicotine 2.5mg orodispersible film (NiQuitin) Strips	Vol 8 No 1	8	2014 January
Nicotine replacement lozenges, microtablets and oral dispersible films	Vol 8 No 17	13	2014 October
Nicotine replacement oral sprays, nasal sprays and inhalators	Vol 8 No 17	14	2014 October
Nicotine replacement Therapy (NRT)	Vol 8 No 17	1	2014 October
Nicotine replacement Therapy (NRT) update June 2017	Vol 11 No 10	5	2017 June
Nicotinell Gum	Vol 8 No 17	12	2014 October
Nicotinell Patch	Vol 8 No 17	9	2014 October
Nicotinic Acid	Vol 4 No 2	3	2010 March
Nicotinic Acid - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	2	2013 February
Nicotinic Acid and CVD	Vol 8 No 23	6	2014 December
Nintedanib	Vol 9 No 15	4	2015 July
Nipatra	Vol 8 No 12	6	2014 June
Niquitin Gum	Vol 8 No 17	12	2014 October
Niquitin Patch	Vol 8 No 17	9	2014 October
Nitrofuantoin	Vol 8 No 18	10	2014 October
Nitrofuantoin MR in UTI	Vol 8 No 22	3	2014 December
Nitrofurantoin	Vol 7 No 13	6	2013 August
Nivolumab	Vol 11 No 13	7	2017 October
Nivolumab TA 484	Vol 12 No 2	8	2018 January
Nizoral 200mg tabs are RED RED for fungal infections	Vol 7 No 18	3	2013 October
Nocturnal enuresis - management of bedwetting in children and young people	Vol 5 No 7	11	2011 April
Non-steroidal anti-inflammatory drugs	Vol 5 No 15	8	2011 September
Non-steroidal anti-inflammatory drugs (NSAIDs) - further evidence that the cardiovascular risk of diclofenac is higher than other non-selective NSAIDs and similar to the selective COX-2 inhibitors.	Vol 7 No 2	14	2013 January
Non-Steroidal Anti-Inflammatory Drugs and cardiovascular risk	Vol 4 No 14	8	2010 September
Non-Steroidal Anti-Inflammatory Durgs - Renal failure and impairment	Vol 3 No 7	17	2009 June
Non-Steroidal Anti-Inflammatory Drugs and cardiovascular risk	Vol 4 No 7	8	2010 May

Non-st-segment elevation myocardial infarction	Vol 4 No 7	5	2010 May
Noqdirna	Vol 12 No 6	2	2018 May
Norethisterone	Vol 8 No 7	10	2014 April
Norgestimate	Vol 8 No 7	10	2014 April
Norgestimate 250 microgram tablets	Vol 8 No 9	1	2014 May
Noyada	Vol 8 No 10	8	2014 May
NPSA - Reducing Risk of Harm from Oral Bowel Cleansing Solutions	Vol 3 No 4	15	2009 April
NPSA - Reducing Risk of Overdose with Midazolam Injections in Adults	Vol 3 No 2	8	2009 March
NPSA - Risks of Incorrect Dosing of Oral Anti-Cancer Medicines	Vol 2 No 13	9	2008 August
NSAIDs in heart failure	Vol 3 No 4	8	2009 April
NSAIDs or Cox-II inhibitors with PPIs	Vol 3 No 10	8	2009 October
Nualtra	Vol 8 No 8	6	2014 May
Nutilis Powder	Vol 8 No 8	2	2014 May
Nutricia	Vol 8 No 8	12	2014 May
Nutrinovo	Vol 8 No 8	12	2014 May
Nutriplen	Vol 8 No 8	6	2014 May
Nutrison	Vol 8 No 8	2	2014 May
Nutrition Special	Vol 2 No 5	1	2008 April
NuvaRing	Vol 3 No 4	3	2009 April
NuvaRing	Vol 3 No 7	5	2009 June
Nystatin Oral Suspension as Nystan - Prescribe	Vol 8 No 11	9	2014 June
Obeticholic acid	Vol 11 No 10	6	2017 June
Obinutuzumab infusion (Glazyvaro)	Vol 9 No 11	2	2015 July
Obinutuzumab infusion (Glazyvaro)	Vol 9 No 11	2	2015 July
Obinutuzumab with bendamustine (follicular lymphoma)	Vol 11 No 15	7	2017 November
Obstructive sleep apnoea, continuous positive airway pressure for the treatment of	Vol 2 No 9	5	2008 May/June
Occuvite complete	Vol 11 No 4	9	2017 March
Ocriplasmin	Vol 7 No 21	12	2013 December
Octasa	Vol 7 No 4	1	2013 February
Octasa	Vol 11 No 13	4	2017 October
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab	Vol 5 No 2	5	2011 February
Ofatumumab infusion	Vol 9 No 11	2	2015 July
Ofatumumab screen for hepatitis B virus	Vol 8 No 6	6	2014 March
Ofatumumab infusion (Arsera)	Vol 9 No 11	2	2015 July
Off label use or unlicensed medicines: prescribers responsibilities	Vol 3 No 5	12	2009 May
Oilatum	Vol 11 No 4	10	2017 March
Olanzapine; generic olanzapine tablets versus branded Zyprexa	Vol 6 No 16	8	2012 September
Olaratumab with doxorubicin	Vol 11 No 13	8	2017 October

Olena	Vol 8 No 16	5	2014 September
Olmesartan and the ROADMAP study	Vol 5 No 9	7	2011 May
Olmesartan/amlodipine tablets 5/20mg 10/20mg and 10/40mg	Vol 3 No 11	6	2009 October
Olopatadine 0.1% eye drops (opatanol)	Vol 6 No 5	6	2012 February
Olopatadine 0.1% eye drops (opatanol)	Vol 11 No 7	6	2017 March
Olysis	Vol 9 No 4	1	2015 March
Omacor	Vol 1 No 2	2	2007 July
Omacor and the Omega Study	Vol 5 No 3	9	2011 February
Omacor Review	Vol 2 No 10	2	2008 July
Omalizumab	Vol 9 No 15	4	2015 July
Omalizumab 150mg Inj	Vol 1 No 2	2	2007 July
Omalizumab for severe allergic asthma	Vol 2 No 1	10	2008 January
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years	Vol 5 No 3	5	2011 February
Omalizumab injection (Xolair) add-on therapy to improve control of asthma in children age 6 to 11 with severe persistent IgE mediated allergic asthma	Vol 7 No 12	7	2013 July
Omalizumab: potential risk of arterial thrombotic events	Vol 5 No 7	14	2011 April
Ombitasvir 12.5mg/paritaprevir 75mg/ritonavir 50mg tablets	Vol 10 No 2	3	2016 January
Omega 3 and CVD	Vol 8 No 23	6	2014 December
Omega 3 fatty acid compounds	Vol 12 No 3	4	2018 June
Omega 3 Fatty Acid Supplementation (Omacor) in the secondary prevention of cardiovascular disease	Vol 6 No 10	2	2012 May
Omega-3-acid ethyl esters capsules	Vol 1 No 2	2	2007 July
Omeprazole	Vol 4 No 2	9	2010 March
Omeprazole 20mg capsules	Vol 9 No 4	4	2015 March
Omeprazole 40mg capsules	Vol 9 No 4	3	2015 March
Ominitest 3 meter and blood glucose testing strips	Vol 8 No 12	7	2014 June
Omnican Lance Soft	Vol 9 No 10	1	2015 July
Onbrez Breezhaler	Vol 4 No 18	3	2010 October
Ondansetron (Zofran): risk of QTc prolongation – important new intravenous dose restriction	Vol 6 No 16	12	2012 September
Ondansetron 4mg and 8mg Oral Film	Vol 8 No 15	8	2014 August
Onglyza	Vol 4 No 2	7	2010 March
ONS	Vol 8 No 8	1	2014 May
ONS - Oral Nutritional supplements (Guidance for Adults)	Vol 12 No 5		2018 May
Opatanol	Vol 6 No 5	6	2012 February
Opiates and Snoring or Sleep Apnoea	Vol 2 No 15	10	2008 November
Opioid analgesics	Vol 8 No 1	11	2014 January
Opioid detoxification	Vol 1 No 6	6	2007 November
Opioids	Vol 8 No 16	10	2014 September

Opticrom eyedrops	Vol 11 No 7	5	2017 March
Opticrom allergy eye drops	Vol 11 No 4	9	2017 March
Opticrom Hayfever eye drops	Vol 11 No 4	9	2017 March
Optive eye drops (carmellose sodium 0.5%/Glycerine 0.9%) for dry eye syndrome	Vol 6 No 8	7	2012 May
Optrex allergy eye drops	Vol 11 No 4	9	2017 March
Optrex eyedrops	Vol 11 No 7	5	2017 March
Oral Anti-Cancer Medicines - NPSA Risks of incorrect dosing	Vol 2 No 13	9	2008 August
Oral bisphosphonates	Vol 5 No 3	11	2011 February
Oral Bowel Cleansing Solutions - Reducing Risk of Harm	Vol 4 No 8	1	2010 May
Oral Contraceptives - New Lower Cost - Rapid Cost Comparison	Vol 9 No 20	5	2015 November
Oral Mesalazine products for the management of inflammatory bowel disease	Vol 7 No 4	3	2013 February
Oral Morphine Modified Release Sulphate Preparations	Vol 4 No 18	9	2010 October
Oral nutritional supplements (ONS)	Vol 8 No 8	1	2014 May
Oral Nutritional supplements (ONS) 1kcal/ml	Vol 11 No 4	7	2017 March
Oral tacrolimus products should be prescribed and dispensed by brand name to avoid the risk of medication errors (MAY 2012)	Vol 6 No 12	11	2012 June
Orciprenaline sulphate (Alupent) reminder of withdrawal from the market on September 30th 2010	Vol 4 No 14	9	2010 September
Orciprenaline sulphate syrup planned withdrawal of	Vol 3 No 13	15	2009 December
Orglyza	Vol 8 No 10	3	2014 May
Orlistat	Vol 4 No 3	7	2010 March
Orlistat	Vol 8 No 10	12	2014 May
Orlistat (Xenical) supply problems	Vol 6 No 8	5	2012 May
Orlistat Prescribing	Vol 5 No 5	9	2011 March
Ortho-Gynest	Vol 8 No 18	7	2014 October
Oseltamivir (Tamiflu) - changed concentration and dosing dispenser of oral suspension from October 2012	Vol 7 No 2	12	2013 January
Oseltamivir and Zanamivir	Vol 3 No 11	13	2009 October
Oseltamivir for the treatment of influenza	Vol 3 No 4	8	2009 April
Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza	Vol 2 No 18	8	2008 November
Osmolite	Vol 8 No 8	2	2014 May
Osteoarthritis	Vol 2 No 7	2	2008 May
OTC drop list	Vol 11 No 4	1	2017 March
OTC guidance 2018	Vol 12 No 8		2018 August
OTC multivitamins & vitamin C	Vol 11 No 4	7	2017 March
Otex ear drops	Vol 11 No 4	10	2017 March

Otezla	Vol 11 No 6	10	2017 March
Otitis Media (Acute) - amoxicillin in	Vol 3 No 11	7	2009 October
Otitis Media, surgical management of with effusion in children	Vol 2 No 9	6	2008 May/June
Otovent Autoinflation device for glue ear	Vol 8 No 20	8	2014 December
Otrivine	Vol 11 No 4	4	2017 March
Otrivine - Antistin	Vol 11 No 7	6	2017 March
Ovarian cancer advanced	Vol 7 No 14	7	2013 August
Overactive bladder	Vol 7 No 14	1	2013 August
Ovranette	Vol 8 No 1	11	2014 January
Oxalate for the treatment of intermittent claudication in people with peripheral arterial disease	Vol 5 No 12	7	2011 July
Oxazepam	Vol 8 No 16	10	2014 September
Oxazepam	Vol 9 No 7	7	2015 April
Oxylal	Vol 2 No 15	3	2008 November
Oxybutymin 5mg modified release tablets	Vol 8 No 10	7	2014 May
Oxybutymin 5mg tablets	Vol 8 No 10	7	2014 May
Oxybutynin 2.5mg in 5ml and 5mg in 5ml oral solutions sugar-free	Vol 10 No 11	3	2016 August
Oxybutynin 2.5mg in 5ml/5mg in 5ml oral solution sugar-free	Vol 10 No 11	11	2016 August
Oxybutynin 3.9mg/24 hours transdermal patch	Vol 10 No 11	3	2016 August
Oxycodone	Vol 3 No 8	3	2009 August
Oxycodone	Vol 8 No 15	3	2014 August
Oxycodone and Naloxone combi	Vol 12 No 3	1	2018 June
Oxycodone prolonged release tablets	Vol 7 No 7	8	2013 May
Oxycodone prolonged release tablets (longtec)	Vol 6 No 19	7	2012 October
Oxycodone prolonged release tablets 5mg, 10mg, 20mg, 40mg and 80mg (Longtec)	Vol 6 No 19	3	2012 October
Oxycodone standard release capsules	Vol 8 No 5	9	2014 March
Oxycodone sustained release - Rapid Drug Assessment	Vol 10 No 2	5	2016 January
Oxycodone sustained released tablets 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg & 120mg	Vol 10 No 2	3	2016 January
Oxycodone/Naloxone prolonged release tablets	Vol 4 No 12	2	2010 August
Oxycodone/Naloxone prolonged release tablets (Targinact)	Vol 6 No 19	6	2012 October
Oxycodone/naloxone prolonged release tablets 10mg/5mg and 20mg/10mg (Targinact)	Vol 6 No 19	3	2012 October
Oxyletracycline 250mg tablets	Vol 9 No 8	10	2015 May
Oxynorm concentrate	Vol 11 No 10	2	2017 May
Oxynorm injections	Vol 11 No 10	2	2017 May
Oxynorm liquid	Vol 11 No 10	2	2017 May
OxyNorm vs Lynlor vs Shortec	Vol 8 No 5	9	2014 March

PACEF guidance on primary care rebate schemes	Vol 7 No 10	1	2013 June
Paclitaxel (with gemcitabine) for untreated metastatic pancreatic cancer	Vol 11 No 15	7	2017 November
Paclitaxel 100mg and 250mg infusion	Vol 10 No 2	3	2016 January
Palexia	Vol 6 No 4	3	2012 February
Palexia SR	Vol 6 No 4	3	2012 February
Paliperidone	Vol 1 No 6	3	2007 November
Paliperidone (Trevicta®) prolonged release suspension for injections (175mg, 263mg, 350mg, 525mg)	Vol 11 No 11	5	2017 August
Paludrine	Vol 11 No 4	6	2017 March
Paludrine/Avloclor	Vol 11 No 4	6	2017 March
Pancreatin - product supply problem	Vol 9 No 9	9	2015 June
Pandemrix and Celvapan	Vol 3 No 13	10	2009 December
Panitumumab	Vol 6 No 4	5	2012 February
Panitumumab	Vol 11 No 10	6	2017 May
pantoprazole 20mg tablets	Vol 9 No 4	4	2015 March
Pantoprazole 40mg tablets	Vol 9 No 4	3	2015 March
Paracetamol	Vol 6 No 3	9	2012 January
Paracetamol 325mg tablets and effervescent	Vol 10 No 10	5	2016 July
Paracetamol prophylactic at the time of vaccination may affect antibody response	Vol 3 No 13	12	2009 December
Paracetamol to prevent and treat fever after meningococcal group B vaccination	Vol 9 No 18	7	2015 November
Paracetamol: update dosing schedule for children	Vol 5 No 15	9	2011 September
Paraffin Based Skin Emollients on Dressings or Clothing - Fire Risk	Vol 10 No 10	11	2016 July
Paricalcitol capsules	Vol 2 No 12	3	2008 July
Partial onset seizures	Vol 7 No 14	18	2013 August
Patent Expiries 2010	Vol 4 No 1	4	2010 January / Feb
Patent Expiries 2012/13	Vol 6 No 4	6	2012 February
Patent Expiries	Vol 3 No 1	7	2009 January
Pazopanib for the first-line treatment of advance renal cell carcinoma	Vol 5 No 8	11	2011 May
PE	Vol 7 No 15	1	2013 August
Pegaptanib and ranibizumab for the treatment of age-related macular degeneration	Vol 2 No 18	7	2008 November
Pegfilgrastim-risk of potentially life threatening capillary leak syndrome	Vol 7 No 18	4	2013 October
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C	Vol 5 No 3	4	2011 February
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people November 2013	Vol 8 No 1	13	2014 January
Pegylated liposomal irinotecan	Vol 11 No 10	5	2017 June
Pembrolizumab 50mg posder for infusion	Vol 10 No 2	3	2016 January

Pembrolizumab for treating advance melanoma after disease progression with ipilimumab - NICE TA357	Vol 9 No 20	11	2015 November
Pemetrexed	Vol 2 No 3	10	2008 April
Pemetrexed for non-small cell lung cancer	Vol 1 No 5	8	2007 October
Pemetrexed for the maintenance treatment of non small cell lung cancer	Vol 4 No 14	6	2010 September
Pemetrexed for the first-line treatment of non-small-cell lung cancer	Vol 3 No 12	6	2009 November
Pen needles	Vol 8 No 19	4	2014 December
Penfluridol	Vol 1 No 6	3	2007 November
Pentoxifylline	Vol 12 No 7	4	2018 August
Pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease	Vol 5 No 12	7	2011 July
Perampanel approved use for onset seizures	Vol 7 No17	4	2013 October
Perindopril arginine	Vol 12 No 3	3	2018 June
Permetrexed maintenance treatment following induction therapy with permetrexed and cisplatin for non squamous non small cell lung cancer	Vol 8 No 16	6	2014 September
Persantin	Vol 11 No 8	10	2017 April
Pevanti	Vol 9 No 11	3	2015 July
Pharmaceutical Specials - use of unlicensed	Vol 4 No 17	1	2010 November
Pharmalgen for the treatment of bee and wasp venom allergy (February 2012) NICE TA246	Vol 6 No 8	10	2012 May
Pharyngitis / sore throat / tonsilitis	Vol 7 No 13	6	2013 August
Phenindione	Vol 11 No 4	3	2017 March
Phenoxymethylpenicillin in pharyngitis / sore throat / tonsillitis	Vol 8 No 22	1	2014 December
Phenytoin	Vol 4 No 2	11	2010 March
Phenytoin sodium capsules - guidance on the prescribing	Vol 6 No 18	3	2012 September
Pholcodine	Vol 11 No 4	3	2017 March
Phytomenadione inj.	Vol 12 No 6	3	2018 May
Picato	Vol 7 No 14	1	2013 August
Pico Wound Care	Vol 12 No 4	2	2018 May
Pigmanorm Cream	Vol 5 No 7	5	2011 April
Pioglitazone and bladder cancer	Vol 5 No 15	10	2011 September
Pioglitazone	Vol 2 No 1	11	2008 January
Pioglitazone	Vol 3 No 9	7	2009 August
Pioglitazone - guidance on the prescribing of generic	Vol 6 No 16	3	2012 September
Pioglitazone 15mg/metformin 850mg tablets (Competact)	Vol 7 No 10	1	2013 June
Pioglitazone and Bladder Cancer	Vol 5 No 12	2	2011 July
Pipexus (Prampexiole SR)	Vol 12 No 7	6	2018 August
Pipothiazine Palmitate -discontinuation	Vol 9 No 1	4	2015 February

Pixantrone	Vol 8 No 12	7	2014 June
Plavix	Vol 2 No 19	4	2008 December
Plenadren - new drug assessment	Vol 7 No 7	7	2013 May
Polycal	Vol 8 No 8	12	2014 May
Polyvinyl alcohol 1.4% eye drops Sno Tears treatment of dry eyes, approved for joint formulary alternative first line PVA preparation	Vol 7 No 6	1	2013 June
Polypharmacy in the frail elderly	Vol 11 No 8	13	2017 April
Pomalidomide	Vol 9 No 15	5	2015 July
Ponatinib	Vol 9 No 1	8	2015 February
POPADAD: Prevention of Progression of Arterial Disease and Diabetes Trial	Vol 3 No 1	8	2009 January
Potassium Permanganate	Vol 9 No 2	12	2015 February
PPIs and Clopidogrel - interaction	Vol 3 No 2	5	2009 March
PPIs and Clopidogrel - interaction	Vol 4 No 7	8	2010 May
PPIs with NSAIDs or Cox-II inhibitors	Vol 3 No 10	8	2009 October
Pprednisolone Dompe	Vol 10 No 9	5	2016 July
Pradaxa	Vol 6 No 4	10	2012 February
Pradaxa	Vol 9 No 7	1	2015 April
Pradaxa	Vol 9 No 7	2	2015 April
Pradaxa	Vol 10 No 1	4	2016 January
Pradaxa (FAQs)	Vol 7 No 15	15	2013 August
Pradaxa for the prevention of stroke in patients with atrial fibrillation (Second Edition)	Vol 7 No 16	1	2013 October
Pramipexole for parkinsons disease	Vol 5 No 3	3	2011 February
Prampexiole SR	Vol 12 No 7	6	2018 August
Prasugrel	Vol 8 No 20	9	2014 December
Prasugrel (Efient)	Vol 7 No 9	1	2013 June
Prasugrel (Efient), Increased risk of bleeding	Vol 8 No 6	6	2014 March
Prasugrel 5mg and 10mg tablets	Vol 3 No 11	5	2009 October
Prasugrel for the treatment of coronary syndromes with percutaneous coronary intervention	Vol 3 No 13	13	2009 December
Prasugrel tablets 5mg and 10mg (Efient)	Vol 6 No 19	3	2012 October
Prasugrel: Rare but serious hypersensitivity reactions	Vol 5 No 11	11	2011 June
Pravastatin - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	1	2013 February
Pravastatin low intensity statin	Vol 8 No 23	7	2014 December
Prednisolone	Vol 9 No 11	2	2015 July
Prednisolone - Use plain not soluble tablets	Vol 9 No 11	4	2015 July
Prednisolone 2.5mg, 5mg, 10mg, 20mg and 25mg tablets Rapid Drug Assessment	Vol 9 No 11	3	2015 July
Prednisolone 20mg Foam Aerosol	Vol 11 No 10	2	2017 June
Prednisolone oral solution	Vol 10 No 9	5	2016 July
Prednisolone std vs EC	Vol 5 No 2	5	2011 February
Prednisolone suppositories - shortage of	Vol 2 No 18	11	2008 November
Pregabalin	Vol 9 No 11	2	2015 July

Pregabalin - patent expired indications	Vol 9 No 3	2	2015 March
Pregabalin for neuropathic pain (prescribing & dispensing)	Vol 9 No 3	1	2015 March
Pregabalin update	Vol 11 No 8	3	2017 April
Pregabalin Capsules (Lecaent and Rewisca) Rapid Cost Comparison	Vol 9 No 11	6	2015 July
Prenoxad 2mg/2ml IM injection-approved for emergency use for reversal of opioid induced	Vol 7 No 17	5	2013 October
Preparation H gel /ointment	Vol 11 No 4	2	2017 March
Preservative free single dose eye drops	Vol 7 No 14	1	2013 August
Preservex	Vol 9 No 4	2	2015 March
Pressurised metered dose inhalers (pMDI) MHRA - drug safety update	Vol 12 No 7	7	2018 August
Prevention of harm with buccal midazolam (February 2012)	Vol 6 No 10	8	2012 May
Prexige	Vol 1 No 8	7	2007 December
Primary percutaneous coronary intervention (PPCI)	Vol 7 No 9	1	2013 June
Primary prevention of cardiovascular disease (CVD)	Vol 7 No 3	1	2013 February
Pro-Cal	Vol 8 No 8	12	2014 May
Pro-Cal Powder	Vol 8 No 8	10	2014 May
Pro-Cal Shot	Vol 8 No 8	10	2014 May
Prochlorperazine 5mg/5ml liquid	Vol 8 No 18	7	2014 October
Procoralan	Vol 3 No 2	4	2009 March
Procoralan	Vol 5 No 17	7	2011 October
Procoralan	Vol 9 No 4	1	2015 March
Procoralan	Vol 9 No 4	2	2015 March
Progestogens	Vol 8 No 7	10	2014 April
Proguanil	Vol 11 No 4	6	2017 March
Prolilia, Xgeva - Denosumab	Vol 11 Vol 12	3	2017 September
Propantheline	Vol 9 No 2	6	2015 February
Propantheline Bromide tablets	Vol 10 No 9	7	2016 July
Propecia (Finasteride 1mg) - MHRA safety update	Vol 11 No 11	6	2017 August
Propiverine 15mg tablets	Vol 8 No 10	7	2014 May
Propiverine 30mg modified release tablets	Vol 8 No 10	7	2014 May
Propylene Glycol 0.6% eye drops	Vol 8 No 19	7	2014 December
ProSource	Vol 8 No 8	12	2014 May
Prostaglandin analogue eye preparations	Vol 6 No 19	4	2012 October
Prostap 3 DCS	Vol 7 No 21	7	2013 December
Prostap SR DCS	Vol 7 No 21	7	2013 December
Prostate Cancer	Vol 2 No 6	9	2008 May
Protelos	Vol 8 No 10	3	2014 May
Protelos risk of serious cardiac disorders - restricted indications, new contra-indications and warnings	Vol 7 No 11	10	2013 July
Protifar	Vol 8 No 8	12	2014 May

Proton Pump Inhibitors (PPIs) and the risk of Clostridium difficile infection	Vol 4 No 14	6	2010 September
Proton pump inhibitors in long term use: reports of hypomagnesaemia	Vol 6 No 10	9	2012 May
Proton pump inhibitors in long-term use: recent epidemiological evidence of increased risk of bone fracture	Vol 6 No 10	9	2012 May
Proton pump inhibitors: Too much of a good thing?	Vol 5 No 11	9	2011 June
Proton Pump Inhibitors: Verylow risk of subacute cutaneous lupus erythematosus	Vol 9 No 18	9	2015 November
Protopic maintenance treatment of moderate severe atopic dermatitis	Vol 6 No 7	4	2012 May
Provigil - narcolepsy	Vol 5 No 8	9	2011 May
Prucalopride for the treatment of chronic constipation in women	Vol 5 No 7	8	2011 April
Pseudoephedrine and Ephedrine	Vol 9 No 18	10	2015 November
Pseudoephedrine HCL	Vol 11 No 4	4	2017 March
Psoriasis	Vol 2 No 3	9	2008 April
Psychosocial Interventions	Vol 1 No 6	6	2007 November
Pulmicort Inhaler CFC Free	Vol 3 No 7	7	2009 June
Pulmonary embolism	Vol 7 No 15	1	2013 August
Qlaira	Vol 3 No 13	5	2009 December
QT Prolongation Drug Induced	Vol 9 No 14	1	2015 September
Quadrivalent inactivated influenza vaccines	Vol 11 No 6	5	2017 March
Quetiapine	Vol 8 No 1	11	2014 January
Quetiapine	Vol 9 No 11	3	2015 July
Quetiapine MR	Vol 12 No 7	6	2018 August
Quetiapine MR formulations & costs	Vol 9 No 2	3	2015 February
Quetiapine prolonged release tablets	Vol 3 No 1	5	2009 January
Quetiapine prolonged release tablets	Vol 5 No 9	3	2011 May
Quetiapine sustained release tablets	Vol 10 No 9	6	2016 July
Quetiapine sustained release tablets (Mintreleq XL) Updated Cost Comparison	Vol 9 No 11	8	2015 July
Quetiapine: generic quetiapine tablets versus branded Seroquel and Seroquel XL	Vol 6 No 16	9	2012 September
Quinine	Vol 4 No 12	9	2010 August
Quinine	Vol 12 No 4	3	2018 May
Quinolone	Vol 7 No 13	1	2013 August
Quinolone	Vol 9 No 4	8	2015 March
Rabeprazole 20mg	Vol 9 No 4	6	2015 March
Racecadotril sachets 10mg/30mg (Hidrasec Infant/Hidrasec Children) and capsules 100mg (Hidrasec)	Vol 7 No 11	4	2013 July
Racemic menthol 2% topical	Vol 11 No 4	8	2017 March
Radian topical	Vol 11 No 4	8	2017 March
Radisan topical	Vol 11 No 4	8	2017 March

Raloxifene- effective use for chemoprevention, when woman have no diagnosis for breast cancer	Vol 7 No 17	8	2013 October
Raloxifene, strontium ranelate, teiparatide, alendronate, etidronate and risedronate for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)	Vol 2 No 19	7	2008 December
Ramipril capsules and ramipril tablets	Vol 8 No 1	10	2014 January
Ranexa	Vol 4 No 9	6	2010 June
Ranexa	Vol 5 No 17	8	2011 October
Ranibizumab	Vol 6 No 4	5	2012 February
Ranibizumab	Vol 7 No 14	7	2013 August
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia November 2013	Vol 8 No 1	13	2014 January
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration	Vol 2 No 18	7	2008 November
Ranibizumab Intravitreal Injection	Vol 1 No 4	3	2007 September
Ranitidine tablets 150mg	Vol 9 No 4	4	2015 March
Ranolazine	Vol 4 No 9	6	2010 June
Ranolazine	Vol 5 No 17	8	2011 October
Rapid Drug Assessment Colecalciferol 20,000 IU Tablets (Sunvit D3)	Vol 8 No 4	4	2014 February
Rapid Drug Assessment Bimatroprost / Timolol 300 Microgram/5mg per ml unit dose eye drops (GanfortUD)	Vol 8 No 4	4	2014 February
Rapid Drug Assessment Unlicensed clopidogrel oral solution 75 mg in 5ml and clopidogrel oral suspension 75mg in 5ml	Vol 7 No 21	9	2013 Decemember
Rasagiline (Azilect)	Vol 3 No 1	5	2009 January
Rasagiline (Azilect)	Vol 5 No 7	3	2011 April
Rasilez (Aliskiren)	Vol 1 No 8	2	2007 December
Rasilez (Aliskiren) - Risk of Angiodedema and Renal Dysfunction	Vol 3 No 7	16	2009 June
Rasilez (Aliskiren) emerging safety concerns around the use of	Vol 6 No 5	8	2012 February
Rasilez (Aliskiren) risk of cardiovascular and renal adverse reactions – new contraindications and warnings	Vol 6 No 8	12	2012 May
Reboxetine	Vol 5 No 3	9	2011 February
Reboxetine	Vol 5 No 18	3	2011 December
Reductil - suspension of marketing authorisation	Vol 4 No 1	2	2010 January / Feb
Regorafenib	Vol 9 No 8	12	2015 May
Regurin XL	Vol 3 No 13	8	2009 December
Regurin XL	Vol 8 No 10	8	2014 May
Relistor	Vol 3 No 4	3	2009 April
Relvar Ellipta	Vol 8 No 11	5	2014 June

Relvar Ellipta	Vol 12 No 7	3	2018 August
Reminyl	Vol 10 No 5	14	2016 March
Renagel	Vol 8 No 10	11	2014 May
Renavit approved for the dietary management of water soluble vitamin deficiency in renal failure patients receiving dialysis.	Vol 7 No 17	5	2013 October
Renin Angiotensin System Drugs: The Case for First Line Angiotensin Converting Enzyme Inhibitors	Vol 4 No 10	1	2010 July
Renin-angiotensin system blocking agents	Vol 8 No 16	8	2014 September
Renvela	Vol 4 No 20	4	2010 November
Renvela	Vol 8 No 10	3	2014 May
Repinex XL	Vol 8 No 16	3	2014 September
Requip XL	Vol 2 No 12	3	2008 July
Requip XL for parkinsons disease	Vol 5 No 3	3	2011 February
Reslizumab (eosinophilic asthma)	Vol 11 No 15	9	2017 November
Resource 2.0 Fibre	Vol 8 No 8	10	2014 May
Resource Dessert Energy	Vol 8 No 8	10	2014 May
Resource Dessert Fruit	Vol 8 No 8	10	2014 May
Resource Energy	Vol 8 No 8	6	2014 May
Resource Fruit	Vol 8 No 8	9	2014 May
Resource Protein	Vol 8 No 8	9	2014 May
Resource Thickenup	Vol 8 No 8	2	2014 May
Resource Thickenup Clear	Vol 8 No 12	7	2014 June
RESPeRATE	Vol 6 No 8	8	2012 May
Respiratory Tract Infections in Children	Vol 3 No 11	7	2009 October
Retapamulin Ointment 1%	Vol 2 No 6	3	2008 May
Retigabin	Vol 7 No 14	18	2013 August
Retigabine for the adjunctive treatment of partial onset seizures in epilepsy	Vol 6 No 2	8	2012 January
Retinoids oral	Vol 7 No 14	17	2013 August
Revaroxaban (FAQs)	Vol 7 No 15	15	2013 August
Review of Alogliptin (Vipidia and Vipdomet)	Vol 10 No 12	5	2016 August
Review of Dipeptidyl Peptidase 4 Inhibitors (or Gliptins) in Diabetes	Vol 10 No 12	1	2016 August
Review of expiry dates of blood glucose testing strips	Vol 8 No 12	7	2014 June
Review of gonadorelin analogues	Vol 7 No 21	7	2013 December
Review of Lincolnshire Lipid Modification Guidelines	Vol 7 No 3	1	2013 February
Review of Lipid Modification Guidance in response to the new NICE clinical guidance	Vol 8 No 23	1	2014 December
Revlimid	Vol 2 No 1	2	2008 January
Revlimid	Vol 6 No 3	9	2012 January
Revlimid risk of serious hepatic adverse drug reactions	Vol 7 No 7	2	2013 May
Rheumatoid arthritis - The management of rheumatoid arthritis in adults	Vol 3 No 5	10	2009 May
Rhinocort Aqua	Vol 9 No 7	2	2015 April

Rhinocort Aqua	Vol 11 No 7	4	2017 March
Rhinolast	Vol 11 No 7	5	2017 March
Ribavirin Peginterferon alfa and for the treatment of chronic hepatitis C	Vol 5 No 3	4	2011 February
Rifamixin (Xifaxanta)	Vol 7 No 10	1	2013 June
Rifaximin 200mg tablets (Xifaxanta)	Vol 6 No 19	11	2012 October
Rifaximin 200mg tablets (xifaxanta) for travellers diarrhoea	Vol 6 No 7	3	2012 May
Rifaximin tablets 200mg (Xifaxanta)	Vol 6 No 19	3	2012 October
Rifaximin tablets 200mg (Xifaxanta)	Vol 6 No 19	3	2012 October
Rifaximin tablets 550mg (Targaxan) for the reduction in recurrence of overt hepatic encephalopathy	Vol 7 No 10	1	2013 June
Rigevidon	Vol 8 No 1	11	2014 January
Rigevidon	Vol 8 No 9	4	2014 May
Rigevidon, Gedarel 20/150, Gedarel 30/150, Millinette 20/75, Millinette 30/75 and Triregol	Vol 5 No 7	6	2011 April
Rimonabant	Vol 2 No 17	1	2008 October
Rimonabant for the treatment of overweight and obese adults	Vol 2 No 13	4	2008 August
Risedronate and Anastrozole - Patent Expiries	Vol 5 No 11	4	2011 June
Risedronate, raloxifene, strontium ranelate, teiparatide, lendronate and etidronate for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)	Vol 2 No 19	7	2008 December
Risk of dementia with benzodiazepines; Effectiveness of non-benzodiazepine hypnotics in the treatment of adult insomnia	Vol 7 No 5	10	2013 March
Risk of NSAID induced acute kidney injury in patients taking concurrent diuretic	Vol 7 No 5	10	2013 March
Risk of severe harm or death when desmopressin is omitted or delayed in patients with diabetes insipidus	Vol 10 No 5	13	2016 March
Risperdal Consta	Vol 6 No 2	6	2012 January
Risperidone and Paliperidone: Risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery	Vol 8 No 4	8	2014 February
Risperidone Injection	Vol 6 No 2	6	2012 January
Rituximab	Vol 11 No 12	2	2017 September
Rituximab - non-hodgkins lymphoma	Vol 2 No 6	9	2008 May
Rituximab for rheumatoid arthritis	Vol 1 No 5	9	2007 October
Rituximab for the first line maintenance treatment of follicular non-hodkins lymphoma	Vol 5 No 15	6	2011 September
Rituximab for the first line treatment of chronic lymphocytic leukaemia	Vol 3 No 11	9	2009 October

Rituximab for the first line treatment of stage III-IV follicular lymphoma NICE TA243	Vol 6 No 7	7	2012 May
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia	Vol 4 No 18	11	2010 October
Rituximab in combination with Glucocorticoids	Vol 8 No 16	6	2014 September
Rituximab, Adalimumab, Etanercept, Infliximab, and Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	Vol 4 No 18	12	2010 October
Rituximab: Screen for Hepatitis B virus before treatment	Vol 8 No 4	9	2014 February
Rivaroxaban	Vol 9 No 11	3	2015 July
Rivaroxaban (Xarelto)	Vol 7 No 15	1	2013 August
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults	Vol 3 No 7	10	2009 June
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (July 2012) NICE TA261	Vol 7 No 15	1	2013 August
Rivaroxaban for the treatment of pulmonary embolism and prevention of recurrent venous thromboembolism	Vol 7 No 19	1	2013 October
Rivaroxaban in newly diagnosed AF	Vol 8 No 21	6	2014 December
Rivaroxaban price reduction and withdrawal of rebate scheme	Vol 9 No 21	13	2015 December
Rivaroxaban Tablets	Vol 3 No 1	6	2009 January
Rivaroxaban, Guidance on the prescribing of for the prevention of stroke and systemic embolism in atrial fibrillation (Second edition)	Vol 7 No 16	1	2013 October
Rivaroxaban, recommended use for DVT & PE	Vol 7 No 15	1	2013 August
Rivaroxiban	Vol 8 No 21	9	2014 December
Rivastigmine	Vol 8 No 10	11	2014 May
Rivastigmine	Vol 1 No 6	5	2007 November
Rivastigmine patches	Vol 11 No 10	5	2017 May
Rivastigmine Transdermal Patch	Vol 2 No 1	3	2008 January
Rivastigmine Transdermal Patch	Vol 4 No 12	9	2010 August
Rivastigmine transdermal patches (Alzet/Prometax/Voleze/Erastig)	Vol 11 No 1	10	2017 February
Rivastigmine, Memantine, Donepezil and Galantamine for the treatment of Alzheimer's Disease	Vol 5 No 11	4	2011 June
Roaccutane	Vol 7 No 14	17	2013 August
Roaccutane	Vol 9 No 4	1	2015 March
Roflumilast (COPD)	Vol 11 No 13	7	2017 October
Roflumilast (Daxas) risk of suicidal behaviour	Vol 7 No 7	2	2013 May

Roflumilast for the management of severe chronic obstructive pulmonary disease. NICE TA 244	Vol 6 No 7	7	2012 May
Roflumilast NICE TA 461 (COPD)	Vol 12 No 2	5	2018 January
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura	Vol 5 No 11	7	2011 June
Ropinirole 2mg, 4mg, 8mg	Vol 8 No 16	3	2014 September
Ropinirole modified release tablets for parkinsons disease	Vol 5 No 3	3	2011 February
Ropinirole prolonged release tablets	Vol 2 No 12	3	2008 July
Ropinrole modified releast tablets 2mg, 3mg, 4mg, 6mg and 8 mg (Pinna XL)	Vol 11 No 1	6	2017 February
Rosiglitazone	Vol 2 No 3	11	2008 April
Rosiglitazone	Vol 2 No 1	11	2008 January
Rosiglitazone - Safety concerns	Vol 1 No 5	4	2007 October
Rosiglitazone - Suspension of marketing authorisation	Vol 4 No 15	1	2010 September
Rosiglitazone and cardiovascular outcomes	Vol 3 No 8	5	2009 August
Rosuvastatin - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	2	2013 February
Rosuvastatin and rhabdomyolysis high dose	Vol 6 No 3	9	2012 January
Rosuvastatin third line option in CVD	Vol 8 No 23	6	2014 December
Rotigotine patches - new prescribing and storage requirements	Vol 2 No 13	9	2008 August
Rotigotine Transdermal Patch	Vol 1 No 8	3	2007 December
Rotigotine Transdermal Patch	Vol 2 No 13	9	2008 August
Rubifacients (this does not include topical NSAIDs)	Vol 12 No 3	2	2018 June
Rufinamide	Vol 2 No 2	2	2008 February
Rufinamide	Vol 2 No 18	7	2008 November
Rupafin	Vol 4 No 20	3	2010 November
Rupatadine 10mg tablets	Vol 4 No 20	3	2010 November
Ruxolitinib for treating polycythaemia vera - NICE TA356	Vol 9 No 20	10	2015 November
Sacubitril valsartan 49/51mg tablets and 97/103mg tablets	Vol 10 No 11	3	2016 August
Safe and Effective Use of Medicines enable the best possible outcomes (March 2015) CG NG5 Medicines Optimisation	Vol 9 No 16	1	2015 October
Safer administration of insulin	Vol 4 No 14	9	2010 September
Safinamide tablets	Vol 12 No 7	5	2018 August
Saflutan 15mcg/ml preservative free single dose eye drops-have been removed from formulary	Vol 7 No 17	7	2013 October
Salbutamol - Does it really need to be nebulised	Vol 10 No 2	8	2016 January
Salbutamol MDI used with spacer device- requires doses to be administered repeated single aspirations	Vol 7 No 18	8	2013 October

Salicylate 2% topical	Vol 11 No 4	8	2017 March
Salicylate gels new advice for those younger than 16 years	Vol 3 No 7	16	2009 June
Salmeterol (as Xinafoate) Sereflo® MDI	Vol 11 No 11	3	2017 August
Salmeterol 50 microgram	Vol 10 No 6	4	2016 May
Salmeterol and fluticasone	Vol 9 No 12	3	2015 July
Salmeterol as Xinafoate (Aerivio Spiromax) 50/500micrograms powder inhaler	Vol 11 No 11	3	2017 August
Salmeterol and Fluticasone propionate 25mcg/125mcg and 25mcg/250mcg meter dose inhaler (Sirdupla) Rapid Drug Assessment	Vol 9 No 12	4	2015 July
Salofalk foam enemas (Mezalazine)	Vol 12 No 2	5	2018 January
Salofalk Granules	Vol 12 No 4	2	2018 May
Sancuso	Vol 8 No 7	9	2014 April
Sarilumab TA 485	Vol 12 No 2	8	2018 January
Sativex Oromuscosal Spray	Vol 4 No 18	7	2010 October
Saxagliptin	Vol 4 No 2	7	2010 March
Saxagliptin 2.5mg and 5mg tablets	Vol 8 No 10	3	2014 May
Saxagliptin 2.5mg and 5mg tablets	Vol 10 No 12	2	2016 August
Saxagliptin and cardiovacular in patients with type 2 diabeters	Vol 7 No 18	5	2013 October
Saxagliptin/metformin	Vol 7 No 5	1	2013 March
Saxagliptin/metformin 2.5mg/850mg and 2.5mg/1g tablets (Komboglyza)	Vol 10 No 12	2	2016 August
Scandishake Mix	Vol 8 No 8	7	2014 May
Schizophrenia	Vol 7 No 14	8	2013 August
Schizophrenia - Diagnosis and treatment	Vol 3 No 8	6	2009 August
Sebco Ointment	Vol 2 No 9	4	2008 May/June
Sebivo	Vol 2 No 18	6	2008 November
Secondary prevention of cardiovascular disease (CVD)	Vol 7 No 3	2	2013 February
Secukinumab for treating moderate to severe plaque psoriasis NICE TA350	Vol 9 No 18	12	2015 November
Seebri Breezhaler	Vol 7 No 5	1	2013 March
Selincro	Vol 8 No 7	4	2014 April
Sereflo® MDI (Salmeterol as Xinafoate)	Vol 11 No 11	3	2017 August
Seretide Accuhaler	Vol 11 No 11	3	2017 August
Seretide Evohaler	Vol 11 No 8	8	2017 April
Seritide Accuhaler	Vol 11 No 8	7	2017 April
Seroquel	Vol 5 No 9	3	2011 May
Seroquel XL	Vol 3 No 1	5	2009 January
Seroquel XL	Vol 5 No 9	3	2011 May
Seroquel XL	Vol 8 No 1	11	2014 January
SetoFilm	Vol 8 No 15	8	2014 August
Sevelamer - Shared Care Guidelines	Vol 1 No 6	7	2007 November
Sevelamer carbonate 800mg tablets	Vol 8 No 10	3	2014 May
Sevelamer Carbonate Powder	Vol 4 No 20	4	2010 November
Sevelamer Hydrochloride 800m tablets	Vol 8 No 10	11	2014 May

Sevikar (amlodipine/olmesartan) tablets 5/20mg 10/20mg and 10/40mg	Vol 3 No 11	6	2009 October
SGLT2 Inhibitors	Vol 10 No 10	7	2016 July
SGLT2 inhibitors	Vol 11 No 10	4	2017 May
SGLT2 Inhibitors - changes to guidance	Vol 9 No 15	9	2015 October
SGLT2 Inhibitors (Risk of Diabetic Ketocidosis)	Vol 9 No12	10	2015 July
SGLT2 Inhibitors for Diabetes - Review begins - EMA	Vol 9 No 20	8	2015 November
Shared Care Guidelines	Vol 9 No 20	8	2015 November
Shortec concentrate	Vol 11 No 10	2	2017 May
Shortec injections	Vol 11 No 10	2	2017 May
Shortec liquid	Vol 11 No 10	2	2017 May
SHS	Vol 8 No 8	12	2014 May
Sibutramine (Reductil) - suspension of marketing authorisation	Vol 4 No 1	2	2010 January / Feb
Sildenafil 25mg, 50mg and 100mg	Vol 10 No 5	3	2016 March
Sildenafil chewable tablets 25mg, 50mg and 100mg	Vol 8 No 12	6	2014 June
Sildenafil tablets	Vol 8 No 14	3	2014 August
Simbrinza eye drops	Vol 9 No 6	3	2015 May
Simeprevir 150mg capsules	Vol 9 No 4	1	2015 March
Simeprevir 150mg capsules	Vol 9 No 4	2	2015 March
Simeprevir and Sofosbuvir - Risk of severe bradycardia and heart block when taken with amiodarone	Vol 9 No 18	8	2015 November
Simpresvir 150mg capsules	Vol 10 No 2	3	2016 January
Simvastatin - Review of Lincolnshire Modification Guidelines	Vol 7 No 3	1	2013 February
Simvastatin 80mg and Myopathy - MHRA Drug Safety Update	Vol 4 No 11	1	2010 August
Simvastatin second line option in CVD	Vol 8 No 23	5	2014 December
Simvastatin: Updated advice on drug interactions and contraindications	Vol 6 No 15	1	2012 October
Singulair	Vol 7 No 21	10	2013 December
Sipuleucel-T	Vol 9 No 8	12	2015 May
Sirdupla Evohaler	Vol 11 No 8	8	2017 April
Sirdupla Rapid Drug Assessment	Vol 9 No 12	4	2015 July
Sirolimus - shared care guideline	Vol 3 No 8	8	2009 August
Sitagliptin 50mg	Vol 8 No 10	3	2014 May
Sitagliptin	Vol 1 No 5	6	2007 October
Sitagliptin 100mg tablets	Vol 8 No 10	3	2014 May
Sitagliptin 100mg tablets	Vol 10 No 12	2	2016 August
Sitagliptin 50mg/metformin 1g	Vol 10 No 12	2	2016 August
Sitagliptin Tablets (Januvia)	Vol 6 No 5	7	2012 February
Sitagliptin/Metformin 50/1000 Tablets	Vol 4 No 12	4	2010 August
Sivextro	Vol 10 No 7	12	2016 May
Skinnies Silk	Vol 8 No 14	9	2014 August
SMA comfort Infant milk	Vol 11 No 4	8	2017 March
SMA staydown Infant Milk	Vol 11 No 4	8	2017 March

Sodium chloride 5% preservative free eye drops	Vol 8 No 13	5	2014 July
Sodium Chloride 7% nebuliser Solution	Vol 5 No 5	3	2011 March
Sodium cromoglicate 2% eye drops	Vol 11 No 4	9	2017 March
Sodium cromoglicate 2% eye drops	Vol 11 No 7	5	2017 March
Sodium Fusidate (topical)	Vol 9 No 2	7	2015 February
Sodium Hyaluronate 0.1% and dexpanthenol 2% eye drops	Vol 8 No 20	3	2014 December
Sodium hyaluronate 0.1% eye drops hylo tear, treatment of dry eyes, approved for joint formulary third line hyaluronate preparation	Vol 7 No 6	1	2013 June
Sodium hyaluronate 0.2% eye drops hylo forte, treatment of dry eyes, approved for joint formulary third line hyaluronate preparation	Vol 7 No 6	1	2013 June
Sodium Hyaluronate 1% 1.2ml pre-filled syringe (Tenovis and Sportvis) Rapid Drug Assessment	Vol 9 No 12	9	2015 July
Sodium hyaluronate 1% periarticular injections	Vol 9 No 12	3	2015 July
Sodium Hyaluronate Eye Drops	Vol 2 No 15	3	2008 November
Sodium Valproate granules	Vol 5 No 18	6	2011 December
Sodium Valproate MR capsules	Vol 1 No 2	4	2007 July
Sodium Valproate MR Granules	Vol 3 No 1	3	2009 January
Sodium Valproate Prolonged Release Granules	Vol 3 No 1	4	2009 January
Sodium Valproate restrictions in women and girls	Vol 8 No 20	11	2014 December
Sodium Valproate: Risk of Neurodevelopment delay in children following maternal use	Vol 8 No 4	8	2014 February
Sofosbuvir 400mg tablets	Vol 9 No 4	1	2015 March
Sofosbuvir 400mg tablets	Vol 9 No 4	2	2015 March
Solifenacin 5mg tablets	Vol 8 No 10	7	2014 May
Solifenacin 6mg modified release tablet (Vesomni)	Vol 8 No 10	6	2014 May
Solu-Medrone Injection	Vol 12 No 2	6	2018 January
Somatropin - human growth hormone for the treatment of growth failure in children	Vol 4 No 14	5	2010 September
Sorafenib for the treatment of advance hepatocellular carcinoma	Vol 4 No 14	6	2010 September
Sorafenib for the treatment of advance hepatocellular carcinoma	Vol 11 No 15	7	2017 November
Sovaldi	Vol 9 No 4	1	2015 March
Specials - alternatives to prescribing unlicensed pharmaceutical	Vol 6 No 11	1	2012 September
Specials - Use of unlicensed pharmaceuticals	Vol 4 No 17	1	2010 November
Spiriva handihaler	Vol 9 No 7	1	2015 April

Spiriva handihaler	Vol 9 No 7	2	2015 April
Spiriva Respimat	Vol 1 No 6	3	2007 November
Spiriva Respimat	Vol 9 No 7	1	2015 April
Spiriva Respimat	Vol 9 No 7	1	2015 April
Spiriva Respimat	Vol 9 No 7	2	2015 April
Spiriva Respimat - mounting concerns over the safety of	Vol 7 No 2	9	2013 January
Spironolactone - heart failure	Vol 11 No 6	9	2017 March
Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia - clarification	Vol 11 No 6	9	2017 March
Spironolactone and renin-angiotensin system drugs of potentially fatal hyperkalaemia in heart failure	Vol 10 No 6	12	2016 May
Spriva handihaler / Tiotropium 18mcg	Vol 11 No 6	3	2017 March
St John's Wort	Vol 8 No 10	12	2014 May
ST segment elevation MI (STEMI), no STEMI and unstable angina	Vol 7 No 9	1	2013 June
ST segment elevation myocardial infarction (STEMI) Treatment Algorithm	Vol 7 No 9	5	2013 June
ST Segment elevation myocardial infarction (STEMI), Prescribing Guidance	Vol 7 No 9	2	2013 June
Stable Angina management of	Vol 5 No 17	4	2011 October
Standard Prednisolone tablets versus enteric coated prednisolone	Vol 5 No 2	3	2011 February
Statin therapy - side effects and unintended benefits	Vol 4 No 14	7	2010 September
Statins - Benefits & Risks	Vol 8 No 13	8	2014 July
Statins - Improving Adherence	Vol 4 No 3	6	2010 March
Statins (January 2008)	Vol 2 No 3	11	2008 April
Statins adherence	Vol 4 No 2	6	2010 March
Statins for primary prevention of cardiovascular disease	Vol 5 No 7	12	2011 April
Statins update product information	Vol 3 No 13	15	2009 December
Stelara	Vol 9 No 4	1	2015 March
Stelara	Vol 11 No 10	5	2017 May
Stelazine	Vol 6 No 3	11	2012 January
Stexerol-D3	Vol 10 No 3	3	2016 February
Stexerol-D3 25.000 IU	Vol 11 No 15	4	2017 November
Strattera (Atomoxetine) - risk of psychotic or manic symptoms	Vol 3 No 4	14	2009 April
Stroke and systemic embolism in atrial fibrillation the prevention of	Vol 6 No 13	1	2012 August
Strontium Ranelate	Vol 8 No 10	12	2014 May
Strontium ranelate - risk of venous thromboembolism	Vol 6 No 12	10	2012 June
Strontium ranelate (Protelos) risk of serious cardiac disorders – restricted indications, new contra-indications and warnings	Vol 7 No 11	10	2013 July

Strontium ranelate 2g sachets	Vol 8 No 10	3	2014 May
Strontium ranelate, teiparatide alendronate, etidronate, risedronate, raloxifene for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)	Vol 2 No 19	7	2008 December
Subject	Volume & Number	Page Number	Date of issue
Sudafed	Vol 11 No 4	4	2017 March
Sulphanmethoxypyridazine	Vol 4 No 9	6	2010 June
Sumatriptan 50mg and 100mg tablets (generic)	Vol 8 No 11	10	2014 June
Sunitinib - first line treatment of advanced or metastatic renal cell carcinoma	Vol 3 No 5	9	2009 May
Sunitinib for the treatment of advanced and or metastatic renal cell carcinoma	Vol 3 No 11	10	2009 October
Sunitinib for the treatment of Gastrointestinal Stromal Tumours	Vol 3 No 12	5	2009 November
Sunscreens	Vol 9 No 8	4	2015 May
Sunsense Ultra	Vol 9 No 8	4	2015 May
Sunvit D3	Vol 8 No 4	4	2014 February
Sunya	Vol 1 No 2	4	2007 July
Sycrest (Asenapine) 5mg and 10mg sublingual tablets New Drug Assessment	Vol 6 No 8	6	2012 May
Symbicotr Smart	Vol 1 No 6	4	2007 November
Synjardy	Vol 9 No 21	9	2015 December
Synjardy	Vol 11 No 6	11	2017 March
Systane eye drops	Vol 8 No 19	7	2014 December
Systane eye drops, treatment of dry eyes, approved for joint formulary second line, hydroxypropyl guar preparation	Vol 7 No 6	1	2013 June
TA338 Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib	Vol 9 No 15	13	2015 October
TA339 Omalizumab for previously treated chronic spontaneous urticaria	Vol 9 No 15	13	2015 October
TA340 Ustekinumab for treating active psoriatic arthritis	Vol 9 No 15	14	2015 October
TA342 Vedolizumab for treating moderately to severely active ulcerative colitis	Vol 9 No 15	14	2015 October
TA347 Nintedanib for previously locally advanced metastatic or locally recurrent non-small cell lung cancer	Vol 9 No 15	14	2015 October
TA348 Everolimus for preventing organ rejection in liver transplantation	Vol 9 No 15	15	2015 October
TA351 Congrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy	Vol 9 No 15	15	2015 October

Tabphyn MR	Vol 8 No 10	7	2014 May
Tacrolimus - oral products (Update May 2018)	Vol 12 No 4	4	2018 May
Tacrolimus - shared care guideline	Vol 3 No 8	8	2009 August
Tacrolimus Granules for oral suspension	Vol 4 No 3	7	2010 March
Tacrolimus ointment 0.03% and 0.1% (Protopic) for maintenance treatment of moderateto severe atopic dermatitis	Vol 6 No 7	4	2012 May
Tadalafil (Cialis)	Vol 7 No 10	1	2013 June
Tadalafil 10mg and 20mg tablets	Vol 10 No 5	3	2016 March
Tadalafil 10mg and 20mg tablets	Vol 12 No 6	3	2018 May
Tadalafil 2.5mg and 5mg tablets	Vol 3 No 4	5	2009 April
Tadalafil 2.5mg tablets	Vol 10 No 5	3	2016 March
Tadalafil 5mg tablets	Vol 10 No 5	3	2016 March
Tafluprost 15mcg/ml preservative free single dose eye drops-have been removed from formulary	Vol 7 No 17	7	2013 October
Tafluprost 15mcg/timolog 5mg per ml preservative free singe use eye drops	Vol 9 No 21	12	2015 December
Taldafil 2.5mg and 5mg once a day	Vol 12 No 3	3	2018 June
Tamoxifen- effective use for chemoprevention, when woman have no diagnosis for breast cancer	Vol 7 No 17	8	2013 October
Tamsulosin 0.4mg capsules	Vol 4 No 18	5	2010 October
Tamsulosin 400 microgram/solifenacin 6mg modified release tablet (Vesomni)	Vol 8 No 10	6	2014 May
Tapentadol and Nottinghamshire Pain Guidance	Vol 10 No 3	8	2016 February
Tapentadol immediate release tablets	Vol 6 No 4	3	2012 February
Tapentadol prolonged release tablets (Palexia SR)	Vol 7 No 10	1	2013 June
Tapitiqom	Vol 9 No 21	12	2015 December
Targinact	Vol 3 No 8	3	2009 August
Targinact	Vol 4 No 12	2	2010 August
Targinact	Vol 12 No 3	1	2018 June
Tecfidera	Vol 8 No 19	11	2014 December
Tecfidera	Vol 9 No 8	12	2015 May
Tedizolid 200mg tablets and 200mg powder for solution for infusion	Vol 10 No 7	12	2016 May
Telaprevir	Vol 9 No 1	7	2015 February
Telbivudine for the treatment of chronic hepatitis B	Vol 2 No 18	6	2008 November
Temazepam	Vol 7 No 5	1	2013 March
Temazepam	Vol 8 No 16	10	2014 September
Temazepam	Vol 9 No 7	7	2015 April
Temozolomide	Vol 8 No 6	6	2014 March
Temsirolimus for the treatment of advanced and or metastatic renal cell carcinoma	Vol 3 No 11	10	2009 October

Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma	Vol 5 No 7	7	2011 April
Tenofovir Disoproxil for the treatment of chronic hepatitis	Vol 3 No 11	8	2009 October
Teoptic	Vol 9 No 6	10	2015 May
Terparatide, Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teiparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)	Vol 2 No 19	7	2008 December
Testosterone Patch	Vol 1 No 2	4	2007 July
Tetracycline 250mg tablets	Vol 9 No 8	10	2015 May
Tetracycline 500mg	Vol 9 No 4	7	2015 March
Teva levothyroxine 100 microgram tablets: potential reduced efficacy – suspension of marketing authorisation	Vol 6 No 8	13	2012 May
Thalidomide Pharmion Capsules	Vol 3 No 1	5	2009 January
Thalidomide: Reduced starting dose in patients older than age 75 years	Vol 10 No 3	8	2016 February
Thalidomide; Risk of arterial and venous thromboembolism	Vol 5 No 15	8	2011 September
The Patient Journey Through United Lincolnshire Hospitals	Vol 10 No 8	1	2016 July
The use of intranasal corticosteroids in perennial and seasonal allergic rhinitis	Vol 10 No 14	4	2016 October
theiCal-D3 chewable tablets	Vol 9 No 8	6	2015 May
Thick and Easy	Vol 8 No 8	2	2014 May
Thick and Easy Clear	Vol 10 No 3	5	2016 February
Thrombin Inhibitors oral direct and the risk of myocardial infarction	Vol 8 No 6	5	2014 March
Ticagrelor (Brillique)	Vol 7 No 9	1	2013 June
Ticagrelor 90mg tablets (Brilique)	Vol 6 No 19	3	2012 October
Ticagrelor for the treatment of acute coronary syndromes (October 2011) TA236	Vol 6 No 19	13	2012 October
Timolol	Vol 8 No 4	4	2014 February
Timolol 0.1% single dose preservative free eye gel (Tiopex) and timolol 0.25% and 0.5% ophthalmic gel forming solution (Timoptol) LA	Vol 8 No 1	9	2014 January
Timolol 0.25% and 0.5% eye drops	Vol 9 No 6	2	2015 May
Timoptol - LA	Vol 9 No 6	2	2015 May
Tiotropim 2.5 microgram	Vol 9 No 7	2	2015 April
Tiotropium	Vol 5 No 15	7	2011 September
Tiotropium	Vol 5 No 3	12	2011 February
Tiotropium 10 microgram inhalation powder	Vol 11 No 6	3	2017 March
Tiotropium 10mcg / Braltus Zonda	Vol 11 No 6	3	2017 March
Tiotropium 18mcg / Spriva handihaler	Vol 11 No 6	3	2017 March

Tiotropium 18mcg handihaler (Braltus Zonda 10mcg)	Vol 11 No 6	3	2017 March
Tiotropium Bromide	Vol 1 No 6	3	2007 November
Tiotropium Bromide	Vol 3 No 11	8	2009 October
Tiotropium bromide - mounting concerns over the safety of	Vol 7 No 2	9	2013 January
Tiotropium Bromide Monohydrate 2.5microgram per actuation (spiriva respimat) price reduction	Vol 10 No 16	6	2016 October
Tiotropium spiriva respimat inhaler-reclassified from RED RED to GREEN	Vol 7 No18	5	2013 October
Tobramycin 3mg/ml eye drops	Vol 5 No 12	5	2011 July
Tobravisc	Vol 5 No 12	5	2011 July
Tocilizumab	Vol 8 No 19	7	2014 December
Tocilizumab for the treatment of Rheumatoid Arthritis	Vol 4 No 20	5	2010 November
Toctino	Vol 3 No 5	3	2009 May
Toctino	Vol 7 No 14	17	2013 August
Tofacitinib TA 480	Vol 12 No 2	8	2018 January
Tolterodine 2mg tablets	Vol 8 No 10	7	2014 May
Tolterodine 4mg sustained release capsule	Vol 9 No 8	7	2015 May
Tolterodine 4mg sustained release capsules	Vol 8 No 10	8	2014 May
Tolvaptan (Samsca) risk of liver injury; Thalidomide - risk of second primary malignancies; Liothyronine 20 microgram tablets - continuity of supply and potential need for patient monitoring	Vol 7 No 12	9	2013 July
Tolvaptan 15mg and 30mg tablets (Samsca)	Vol 6 No 8	7	2012 May
Tolvaptan tablets 15mg, 30mg, 45mg and 60mg	Vol 10 No 2	3	2016 January
Tomoxifen for breast cancer	Vol 5 No 3	10	2011 February
Topical antibiotics for acute infective conjunctivitis: to treat or not to treat?	Vol 6 No 2	9	2012 January
Topical ketoprofen	Vol 4 No 18	15	2010 October
Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin	Vol 10 No 13	12	2016 August
Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Vol 6 No 4	4	2012 February
Topotecan for the treatment of recurrent and stage IVB cervical cancer	Vol 3 No 13	14	2009 December
Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)	Vol 4 No 1	6	2010 January / Feb
Toujeo	Vol 9 No 21	9	2015 December
Toviaz	Vol 2 No 15	2	2008 November
Toviaz	Vol 8 No 10	7	2014 May
Trabectedin - Treatment of advance soft tissue sarcoma	Vol 4 No 6	11	2010 May

Trabectedin for the treatment of relapsed ovarian cancer	Vol 5 No 11	8	2011 June
Trajenta	Vo 8 No 10	3	2014 May
Tramacet	Vol 12 No 3	1	2018 June
Tramacet (tramadol 37.5mg/paracetamol 325mg)	Vol 11 No 4	5	2017 March
Tramacet Effervescent	Vol 10 No 10	5	2016 July
Tramadol	Vol 8 No 11	2	2014 June
Tramadol 37.5mg	Vol 10 No 10	5	2016 July
Tramadol Cost Comparison	Vol 10 No 10	6	2016 July
Trametinib - risk of gastrointestinal perforation and colitis	Vol 10 No 6	13	2016 May
Transdermal Fentanyl patches	Vol 8 No 16	10	2014 September
Transient Ischaemic attack and stroke	Vol 2 No 15	6	2008 November
Transtec and Butrans	Vol 8 No 15	5	2014 August
Transvasin topical	Vol 11 No 4	9	2017 March
Trastuzumab emtansine	Vol 11 No 13	7	2017 October
Trastuzumab for the treatment of HER2-Positive metastatic gastric cancer	Vol 5 No 7	7	2011 April
Trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 (June 2012) TA257	Vol 7 No 2	11	2013 January
Travel Vaccines	Vol 12 No 3	3	2018 June
Travoprost	Vol 9 No 6	1	2015 May
Travoprost 40mcg / timolol 5mg per ml drops	Vol 9 No 6	2	2015 May
Tredaptive	Vol 4 No 2	3	2010 March
Tredaptive product withdrawn	Vol 7 No 4	1	2013 February
Treloegy Ellipta	Vol 12 No 7	2	2018 August
Trevicta®- Paliperidone prolonged release suspension for injections (175mg, 263mg, 350mg, 525mg)	Vol 11 No 11	5	2017 August
Triamcinolone acetonide	Vol 11 No 7	5	2017 March
Trifluoperazine Tablets	Vol 6 No 3	11	2012 January
Trimbow Inhaler	Vol 12 No 4	2	2018 May
Trimethoprim in UTI	Vol 8 No 22	3	2014 December
Trimipramine	Vol 12 No 3	2	2018 June
Trioptassium dicitratobismuthate 120mg	Vol 9 No 4	7	2015 March
Triotropium bromide 18 micrograme	Vol 9 No 7	2	2015 April
Triptans	Vol 8 No 11	10	2014 June
Triptorelin	Vol 7 No 21	7	2013 December
Triptorelin	Vol 11 No 5	1	2017 February
Trobalt	Vol 7 No 14	18	2013 August
Trospium chloride 60mg sustained release capsules	Vol 8 No 10	8	2014 May
Trospium chloride sustained release capusles 60mg	Vol 3 No 13	8	2009 December
Trospium chloride tablets 20mg	Vol 8 No 10	8	2014 May

Truberzi	Vol 12 No 4	4	2018 May
Trulicity	Vol 9 No 18	5	2015 November
Tubifast 2-way stretch elasticated tubular bandage	Vol 10 No 5	7	2016 March
Type 2 diabetes	Vol 7 No 14	8	2013 August
Type 2 diabetes in adults - NICE Guideline NG28	Vol 9 No 21	9	2015 December
Tysabri	Vol 4 No 6	12	2010 May
Ulipristal	Vol 8 No 16	11	2014 September
Ulipristal 30mg tablet (Ellaone) - New Drug Assessment	Vol 4 No 1	3	2010 January / Feb
Ulipristal 30mg tablets (ellaone)	Vol 6 No 16	5	2012 September
Ulipristal acetate	Vol 12 No 6	5	2018 May
Ulipristal acetate 5mg tablets	Vol 7 No 2	6	2013 January
Ulipristal acetate 5mg tablets (Esyma)	Vol 11 No 11	2	2017 August
Uncomplicated UTI in men or women	Vol 7 No 13	8	2013 August
Unlicensed clopidogrel oral solution 75 mg in 5ml and clopidogrel oral suspension 75mg in 5ml	Vol 7 No 21	9	2013 December
Unstable angina	Vol 4 No 7	5	2010 May
Updated Meningococcal Guidance	Vol 5 No 12	9	2011 July
Upostelle	Vol 8 No 9	6	2014 May
Upostelle - Rapid Cost Comparison	Vol 8 No 9	6	2014 May
Urinary incontinence	Vol 7 No 14	1	2013 August
Urinary Tract Infection in Children	Vol 1 No 7	3	2007 November
Ustekinumab	Vol 9 No 15	5	2015 July
Ustekinumab	Vol 11 No 10	5	2017 May
Ustekinumab	Vol 11 No 13	6	2017 October
Ustekinumab 90mg/ml injection	Vol 9 No 4	2	2015 March
Ustekinumab for the treatment of adults with moderate to severe psoriasis	Vol 3 No 12	5	2009 November
Ustekinumab for treating active psoriatic arthritis	Vol 8 No 16	7	2014 September
Ustekinumab	Vol 9 No 4	1	2015 March
UTI in pregnancy	Vol 7 No 13	8	2013 August
Uvistat Lipscreen	Vol 9 No 8	4	2015 May
Uvistat Suncream	Vol 9 No 8	4	2015 May
Vaccine Cold Storage	Vol 4 No 3	9	2010 March
Vaccines Live Attenuated	Vol 10 No 10	8	2016 July
Vaginal and vulval infections	Vol 8 No 1	11	2014 January
Valdoxan	Vol 3 No 11	4	2009 October
Valdoxan	Vol 4 No 20	2	2010 November
Valproate - Drug safety update April 2017	Vol 11 No 10	4	2017 June
Valproate and risk of abnormal pregnancy outcomes	Vol 10 No 6	10	2016 May
Vamju Rapid Drug Assessment	Vol 9 No 11	5	2015 July
Vancomycin	Vol 9 No 15	5	2015 July
Vaniqa	Vol 6 No 3	9	2012 January
Vaniqa 11.5% cream	Vol 11 No 6	8	2017 March
Vardenafil (Levitra)	Vol 7 No 10	1	2013 June

Vardenafil 10mg orodispersible tablets	Vol 10 No 5	3	2016 March
Vardenafil 5mg, 10mg and 20mg tablets	Vol 10 No 5	3	2016 March
Vardenafil Orodispersible Tablets	Vol 5 No 12	4	2011 July
Varenicline	Vol 2 No 3	6	2008 April
Varenicline - Suicidal Thoughts and Behaviour	Vol 2 No 13	7	2008 August
Varenicline (Champix)	Vol 8 No 17	7	2014 October
Varenicline for smoking cessation	Vol 1 No 4	5	2007 September
Varenicline in patients with cardiovascular disease	Vol 4 No 2	9	2010 March
Varicella zoster virus vaccine (Zostavax)	Vol 6 No 10	5	2012 May
Varicella zoster virus vaccine (Zostavax)	Vol 7 No 2	3	2013 January
Varicella zoster virus vaccine (Zostavax)	Vol 7 No 7	1	2013 May
Varicella zoster virus vaccine (Zostavax)	Vol 8 No 1	10	2014 January
Vectibix	Vol 11 No 10	6	2017 May
Vedolizumab	Vol 9 No 15	5	2015 July
Vedolizumab for treating moderately to severely active crohn's disease after priory therapyt - NICE TA352	Vol 9 No 20	9	2015 November
Vemurafenib (Zelboraf) risk of potentiation of radiation toxicity	Vol 9 No 21	13	2015 December
Venlafaxine	Vol 5 No 9	3	2011 May
Venlafaxine - for generalised anxiety disorder (GAD) and social phobia	Vol 2 No 12	4	2008 July
Venlafaxine Modified Release Capsules (Venlablue XL/Vensir XL)	Vol 11 No 1	5	2017 February
Venlafaxine Modified Release Formulations	Vol 8 No 4	5	2014 February
Venous thromboembolism	Vol 4 No 7	3	2010 May
Venous thromboembolism	Vol 7 No 15	1	2013 August
Venous Thromboembolism	Vol 1 No 1	3	2007 June
Verapamil prescribing notes with simvastatin	Vol 8 No 23	8	2014 December
Versatis	Vol 1 No 5	7	2007 October
Versatis	Vol 12 No 3	1	2018 June
Vesicare	Vol 8 No 10	7	2014 May
Vesomni	Vol 8 No 10	6	2014 May
Veterans Affairs Diabetes Trial (VADT) - New trial assessment	Vol 3 No 5	5	2009 May
Viagra June 2013 patent expiry	Vol 7 No 10		2013 June
Vibro-Pulse	Vol 8 No 11	4	2014 June
Vibro-Pulse Cycloidal Vibration Accessories	Vol 8 No 11	4	2014 June
Victoza	Vol 3 No 12	2	2009 November
Victoza	Vol 4 No 3	2	2010 March
Vidagliptin 50mg tablets	Vol 8 No 10	3	2014 May
Vidaza (azacitidine) treatment of myelodysplastic syndromes	Vol 5 No 9	7	2011 May
Vigabatrin for infantile spasms	Vol 3 No 13	15	2009 December
Vildagliptin	Vol 2 No 10	4	2008 July
Vildagliptin 50mg tablets	Vol 10 No 12	2	2016 August

Vildagliptin/metformin 50mg/850mg and 50mg/1g tablets	Vol 10 No 12	2	2016 August
Vildagliptin/metformin 50mg/950mg and 50mg/1g tablets	Vol 8 No 10	3	2014 May
Vimovo	Vol 5 No 5	3	2011 March
Vimovo	Vol 6 No 2	5	2012 January
Vimpat	Vol 4 No 9	5	2010 June
Visioncare	Vol 11 No 4	10	2017 March
Visual impairment caused by macular oedema	Vol 7 No 14	7	2013 August
Vitaflo	Vol 8 No 8	7	2014 May
Vitaflo	Vol 8 No 8	12	2014 May
Vitaflo	Vol 8 No 8	12	2014 May
Vitajoule	Vol 8 No 8	12	2014 May
Vitamin C & multivitamins	Vol 11 No 4	7	2017 March
Vitamin D & Falls	Vol 3 No 12	4	2009 November
Vitamin D (coleciferol) capsules (unlicensed imported): potential peanut oil and soya oil allergens.	Vol 6 No 8	13	2012 May
Vitamin D and Calcium supplementation	Vol 4 No 6	9	2010 May
Vitamin D Deficiency	Vol 6 No 6		2012 May
Vitamin D deficiency in at risk adults	Vol 9 No 13	1	2015 September
Vitamin D Deficiency in at-risk groups: Part 2 Treatment	Vol 6 No 14		2012 September
Vitamin K antagonist in existing AF patients	Vol 8 No 21	8	2014 December
Vitapro	Vol 8 No 8	12	2014 May
Vitaros cream	Vol 11 No 10	3	2017 May
Vitasavoury	Vol 8 No 8	7	2014 May
Viteyes	Vol 11 No 4	10	2017 March
Vividrin	Vol 11 No 7	6	2017 March
Vocanamet	Vol 11 No 6	11	2017 March
Voriconazole	Vol 8 No 13	8	2014 July
Voriconazole	Vol 9 No 15	5	2015 July
Voriconazole 1% eye drops for corneal ulcers and fungal keratitis (unlicensed)	Vol 10 No 14	9	2016 October
VT	Vol 7 No 15	1	2013 August
Warfarin – reports of calciphylaxis	Vol 10 No 14	11	2016 October
Warfarin (vs Rivaroxaban)	Vol 7 No 14	10	2013 August
Warfarin conversion to dabigatran, rivaroxaban or apixaban	Vol 8 No 21	8	2014 December
Warfarin in newly diagnosed AF	Vol 8 No 21	7	2014 December
Warfarin risk of confusion between 0.5mg and 5mg strengths	Vol 10 No 17	11	2016 December
Warfarin to Apixaban	Vol 8 No 21	8	2014 December
Warfarin to Dabigatran	Vol 8 No 21	8	2014 December
Warfarin to Rivaroxaban	Vol 8 No 21	8	2014 December
Warfarin, Guidance on the prescribing of for the prevention of stroke and systemic embolism in atrial fibrillation (Second Edition)	Vol 7 No 16	1	2013 October

Waste Campaign 2008	Vol 2 No 7	4	2008 May
Waste Medicines - evaluation of scale, causes and costs	Vol 5 No 8	8	2011 May
White soft paraffin/liquid 50:50	Vol 9 No 5	4	2015 May
Wound Management Formulary	Vol 2 No 15	9	2008 November
Wound Management Formulary	Vol 6 No 17	1	2012 October
Xadago tablets (Safinamide)	Vol 12 No 7	5	2018 August
Xamiol (Calcipotriol/betamethasone gel)	Vol 3 No 4	4	2009 April
Xarelto	Vol 3 No 1	6	2009 January
Xarelto	Vol 7 No 15	1	2013 August
Xarelto (FAQs)	Vol 7 No 15	15	2013 August
Xarelto for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (July 2012) NICE TA261	Vol 7 No 15	1	2013 August
Xarelto for the treatment of pulmonary embolism and prevention of recurrent venous thromboembolism	Vol 7 No 19	1	2013 October
Xarelto, Guidance on the prescribing of for the prevention of stroke and systemic embolism in atrial fibrillation (Second edition)	Vol 7 No 16	1	2013 October
Xenidate XL	Vol 9 No 8	7	2015 May
Xifaxanta	Vol 6 No 7	3	2013 May
Xigduo	Vol 11 No 6	11	2017 March
Xolair	Vol 1 No 2	2	2007 July
Xultophy	Vol 10 No 9	3	2016 July
Xultophy Rapid Drug Assessment	Vol 9 No 9	6	2015 June
Xylometazoline HCL	Vol 11 No 4	4	2017 March
Xylometazoline HCL	Vol 11 No 7	6	2017 March
Xysal	Vol 11 No 7	2	2017 March
Yasmin - risk of venous thromboembolism	Vol 4 No 7	8	2010 May
Yasmin: risk of venous thromboembolism higher than levonorgestrel- containing pills.	Vol 5 No 12	10	2011 July
Yellox	Vol 6 No 3	8	2012 January
Zafirlukast	Vol 7 No 21	10	2013 December
Zafirlukast 20mg tablets	Vol 9 No 4	1	2015 March
Zafirlukast 20mg tablets	Vol 9 No 4	2	2015 March
Zaleplon	Vol 8 No 11	2	2014 June
Zanamivir for the treatment of influenza	Vol 3 No 4	8	2009 April
Zanamivir, oseltamivir and amantadine for the prophylaxis of influenza	Vol 2 No 18	8	2008 November
Zarfirlukast / Accolate	Vol 12 No 6	4	2018 May
Zeaxanthin	Vol 9 No 9	2	2015 June
Zemplar	Vol 2 No 12	3	2008 July
Zentiva	Vol 10 No 10	3	2016 July
Zeroderma range of emollients	Vol 10 No 7	5	2016 May
Zinbryta suspension	Vol 12 No 6	5	2018 May
Zoladex	Vol 7 No 21	7	2013 December
Zoladex	Vol 11 No 5	1	2017 February

bruary

bruary

bruary

bruary

bruary

bruary

bruary

bruary

bruary

bruary

January

bruary